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ABSTRACT
The folding, quality control, and secretion of collagen presents a significant challenge to
collagen-producing cells. Each monomeric polypeptide must undergo extensive post-
translational modifications, folding and assembly of the C-terminal propeptide globular domain,
and isomerization of hundreds of prolyl bonds into the trans conformation before the mature
triple helix can form. The triple-helical domain lacks a traditional hydrophobic core that often
drives the assembly and folding of globular proteins. Even once folded, the triple helix is at best
marginally stable at body temperature and is prone to local regions of unwinding. The process
must be highly orchestrated by the endoplasmic reticulum's chaperone network, including
maintaining newly synthesized collagen polypeptides in an unfolded, non-aggregated, and
unassembled form until after the extreme C-terminus adopts its folded structure. Despite
decades of work, however, the mechanisms of collagen folding remain poorly understood, and
collagen quality control is largely unexplored. Misfolding collagen variants cause disease,
including osteogenesis imperfecta in the case of collagen-I variants. The origins of pathology in
osteogenesis imperfecta and the other collagenopathies are still debated, but what is clear is
that collagen proteostasis is strongly disrupted.
In this thesis, I report a series of studies targeted at elucidating mechanisms of
proteostasis for collagen type-1, the most abundant collagen in the human body. First, I explore
the folding and assembly of the critically important C-terminal, globular propeptide domains of
collagen-. My data demonstrate the importance of a single amino acid in the globular C-
terminal domain that regulates the oligomerization propensity of 30 kDa C-propeptide
monomers. Ultimately, I show that this single amino acid guides the assembly of the C-
propeptides of all the fibrillar collagens. Second, I use a quantitative mass spectrometry-based
interactomics approach and a novel human cell-based model system to map the components of
the wild-type collagen-I proteostasis network. This approach resulted in the discovery of > 25
new putative proteostasis mechanisms that engage collagen-1, as well as led to the discovery of
a previously unidentified post-translational modification in collagen-1. Finally, I leveraged this
improved understanding of the collagen-I proteostasis network to discover a strategy to
selectively increase the secretion of collagen-I from primary cells expressing a collagen-I variant
that causes osteogenesis imperfecta. Resolving the disease-associated collagen-I secretion
defect may prove valuable in disease.
Thesis Supervisor: Matthew D. Shoulders
Title: Whitehead Career Development Associate Professor
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Chapter 1:
Collagen structure, folding, and function in health and disease
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1.1 The collagen family of proteins is an indispensable component of the extracellular matrix
The extracellular matrix (ECM) is an essential component of life that extends far beyond solely
structural support of tissues and organs. Composed of over 300 proteins, 1-3 the ECM is a
dynamic scaffold that simultaneously supports organ structure, transduces signals between
cells, and plays an important role in regulating immune system responses and transduction of
cytokines.4 The major components of the ECM can be categorized as glycoproteins,
proteoglycans, and collagens," with some molecules spanning multiple categories.
Glycoproteins, such as the laminin family, are ubiquitous throughout the ECM, and are
often intermediate molecules receiving signals from the ECM and propagating them
intracellularly.9 They also play essential roles in cell adhesion and migration,10 ensuring proper
assembly of tissues and organs.1 ,12 Proteoglycans are proteins that have one or more di-sugar
group called glycosaminoglycans (GAGs) attached to their structure.13 Proteoglycans are also
4,14,15important molecules involved in signal transduction and immune responses.
The third ECM protein category, collagens, comprises the most fundamental component
of the ECM and the most abundant protein in the human body. There are 28 types of human
collagen that can be further classified into one of five main categories based on their structures
and functions: fibrillar, network, anchoring, fibril-associated collagen with interrupted triple
helices (FACIT) and membrane-associated collagen with interrupted triple helices (MACIT). 6
Each type of collagen plays important roles in maintaining the structural integrity of the ECM.
For example, collagen type-, the most prevalent collagen, is the main proteinaceous
component of bone and skin. 7
While the details of collagen type-specific structure and function vary, the unifying
feature of the collagen family is the triple-helical domain, which is the primary structural feature
observed in all mature collagens deposited into the ECM. 18 Proper folding and secretion of
triple-helical molecules are essential for maintaining a functioning ECM, and therefore for
human health. The protein homeostasis (proteostasis) network of the endoplasmic reticulum is
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responsible for producing and secreting properly folded triple helices, and selectively degrading
misfolded collagen molecules.
The collagenopathies are a class of currently incurable diseases that affect almost every
organ system in the human body. The collagenopathies are most commonly caused by
autosomal dominant missense mutations in a collagen gene (Table 1.1).1922 In rare cases,
autosomal recessive mutations to essential collagen chaperones prevent collagen from folding
properly, and also result in disease.2327 Regardless of the genetic cause, a unifying feature of
many collagenopathies is a decrease in collagen secretion, reducing the structural integrity of
the ECM. Treatment for these diseases is primarily palliative, and knowing the genotypic cause
of each disease is insufficient information for the design of adequate treatment, as genotype-
phenotype relationships are inconsistent. 28,29 The collagenopathies manifest as a result of (1)
misfolding variants causing a blockage to secretion, decreasing the total amount of collagen that
reaches the ECM, and/or (2) allowing misfolding variants to be secreted and contribute to
malformation of the ECM. One way to identify alternative treatment strategies from what is
currently available is to probe the mechanisms of collagen assembly and quality control
regulating these underlying manifestations of the collagenopathies.
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Table 1.1 List of collagenopathies
Type of collagen Collagenopathy
Osteogenesis imperfecta; 20 Ehlers-
Collagen-I Danlose syndrome137
Collagen-Il Achondrogenesis;13 sponyloepiphyseal
dysplasia139
Collagen-Ill Ehlers-Danlos syndrome
140
-
14 2
Collagen-IV Alport syndrome143
Collagen-V Ehlers-Danlos syndrome"4
Collagen-VI Bethlem myopathy 9 145
Collagen-VII Epidermolysis bullosa dystrophica 14
Collagen-IX Multiple epiphyseal dysplasia1 46
Collagen-X Metaphyseal chondrodysplasia",19
Collagen-XI Stickler syndrome14'
Collagen-XVII Epidermolysis bullosa dystrophica
Collagen-XVIII Knobloch syndrome 14
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1.2 Domain architecture and structure of the collagens
Although the different types of collagen have unique distributions throughout human tissue and
assemble into distinctive supramolecular structures extracellularly, the general types of domains
present in any given collagen can be divided into two unifying categories: non-collagenous (NC)
and triple-helical domains. In the case of fibrillar collagens, both the N- and C-terminal NC
domains are commonly referred to as N- and C-propeptides, respectively. The propeptide
domains of fibrillar collagens are cleaved extracellularly by specific proteinases in order to free
the mature, triple-helical molecule to assemble into fibrils. Other types of collagen can also
undergo proteolytic cleavage of their NC domains, but references to propeptides hereafter will
refer to the N- or C-terminal propeptides of the fibrillar collagens, which are always cleaved after
secretion, unless specifically noted otherwise.
The C-terminal NC domain is of particular importance for every collagen molecule.
Collagen folds from the C- to N-direction with the C-terminal NC domain guiding assembly,
nucleation, and composition of the triple helix. 30-32 Depending on the gene composition of a
given type of collagen, the C-terminal NC domain will assemble trimers into one of three
possible patterns: homotrimers, 2:1 heterotrimers, or 1:1:1 heterotrimers (the last only in the
case where a type of collagen includes three or more genes). The C-propeptide domains of the
fibrillar collagens form interstrand disulfide bonds between monomers after or during trimeric
assembly.33 In contrast, network collagen NC domains rely primarily on hydrophobic interfaces
to drive trimer assembly.34 While the stoichiometry of different types of collagen varies, the code
for assembly into a homotrimer or a heterotrimer resides within the C-terminal NC domain (see
Chapter 2 for work towards understanding the requirements for fibrillar collagen assembly).
Once the C-terminal NC domain nucleates assembly of the three monomeric strands,
the triple-helical domain can begin to fold. The triple helix is the defining structural feature of all
types of collagen. Collagen triple helices are composed of hundreds of Gly-Xaa-Yaa repeats,
with Xaa and Yaa most commonly being either (2S)-proline (Pro) or (2S,4R)-4-hydroxyproline
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(Hyp), respectively. Not every Xaa or Yaa position is, however, occupied by Pro or Hyp. There
is considerable sequence diversity in the triple helical region of collagen providing a diverse
array of binding sites for cell surface receptors and other ECM proteins, as well as impacting the
stability of local triple-helix regions.
35
-
39
Although we still lack a high-resolution structure of the intact, mature collagen molecule,
structural biologists have studied collagen structure for > 70 years. The first X-ray diffraction
pattern of collagen was obtained from rat tail tendon in 1955.40'41 Analysis of the data led to the
first structural model of the collagen triple-helical domain, suggesting the fundamental
architecture and the presence of a ladder of interstrand hydrogen bonds between backbone
amides that stitch the triple helix together. In 1994, the first high resolution crystal structure of a
short, triple-helical collagen-like peptide with the sequence (Pro-Hyp-Gly)1 o containing a glycine
to alanine mutation was solved. The structure showed that three left-handed polyproline II
helices coil together to form a parallel, right-handed triple helix largely consistent with the
structure proposed in 1955 (Figure 1.1).4244 Since that time, > 20 high-resolution structures of
Pro-rich triple-helical peptides have been solved. 4 5-50 Despite the extensive structural
information we now have for these short triple helices, we still lack detailed insight into the
structure of the full-length -1000 amino acid-long triple helix of native collagens, and into the
effects of sequence in Pro-poor regions on the structure of the protein.
Full-length collagen does not crystallize, instead forming liquid crystals, 51 so an x-ray
structure is currently not possible to obtain. While attaining an atomic level structure of full-
length collagen is problematic, tunneling and scanning electron microscopy have provided
significant advancement in our understanding of how collagen molecules assemble.52 55 Several
different types of structures are detected by electron microscopy, depending in part on collagen
type, as illustrated in Figure 1.2.
Beyond the triple-helical domain of mature collagen, the structures of the N- and C-
terminal NC domains of collagen are also important to understand. In fibrillar collagens, each
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monomeric N-propeptide is -15 kDa while monomeric C-propeptides are -30 kDa. While the
function of the N-propeptide in fibrillar collagens remains unknown, the C-propeptide structure is
of particular importance. The C-propeptide is the domain that initiates assembly of collagen
trimers.30 In cases where the C-Pro domain is absent due to mutations that insert early stop
codons into collagen genes, collagen monomers cannot be incorporated into triple helices.56 -58
Given its indispensable role in collagen assembly, a considerable amount of effort has been
applied to obtaining high-resolution structures of assembled C-propeptide trimers. Three efforts
have succeeded to date: two structures of homotrimeric fibrillar collagen C-Pro domains,3359
and one structure of the distinctive C-Pro domain of collagen-IV 34 (Figure 1.3A and 1.3B).
Importantly, many of the most abundant fibrillar collagens, including collagen-1, are
heterotrimers. Despite numerous attempts, the structure of collagen C-propeptide heterotrimers
has still not been obtained. As a consequence, the molecular mechanisms that distinguish
collagen homotrimerization from heterotrimerization remain unclear, a question that is
addressed in detail in Chapter 2 of this thesis using a combined biophysical and biochemical
approach.
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Figure 1.1 1 Structural studies of the triple helical domain of collagens
Structure of a collagen-like peptide containing a glycine to alanine mutation, at 1.9 angstroms.
Three views are shown, from left to right: the full triple helical peptide structure in cartoon form,
a zoomed in version of the cartoon form to show the kink caused by the alanine mutation, and
the stick model showing the orientation of the alanine side chain causing the kink."
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Figure 1.2 1 Electron microscopy of different types of collagen structures
(A) Fibril formation showing consistent D-period spacing and cross-section of collagen-I fibrils,
illustrating the average diameter of the fibrils.134 (B) Collagen VI electron microscopy data
demonstrating the bead on a string structure of the network.135 (C) Collagen VII electron
microscopy shows the free amino-terminal NC domain three individual extensions at one end of
the molecule (left image) The right image shows the head to head assembly of two collagen-VII
monomers at their carboxy-terminal ends. 136 (A-C) images demonstrate the variety of structures
that the collagen family can assume in the ECM.
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Figure 1.3 | Crystal structures of globular C-terminal NC domains
(A) Solved crystal structures the head-to-head dimer of trimers of collagen IV NC1 domain.
Strands are differentially colored to identify different amino acid chains, forming a dimer of 2:1
heterotrimers. Left view is oriented down the central axis of the structure, as if the triple helical
domain were in the z-plane (where the two dimensional page is the xy-plane); right view is a
side view of the head to head dimer where the triple helices would be oriented from top to
bottom of the page. (B) Structures of the Cola1 (1) homotrimer C-propeptide domain. Left is a top
down view of the NC domain. Right is a side view, where the helix would orient towards the
bottom of the page.
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1.3 Post-translational modifications
Regardless of the type of collagen in question, extracellular assembly and stability of all
collagen molecules is dictated largely by events and modifications that occur intracellularly. The
most abundant modification of collagen is 4R-hydroxylation of proline residues in the Yaa
position of triple-helical domains by the enzyme prolyl-4-hydroxylase to form Hyp.60 The 4R-
hydroxyl group stabilizes the C7-exo pucker of proline's pyrrolidine ring. This pucker is
necessary to preorganize the peptide backbone of monomeric collagen strands for triple helix
formation, and is required for formation of thermally stable, folded collagen triple helices.61,62
Hydroxylation of lysine is another essential modification, as hydroxylated lysines are the
dominant site for O-linked glycosylation, and for formation of extracellular crosslinks to other
collagen molecules in assembling fibrils. Collagen galactosyltransferase enzymes are
responsible for addition of a galactose sugar to hydroxylysine residues of collagen.63 Lysyl
hydroxylase 3 then adds a second sugar, glucose, resulting in a dicarbohydrate moiety on the
monomeric collagen strand.64'65 These sugar modifications are thought to play a role in
regulating fibril size, mediating interactions extracellularly, and are necessary for endocytosis of
damaged collagen targeted for degradation by the lysosome.66
Hydroxylation of each collagen strand is performed by prolyl and lysyl hydroxylases.67
The hydroxylase enzymes are non-heme iron containing proteins, localized to the endoplasmic
reticulum. The enzymes use a P450-like mechanism to hydroxylate substrates, with molecular
oxygen as the source of the oxygen molecule.67 Each enzyme has a pocket in the active site to
bind ascorbate, an essential co-factor that acts as a built-in rescue mechanism to prevent the
iron atom from falling into a high oxidation state that renders the protein inactive. 8 It is unclear
whether the hydroxylation events occur co- or post-translationally, but the modifying enzymes
only show activity toward monomeric collagen in vitro and therefore must act prior to triple-helix
formation.67'69
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Delays in triple helix formation increase the amount of time each monomer is exposed to
the hydroxylase enzymes, resulting in over hydroxylation in the triple helical domain. Excessive
hydroxylation alters the structural and functional characteristics of the triple helix, especially
causing excessive hydroxylysine formation. An increase in hydroxylysine modification
decreases N-propeptide cleavage efficiency, effectively reducing the amount of collagen
available to incorporate into fibrils.70 Therefore the kinetics of folding are essential to ensure that
collagen can function properly.
Collagen molecules are also N-glycosylated, specifically in their NC domains. A single
N-glycan sequon is highly conserved across all types of fibrillar collagen, and each collagen-IV
gene also has a putative N-glycosylation site, although the actual presence of the modification
has not been confirmed. Given that the N-glycan is located in the NC domain for fibrillar
collagens, a domain that is cleaved after secretion, an extracellular function of the N-glycan
seems unlikely. N-Linked glycosylation allows nascent proteins to engage the extensive lectin-
based chaperone and quality control machineries in the ER.7 ' Thus, a more likely role for this
conserved N-glycan is enhancing collagen folding. Surprisingly, in the case of otherwise wild-
type collagen-1, removal of the N-glycosylation site by substituting the N-glycosylated Asn with
Gln resulted in no measurable effect on trafficking, expression, or secretion.72 Thus, unlike other
common collagen post-translational modifications, the function of the conserved NC N-glycan
on collagen remains unknown.
1.4 Collagen chaperones and ER function
Folding collagen into a functional triple helix presents a formidable task to the cell. The protein is
large, with each collagen monomer for type-I being > 1400 amino acids in length and the
assembled protein being > 400 kDa. Moreover, unlike most or perhaps all other large proteins,
collagen folds from the C- to N- direction.30 Thus, each strand must remain in a monomeric,
non-aggregated form until the extreme C-terminus of the protein enters the ER and nucleation
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can begin. The C-propeptide domain must then fold into its globular structure and nucleate the
three monomeric strands in the correct stoichiometry. Proper kinetics of folding are essential
because delays in assembly expose the triple-helical domains to the hydroxylases for more time
than is necessary, causing over-modified helices to be formed. Furthermore, the properly
modified triple helix is unstable at body temperature, likely to provide dynamics necessary for
formation of supramolecular structures, but nonetheless meaning that collagen folding faces a
challenging thermodynamics problem. Finally, collagen cannot be secreted by normal
methods due to its > 300 nm length, when traditional vesicles for secretion average -70 nm in
diameter.75
Only limited efforts have been made to map the folding and quality control networks
required for collagen biogenesis owing to the following difficulties: (1) collagen is a massive,
rigid protein making biochemical purification and analysis difficult; (2) collagen lacks any type of
enzymatic activity or significant small-molecule binding affinity that could be used to track its
subcellular localization or assess its foldedness; (3) genetically malleable systems to study
collagen are not available, or are unwieldy to produce; 76 77 (4) a lack of high quality, specific
antibodies precludes immunoprecipitation of collagen to identify protein-protein interactions
involved in its folding pathway; and (5) the collagen genes are over 4000 base pairs in length,
and contain highly repetitive GC-rich regions that are readily recombined in bacterial cells. As a
result, until recently (see Chapter 3), only a handful of ER chaperones were known to play a role
in collagen biogenesis. A schematic of the ER nodes that collagen engages is shown in Figure
1.4.
Most of the known collagen chaperones were identified due their abundance in
collagen-producing cells (e.g., HSP47),71'79 the existence of collagenopathies caused by genetic
mutations in a chaperone (e.g., FKBP10),8 0 -82 or by logical prediction (e.g., peptidyl prolyl
isomerases or protein disulfide isomerases likely to be critical for a cysteine-containing, ER
protein). 3 Although seminal to our understanding of collagen folding, the three aforementioned
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methods of chaperone discovery are inherently limited in their scope, and an unbiased
discovery approach had not been applied to the problem prior to the work described in Chapter
3. Fewer than 4 chaperone families were proposed to have a role in collagen biogenesis prior to
our work, and virtually nothing was known about collagen quality control. The previously known
chaperone families are described in greater detail below.
Most striking is the existence of a collagen-specific chaperone, known as heat shock
protein 47 (HSP47). HSP47 was discovered based on its sheer abundance in avian collagen-
producing cells.78 HSP47 is thought to act as a clamp at certain locations on the triple helix
during folding in the ER, ensuring that newly folded regions do not locally unfold. A co-crystal
structure of HSP47 and a collagen-like peptide highlights the GPRG binding motif in the
collagen triple helix that is bound by HSP47. 4 While this sequence is present at nine and ten
locations throughout the triple helical domains of Cola1 (1) and Cola2(l), respectively (collagen-I
was the model used for the collagen-like peptides), the register of the heterotrimeric collagen-I
triple helix remains unknown. Therefore, the precise locations for HSP47 binding have not yet
been elucidated.
HSP47 escorts collagen from the ER to the Golgi apparatus, where the lower pH
protonates histidine residues in the collagen-binding domain of HSP47, causing a
conformational change that releases the folded collagen molecule. HSP47 is then recycled back
to the ER.1 5 HSP47 knockout causes a lethal phenotype in mice. In mouse embryonic
fibroblasts knocked out for HSP47, collagen-I is retained in the ER and eventually degraded
(possibly by autophagy although the mechanism remains unclear), significantly decreasing the
amount of collagen secreted from the cell.86
Peptidyl prolyl isomerases (PPlases) were predicted to play a role in collagen folding
and maturation owing to the high abundance of proline residues in the collagen triple-helical
domain. These enzymes assist the isomerization of all collagen's proline residues into the trans
configuration, which is required for triple-helix formation, as in the case of the hydroxylase
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enzymes. The PPlase family of enzymes act only on monomeric collagen in vitro. 7 The ER
contains a considerable number of distinctive PPlases, each with different specificity for
different types of collagen in vitro.88 The molecular factors and interactions that define which
collagen proteins interact with each PPlase domain are not yet clear, and possible rules for the
PPlases in collagen quality control have not been elucidated.
Protein disulfide isomerases (PDI) are also implicated in collagen folding and maturation.
PDIA1 is the beta subunit of the prolyl 4-hydroxylase enzyme complex responsible for the large
majority of proline hydroxylation in collagen.' 90 PDIA1 has two catalytically active sites 91 that
could carry out disulfide bond isomerization or assist disulfide bond formation. While each active
site has been probed for activity towards different substrates,92 such analysis has not been
performed for collagen. In fact, it is likely that PDIAI is not the sole PDI family member that
interacts with collagen, and may only be known as a collagen-interacting protein because of its
function as a member of the prolyl 4-hydroxylase complex.
Finally, collagen engages the HSP70/90 system in the ER by interacting with BiP and
GRP94.93 97 BiP is responsible for many roles in the ER, including binding nascent protein
chains as they enter the ER, preventing each chain from misfolding or aggregating.98 However,
the specifics of collagen binding to these chaperones, or the requirements for each in the
biogenesis of collagen are not known. Furthermore, this ATP-dependent chaperoning family
contains seven HSP40 proteins99 in the ER that shuttle unfolded or nascent protein chains to
BiP, to then be delivered to a variety of fates. Our recent work identifies Erdj3 as the specific
HSP40 that interacts with collagen (see Chapter 3), but the molecular details of this interaction
are not yet known.
In Chapter 3 1 describe an unbiased approach to more comprehensively define the
collagen proteostasis network. The work resulted in the identification of an additional 25-30
proteostasis factors that putatively assist collagen-I biogenesis. Mechanistic follow-up confirmed
roles of a number of these new interactors, including the discovery of a new collagen post-
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translational modification and the first collagen quality control pathway identified to date.
Building on these discoveries and the platform reported in Chapter 2, ongoing work to define
how cells engage misfolding, disease-causing collagens is providing further important insights
into collagen proteostasis, and suggesting potential new targets for treatment of the
collagenopathies.
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Figure 1.4 | Schematic of collagen folding and maturation in the ER
Collagen traverses the ER and engages each of the nodes highlighted here. The solved
Colal (I) crystal structure was used to demonstrate the point at which the C-terminal NC domain
would be completely folded (prior to triple helix folding). The schematic is not intended to
indicate the order in which collagen engages each node, but instead to indicate that collagen is
known to interact with proteins within each functionally distinct group of enzymes and
chaperones in the ER.
35
1.5 Extracellular assembly of secreted collagens
Each sub-classification of the collagen family has a different extracellular assembly pattern for
establishing the ECM. For the fibrillar collagens, such as types 1, 11, and Ill, proteinases cleave
the globular NC domains anytime starting in the late stages of the secretory pathway through to
post-secretion,12 freeing the mature molecule composed of a lengthy triple helix and short
-15 amino acid telopeptides at its N- and C-termini. Cleavage of the NC domains allows the
triple helical domain to begin self-assembly into fibrils (Figure 1.5). The non-triple helical
telopeptides are essential for proper collagen crosslinking in fibrils, contributing to the strength
of the overall fibrils.103
In the case of most other types of collagen, the NC domains are maintained
extracellularly, and play an essential role in the function of the collagen molecule.1 04-107 For
example, the N- and C-terminal NC domains of type-IV collagen differentially oligomerize,
initiating the creation of a network of collagen molecules that form the proteinaceous foundation
of basement membranes. The amino-terminal NC domain tetramerizes in a non-covalent
manner, driven by hydrophobic/hydrophilic interactions creating a node of four individual
collagen-IV molecules projecting in four different directions of the xy-plane, maximizing spatial
coverage. The carboxy-terminal NC domain forms a head-to-head dimer with a proximal
collagen-IV molecule, initiating the formation of a sulfilimine crosslink between the two NC
domains (Figure 1.5).108-112 In the case of collagen-VI, the NC domains are also maintained,
and monomers tetramerize intracellularly in an antiparallel structure, forming the precursor for
networks that resemble beads on a string. 10 4
Anchoring fibrils of collagen-Vil only have their carboxy-terminal NC domain proteolyzed,
keeping the amino-terminal NC domain intact. Once cleaved, the carboxy-terminal ends form a
head-to-head dimer with one another while the amino-terminal ends bind to cell surface
receptors, forming interstitial loops throughout the ECM. 13 ,114 FACIT and MACIT collagen
molecules are more complex, with triple-helical domains interrupted by multiple NC domains
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(Figure 1.5).106 These types of collagen maintain their NC domains, as they are essential for
binding cell surface receptors or other ECM proteins, maintaining connections throughout the
ECM.
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Figure 1.5 1 Schematic representation of different types of collagen assembly
Collagen assembles intracellularly in a similar way from monomer to trimer for all types of
collagen. At that point, each type of collagen diverges to form different extracellular structures,
depicted as fibrils, networks, anchoring fibrils, or cell-cell contact molecules. Examples of the
types of collagen that fall into each category are given in parenthesis (not an exhaustive list).
NC1 and NC2 indicate functionally distinct NC domains.
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1.6 Non-canonical secretion of large, rigid collagen molecules
Collagen triple helices are typically -300 nm in length, and can be larger in collagen types with
more complex domain architectures.62 Although collagen secretion is COPII-dependent,
standard COPII vesicles that traffic proteins from the ER to the Golgi cannot accommodate such
a long, relatively rigid protein, as their average diameter is only about 70 nm.75 Collagen must,
therefore, be packaged and trafficked by a non-canonical COPII pathway, involving expansion
of vesicles to accommodate collagen. A mechanism requiring monoubiquitination of COPII
vesicles signals for vesicle expansion, accommodating and secreting collagen molecules. A
localized increase in calcium concentration recruits the necessary E3 ubiquitin ligase, KLHL12,
to the site of COPII vesicle formation. KLHL12 then monoubiquitinates a coat protein, Sec3l,
allowing for enlargement of the vesicle.'15'116 This expansion accommodates the large, 300-400
nm rod structure of collagen, and allows for trafficking to the Golgi for subsequent secretion
(Figure 1.6).
While many essential details have been elucidated, the molecular-level details of
signaling for this expanded Sec3l-dependent expansion are not yet clear. How does folded
collagen in the ER lumen transduce a signal in the cytosol to modify the vesicular machinery?
What is the source of the calcium ions that induce activation of the ubiquitin ligase complex on
the cytosolic side of the ER membrane? Further, how is collagen loaded into the expanded
vesicles? Recent work suggests that TANGO, an integral membrane protein required for
collagen secretion,'17 may use HSP47 as a handle to load triple-helical, folded collagen
molecules into these expanded vesicles.' 18 Although compelling, the work was performed in
vitro and biological validation is required. In summary, collagen secretion is an area of ECM
biology that remains incompletely understood, although important given that many of the
collagenopathies involve collagen trafficking defects.
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Figure 1.6 1 Expanded COPI vesicles are required for collagen secretion and trafficking
Collagen molecules require expanded COPII vesicles owing to their long, rigid structures.
Signaling in the cytosol initates vesicle expansion in a calcium dependent manner. Calcium
triggers a conformational change in the PEF1/ALG2 complex, enabling binding to the
CUL3/KLHL12 complex. PEF1/ALG2 then acts as a scaffold for the interaction between
CUL3/KLHL12 and Sec3l to facilitate monoubiquitination and vesicle expansion.
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1.7 Collagen quality control and disease
Due to the inherent complexity of collagen molecules, it is clear that they present a formidable
folding task to cells. Inevitably, misfolding events will occur even for wild-type collagen, and
misfolding is an even bigger problem in the case of disease-related misfolding collagen variants
or when collagen chaperones are genetically disrupted. Failed quality control of misfolded
collagen results in either toxic intracellular accumulation of collagen aggregates or secretion of
non-functional triple helices. 19,120 Thus, one of the most important gaps in our understanding of
collagen proteostasis is a lack of knowledge regarding collagen quality control mechanisms.
Very little is known about how misfolded collagens are recognized or how they are
degraded. Autophagy and endoplasmic reticulum associated degradation (ERAD)121 have both
been proposed to be involved, but the data are inconclusive.93122 In order for collagen to be
degraded by ERAD, the misfolded molecules must be selectively recognized by the cell,
disulfides must be cleaved to facilitate retrotranslocation, residual structure must be denatured,
and any trimerization must be reversed. In order for collagen to be degraded by autophagy,
there must be some mechanism for selective autophagy of a misfolded ER client protein.
Despite the recent provocative discovery of ER-phagy,12 3 1 24 no such mechanism is currently
known.
The prototypical collagenopathy is osteogenesis imperfecta (01), an incurable brittle
bone disease.2 0 01 is most commonly caused by missense mutations in one of the collagen-I
genes, causing a range of phenotypes from mild reductions in bone strength to perinatal
lethality. Mutations occur throughout the entire triple helical region, as well as the NC domains
of ColAI and CoIIA2, with no obvious genotype-phenotype link based on location in the
gene.125-127 In general, however, mutations closer to the 3'- end of either gene are more severe,
possibly because mutations in or near the C-terminus of the protein cause more severe delays
in trimerization and folding, resulting in excessive post-translational modifications in the triple
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helical region. In the presence of 01-causing variants of collagen, collagen-I secretion is
reduced and misfolded proteins are retained and accumulate in the ER.
In general, accumulation of a misfolded protein activates the unfolded protein response
(UPR), a transcriptional response to an unfolded protein stress sensed in the ER.1 8 13 ' The
UPR has three signaling pathways, referred to as arms, that sense misfolded proteins in the ER
lumen and signal for the transcriptional upregulation of ER protein chaperones to help
ameliorate the folding stress. ATF6 and IRE1 are the two UPR arms that predominantly
upregulate ER chaperones to buffer the folding capacity and clear the misfolded protein.99 When
a protein misfolding stress is chronic and cannot be addressed by upregulation of chaperones,
PERK, the third arm, induces cellular apoptosis132 (Figure 1.7).
While select collagen variants may activate the UPR or a non-canonical stress
pathway,1 20 ,12 8 the vast majority of 01-variants that cause collagen-I misfolding do not activate
the UPR. Cells do, however, retain collagen intracellularly and prevent it from being secreted.
Therefore, the cells likely can recognize misfolded collagen, but may not have the capacity to
respond to collagen misfolding by activating the UPR to address the defect. One possibility is
that collagen's non-traditional structure escapes notice by the UPR's sensors of protein
misfolding, which tend to recognize exposed hydrophobic domains that are absent from an
unfolded or misfolded triple helix.
Given that most collagenopathies are autosomal dominant like 01, each collagen-
producing cell has the capacity to synthesize and selectively secrete wild type collagen, while
degrading disease-variant collagen. Therefore, identification of differential mechanisms between
wild type and disease-variant collagen would illuminate a therapeutic window for treatment of
the underlying cause of the collagenopathies. Before treatment can be considered, however, we
must have a better understanding of wild type collagen proteostasis to then understand how
disease-variant collagen proteostasis diverges from the wild type mechanisms.
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Figure 1.7 j Schematic representation of the unfolded protein response
The ER's UPR has three main arms: IRE1, ATF6, and PERK. Each arm has a subset of
transcriptional targets that assist in ameliorating protein folding stress, and induce apoptosis if
the stress cannot be remedied. XBP1s and ATF6 predominantly upregulate ER chaperones,
while PERK induces a signal cascade to induce apoptosis in the event of chronic unfolded
protein stress.
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1.8 Summary
Collagen is the most abundant protein the human body, yet we still do not understand many of
the mechanisms that are required for its biogenesis, quality control, degradation, and secretion.
Malfunctions in collagen folding and secretion lead to the debilitating collagenopathies, a
category of diseases that currently has no cure, and treatment is only palliative. Without
molecular-level detail of interactions that govern folding, assembly, secretion and degradation,
the design of viable therapeutic strategies for the collagenopathies will likely remain challenging.
In Chapter 2, I describe our analysis of the C-terminal NC domains of collagen-1.
Collagen-I is a heterotrimeric triple helix, whose stoichiometry and register is determined by C-
propeptide-initiated assembly, prior to triple helix folding. Our biochemical and biophysical data
reveal a simple, cysteine-based molecular code that controls whether fibrillar collagen strands
homo- versus hetero-trimerize.
In Chapter 3, I describe our efforts to better define the collagen proteostasis network.
Prior to our work, only a few factors were known to play a role in collagen folding and secretion.
Development of the first platform for quantitative collagen-I interactomic studies using mass
spectrometry-based proteomics provided an expanded, higher resolution map of the collagen
proteostasis network and led to a number of interesting discoveries. These include the
identification of a previously unknown collagen post-translational modification and identification
of the first collagen quality control-related ER proteostasis network component.
In Chapter 4, I outline our efforts using stress-independent UPR activation to improve
collagen folding and secretion from 01 patient primary cells. A subset of the interactors identified
in Chapter 3 is transcriptionally regulated by the UPR. We hypothesized that activation of the
UPR may both ameliorate collagen misfolding stress in 01-variant lines by enhancing folding,
and improve collagen quality control. Indeed, we find that forced XBP1 s expression resolves the
01-associated collagen-I secretion defect, at least for selected 01 genotypes. Our data suggest
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that XBP1s enhances autophagic clearance of misfolded collagen-1, while simultaneously
improving the capacity of the ER to fold and secrete 01 collagen-I variants.
In the appendices, I outline our work aimed at elucidating the role in regulating assembly
of each cysteine residue in the collagen-I C-Pro domain, and understanding how select cysteine
variants affect full-length collagen assembly.
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2.2 Introduction
Construction of the functionally diverse collagenous extracellular matrices, including bone, skin,
cartilage, tendon, and beyond, is perhaps the most remarkable biological supramolecular
assembly process.1 ,2 The formation of these distinctive tissues begins with and depends upon
proper folding of individual collagen triple helices in the endoplasmic reticulum (ER). There are
28 different types of collagen, which assume a wide range of extracellular structures that are
necessary to support tissue and organismal health.3 It is common for many different types of
collagen to be synthesized and secreted from the same cell type. As such, improper assembly
of different types of collagen monomers must be prevented, while concurrently ensuring that
each type of collagen assembles into a trimer with the correct stoichiometric composition. This
complex process is initiated and guided by the C-terminal non-collagenous (NC) domain, the
globular, cysteine-rich, N-glycosylated -30 kDa collagen C-propeptide (referred to as C-Pro for
the remainder of this chapter) present on each nascent collagen polypeptide.
Initial work aimed at understanding how the C-Pro domain addresses the ability of a
given strand to form homotrimers used Cola (Ill) and Cola2(l) as prototypical collagen strands.
Cola1(Ill) can form homotrimers, while Cola2(l) only forms heterotrimers with Colal(l). Mini-
collagen genes consisting of each protein's endogenous N-propeptide, a shortened, ~ 200-
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amino acid triple helical domain, and C-propeptide, were expressed in a cell-free translation
system, and each protein's corresponding trimerization propensities were assessed by non-
reducing and reducing SDS-PAGE. As expected, wild-type Cola (Ill) formed homotrimers, while
wild-type Cola2(1) remained monomeric under non-reducing conditions. When each sample was
treated with reducing agent, both species migrated as monomers, indicating the disulfide-linked
nature of the Cola1 (Ill) homotrimer. Rationalizing that the propensity to form homotrimers lies in
the C-Pro nucleation domain, and knowing that Colal(Ill) formed disulfide-linked homotrimers,
Lees, and co-workers6 noted the difference in the cysteine composition of Cola1(III) and
Cola2(1). Colal(Ill) maintained eight highly conserved cysteine residues, while Cola2(1) only
contained seven (Figure 2.1). Mutating the second position in Cola2() to a cysteine and
monitoring assembly under non-reducing conditions, however, did not restore Cola2(l)'s ability
to form a homotrimer in this system. In contrast, mutation of any of the first four cysteine
residues to serine residues in Colal(lll) prevented disulfide-linked homotrimerization. The
authors used this data to conclude that the cysteine network is not responsible for regulating
homo- versus hetero-trimerization, and that there must be other factors in the sequence of the
C-Pro domain.6
Building on the aforementioned experiments, later work created another set of mini-
collagen genes with the same template (N-propeptide, short triple helical domain, C-Pro), but
this time using complex chimeras of Colal (Ill) and Cola2(1). The authors replaced regions of the
Cola2(1) C-Pro with corresponding sequences derived from the homotrimerizing Colal(lll) C-
Pro domain, in an effort to drive Cola2(1) homotrimerization. Each construct was expressed in
cell-free lysate, and analyzed by reducing and non-reducing SDS-PAGE as well as proteolysis
assays to assess the foldedness of the triple helix. (Triple helical collagen is resistant to
protease treatment such as pepsin, while monomeric collagen is succeptible.) While the wild-
type construct of Cola2(1) was completely degraded, the authors observed triple helical stability
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of a Cola2(1) construct that had 23 amino acids in its C-Pro domain replaced with the
corresponding 23 amino acid sequence from Colal (Ill). This led to the identification of a region
within the C-Pro domain that regulates type-specific collagen assembly, now known as the
collagen recognition sequence (CRS).7 Further work has confirmed a role for the CRS in
ensuring that collagen polypeptides assemble only with their own collagen type,''9 but the CRS
appears to have little or no role in defining whether a given collagen strand will form homo-
versus hetero-trimers.
More recently, crystal structures -of homotrimeric Colcl(ll)l0 and Colal(1)8 C-Pro
domains were solved (the Colal(1) homotrimer structure is shown in Figure 2.2A). The
disulfide-bonding pattern of collagen homotrimers was also revealed by the solved structure
(Figure 2.2B). The structures are consistent with a role for the CRS in type-specific assembly,
with salt bridges between adjacent monomers in the assembled trimer formed by residues
within the CRS. Using site-directed mutagenesis and protein purification, the authors found that
Lys129 and Glu130, which are both in the CRS, as well as Arg45 and Lys247 in Cola2(l) can
promote assembly of Cola2(1) into a heterotrimer. Thus, this recent structural data provides
significant insight into how the CRS guides type-specific collagen assembly and how Cola2(1)
incorporates into a heterotrimer, but does not address the fundamental question of how homo-
versus hetero-trimerization is encoded in the C-Pro domain.
None of the aforementioned work identifies an amino acid or sequence of amino acids
that are responsible for driving homotrimerization of the collagen C-Pro domain. To date, no one
has successfully converted a constitutively monomeric collagen C-Pro into one that can
homotrimerize, indicating that we still do not understand the answer to this fundamental
question. The early work of Lees and co-workers6 concluding that cysteine residues are not the
key feature has steered the field away from that possibility, even though the conclusions were
based on complex protein chimeras and low-resolution experimental results. It is plausible that
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fusion to an abiological, short triple-helical domain in the Lees and co-workers6 work obfuscates
the normal role of the C-Pro in initiating trimerization, as short triple-helical sequences are able
to assemble in vitro even in the absence of a C-Pro.'"' Moreover, practical limitations at the
time meant that purified proteins were neither obtained nor biophysically characterized to
assess the proteins' oligomeric states. Furthermore, evaluating homo- versus hetero-
trimerization depended largely on proteolysis assays, which interrogate the structural integrity of
triple helices, not the assembly of the C-Pro domain. A subset of constructs studied may be able
to form assembled homotrimers (directed by elements in the C-Pro domains) with proteolytically
sensitive triple helices.
In this chapter, I describe our efforts to revisit the fundamental question of the elements
that drive homo- versus hetero-trimerization of fibrillar collagen C-Pro domains. Here, I describe
the resulting comprehensive suite of biochemical and biophysical studies that reveal the
cysteine network as an ancient and the primary contributing factor governing collagen C-Pro
trimerization propensity, which we ultimately show relies on the identity of just one single atom
in the entire -30 kDa protein domain.
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Cola1(Ill) SRKNPARNCRDLKFCHPELKSGEYWVDPNQGCKLDAIKVFCNMETGETCISANPLNVPRK
CO1a2(l) SRKNPARTCRDLRLSHPEWSSGYYWIDPNQGCTMDAIKVYCDFSTGETCIRAQPENIPAK
Cola1(Ill) HWWTDSSAEKKHVWFGESMDGGFQFSYGNPELPEDVLDVQLAFLRLLSSRASQNITYHCK
Cola2(l) NWYRS-SKDKKHVWLGETINAGSQFEYNVEGVTSKEMATQLAFMRLLANYASQNITYHCK
Cota1(Ill) NSIAYMDQASGNVKKALKLMGSNEGEFKAEGNSKFTYTVLEDGCTKHTGEWSKTVFEYRT
Cola2() NSIAYMDEETGNLKKAVILQGSNDVELVAEGNSRFTYTVLVDGCSKKTNEWGKTIIEYKT
Colal(Ill) RKAVRLPIVDIAPYDIGGPDQEFGVDVGPVCFL
Cola2() NKPSRLPFLDIAPLDIGGADQEFFVDIGPVCFK
Figure 2.1 1 Alignment of the C-Pro domains of Cola 1(III) and Cola2()
Alignment of Colal(Ill) and Cola2(I) C-Pro domains was done using Clustal Omega.28 29 This
alignment highlights a high degree of similarity between the two domains. Each cysteine residue
is bolded in red. Note that the second cysteine is missing in Cola2(1).
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AB
C1C2 C3 C4 C5 C6 C7 C8
Collagen al() N C
Collagen al(0) N C
Collagen al(l) N C
Figure 2.2 1 Crystal structure highlights the disulfide bonds within the assembled
homotrimer
(A) Three views of the crystal structure of Colal(I) previously published (PDB: 5K31).8 Left to
right: top-down view to show the interstrand disulfide bonds (red); side view to show the overall
shape of the C-Pro domain, as well as the intrastrand disulfide bonds (blue); and side view of a
single monomer for simplicity. (B) Schematic representation of the disulfide bonding pattern in
the Colal (1) homotrimer. Each cysteine is represented by a colored square in (B). In both (A)
and (B) the intrastrand disulfide bonds are shown in blue, and interstrand disulfide bonds are
shown in red.
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2.3 Results
2.3.1 Collagen-I C-Pro Sequence Analysis
The most abundant collagen, type-1, is the most prominent example of otherwise quite similar
collagen strands displaying unique trimerization propensities.15 Human collagen-I is formed from
two distinctive polypeptide strands, Colal(I) and Cola2(1), which are encoded by the Co/IAI
and CoIIA2 genes, respectively. The predominant secreted form is a 2:1 heterotrimer of
Colal(I) to Cola2(1). Although homotrimers of Colal(l) have been identified in carcinomas,16
fetal tissue,17 and fibrotic wounds,18 homotrimers of Cola2(1) have never been detected (Figure
2.3A). Alignment of human Colal(l) and Cola2(l) reveals strong similarities in the C-Pro
domain, with 62% sequence identity and 78% similarity. One striking difference, however, is that
the homotrimer-forming Colal(l) C-Pro has eight cysteine residues, (like Colal(Ill) in Figure
2.1), while the heterotrimer-forming only Cola2(1) C-Pro has only seven cysteine residues
(Figure 2.3B).
We began by aligning ancestral collagen C-Pro domains to track the appearance of each
factor known to play a role in collagen assembly through evolutionary history. Our goal was to
identify a conserved factor that emerged at the same evolutionary time-point as collagen-I
heterotrimers, which likely begin to appear as early as hydra. 19 First, we noted that the CRS is a
recently evolved vertebrate mechanism of chain selection. This sequence did not emerge until
the problem of type-specific collagen assembly became significantly complicated by the
presence of many types of collagen in a single organism.202 For example, collagen sequences
older than sharks do not contain a CRS at all, suggesting the CRS is a relatively recent
evolutionary development. Second, modeling by Sharma and co-workers8 based on the crystal
structure of a Colal (1) homotrimer suggested the importance of Lysl29 and Glul30 in the CRS
of human Cola2(l) in forming salt bridges with the adjacent Colal(l) of the heterotrimer.
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However, Lys129 did not fix in the evolutionary tree until coelacanths and Glu130 is present
only in humans (an aspartic acid is present in frogs). Species older than frogs do not contain a
negatively charged amino acid in this location. It therefore seems unlikely that Lys129 and
Glul 30 are responsible for the inability of Cola2(1) to homotrimerize. For Cola1 (1), the negatively
charged amino acids Aspl26 and Asp1 29 proposed to be important by Sharma and co-workers8
were not yet fixed in sharks, one of the early-diverging vertebrates that later lost bone (relevant
amino acids highlighted in bold red in Figure 2.4). Bearing in mind that heterotrimeric collagens
possibly emerged as early as hydra, these observations suggest that the CRS, while certainly
important for type-specific assembly in modern collagens, is not the defining factor controlling
whether a given collagen strand homo- versus hetero-trimerizes.
Examination of the crystal structure followed by biochemical characterization identified
several other amino acids that influenced the ability of Cola2(1) to incorporate into
heterotrimers.8 While there is considerable variability in the early portions of the evolutionary
tree, Arg45 and Lys247 both fix at about the same time. Lamprey collagen has Arg45, but no
Lys247, while tunicate collagen contains Lys247, but not Arg45. Without a CRS domain in
lampreys or tunicates, however, the other half of the salt bridge (proposed to be Asp126 and
Asp129 in Colal(I)) does not exist. Arg45 and Lys247 therefore also seem unlikely to be the
key feature controlling the ability to homotrimerize.
In contrast to the low evolutionary penetrance of the CRS and specific amino acids
proposed to be important by modeling Cola2(l) into the homotrimeric Colal (1) crystal structure,
the C-Pro cysteine network emerges early and is extremely well-conserved across evolutionary
time. [We note that for simplicity and clarity in this chapter, each conserved cysteine residue is
numbered from 1 to 8, as shown in Figure 2.4. The numbering is in reference to the order of the
cysteine residues, from the N to C direction, and is not related to the specific amino acid number
in each collagen strand. For example C2 in Cola1 (1) is amino acid number 1265, numbered from
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the first amino acid translated, while C2 in Cola2(l) is amino acid number 1169.] The cysteine
residues involved in intrastrand disulfide bonding, C1, C4 and C5-C8, are conserved through
sponges and hydra, the evolutionary counterparts of bilateria, with no variability in their
presence or sequence location. The interstrand disulfide bonding cysteine residues, however,
C2 and C3, show considerable variability across the early portions of the phylogenetic tree
(Figures 2.4 and 2.5). Protostomes (arthropods and mollusks) appear to have collagen genes
without either C2 or C3, while all of the deuterostomes examined have variability in cysteine
occupancy in these two positions. However, the alignments in Figure 2.4 beginning with
chordates strongly suggest that the common ancestor of all chordates locked in to a pattern
where one collagen-I strand conserves all eight cysteine residues, while the other consistently
contains only seven cysteine residues. The strand that contains only seven cysteine residues is
always missing either C2 or C3, the proposed interstrand disulfide bonding cysteine residues.
These observations motivated us to revisit the question of a fundamental role for intermolecular
disulfide bonds in governing collagen homo- versus hetero-trimerization.
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A The C-Pro domain of collagen directs assembly of collagen strands
N-Pro Triple Helix C-Pro
Cola1 (1)5\\\/
Cola1 (I)
ColcE2(l) 5\
B Alignment of the human collagen-I C-propeptides
Ci C2
Colal(I) AD---DANVVRDRDLEVDTTLKSLSQQIENIRSPEGSRKNPARTCRDLMCHSDWKSGEY 1274
Cola2 ( I) ADQPRSAPSLRPKDYEVDATLKSLNNQIETLLTPEGSRKNPARTCRDLRLSHPEWSSGYY 1178
C3 C4 C5
Colal(I) WIDPNQGCNLDAIKVFCNMETGETCVYPTQPSVAQKNWYISKNPKDKRHVWFGESMTDGF 1334
Cola2(I) WIDPNQGCTMDAIKVYCDFSTGETCIRAQPENIPAKNWYRS--SKDKKHVWLGETINAGS 1236
Cs
Colal(I) QFEYGGQGSDPADVAIQLTFLRLMSTEASQNITYHCKNSVAYMDQQTGNLKKALLLQGSN 1394
Cola2(I) QFEYNVEGVTSKEMATQLAFMRLLANYASQNITYHCKNSIAYMDEETGNLKKAVILQGSN 1296
C7
Colal(I) EIEIRAEGNSRFTYSVTVDGCTSHTGAWGKTVIEYKTTKTSRLPIIDVAPLDVGAPDQEF 1454
Cola2(I) DVELVAEGNSRFTYTVLVDGCSKKTNEWGKTIIEYKTNKPSRLPFLDIAPLDIGGADQEF 1356
Cs
Colal(I) GFDVGPVCFL 1464
Cola2(I) FVDIGPVCFK 1366
Figure 2.3 1 C-Pro domain-mediated assembly of collagen type-I
(A) Schematic representation of collagen-I assembly. Two strands of Cola1 (1) and one strand of
Cola2(l) typically assemble into heterotrimers, a process that is initiated by their C-Pro domains.
Cola (1) is also known to form homotrimers, while Cola2(l) can only form heterotrimers. A
crystal structure of a homotrimeric C-Pro domain is shown for illustration purposes (PDB-ID
5K31). (B) Alignment of Colal(1) and Cola2(l) C-Pro domains highlights a high degree of
similarity between the two domains. The cysteine network is numbered from C1-C8 from the N-
to C- direction, with each cysteine residue colored in red, and the location of the missing
cysteine residue in Cola2(l) shown with a red asterisk (*).
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Hydra colal(I)
Hydra coll
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Figure 2.4 1 Ancestral collagen C-Pro sequence alignment suggests the cysteine network
is one of the more ancient sequence elements of the C-Pro domain
Ancestral collagen C-Pro domains were aligned using Clustal Omega. 28 ,2 9 Locations of the
conserved cysteine residues are highlighted in yellow, with the cysteine number indicated at the
top of the alignment. Residues other than cysteine in the conserved locations are bolded. Red
bolded residues are the proposed8 essential residues for salt bridge formation tracked through
the evolutionary tree.
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Figure 2.5 Cladogram of ancestral collagen C-Pro domains as it relates to Figure 2.4
Evolution of the collagen-I C-Pro domain from sponges to humans, with the names of each
clade indicated at each break point.
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2.3.2 Wild-type C-Pro domains are secreted as expected from cultured cells
We began by creating plasmids for expression of HA-tagged C-Proal (1) and FLAG-tagged C-
Proa2(l) in human cells. The distinctive antibody epitopes were included to enable differential
detection by immunoblotting. We incorporated a preprotrypsin signal sequence to target the
proteins to the endoplasmic reticulum for folding and subsequent secretion. We found that,
when expressed alone in HEK293 cells, both C-Proal (I) and C-Proa2(l) were robustly secreted.
SDS-PAGE immunoblot analysis of the media demonstrated the expected disulfide-dependent
assembly patterns for these proteins. C-Proal (1) migrated as a homotrimer and C-Proa2(l)
migrated as a monomer under non-reducing conditions, while both migrated as monomers
under reducing conditions (Figure 2.6A). Moreover, co-expression of both C-Proal (1) and C-
Proa2(l) rescued C-Proa2(l) into a disulfide-linked heterotrimer. This assembly pattern fully
recapitulates the known assembly of full-length Colal (I) and Cola2(l), indicating that these
biochemically amenable constructs provide a valid system to study the molecular code for
collagen homo- versus hetero-trimerization.
2.3.3 Cysteine swapping transposes oligomerization patterns of collagen-I C-Pro domains
We next tested the hypothesis that the homo- versus hetero-trimerization propensities of
Colal (1) and Cola2(l) C-Pro domains can be transposed simply by replacing C2 with a serine
residue in C-Proal (1) and restoring the C2 residue in C-Proa2(l) (Figure 2.3B). Strikingly, the
C2S variant of C-Proal (I) migrated as a monomer on a non-reducing SDS-PAGE gel when
expressed alone in HEK293 cells, whereas the S2C variant of C-Proa2(l) migrated as a
homotrimer (Figure 2.6B). Under reducing conditions, all of the protein samples migrated as
monomers. These results suggest that changing just one amino acid is sufficient to transpose
the functions of C-Proal(1) and C-Proa2(1). To our knowledge, our results provide the first
example of a homotrimerizing variant of Cola2(l) as a result of a only a single amino acid
70
change. Neither changes to the CRS nor to the Arg45 or Lys247 residues proposed to play a
role by Sharma and co-workers8 is required.
Complete function swapping requires, in addition, that S2C C-Proa2(1) can rescue C2S
C-Proal (1) into a heterotrimer upon co-expression. Indeed, we found that co-expression of both
variants does rescue C2S C-Proal(l) into a disulfide-linked heterotrimer with S2C C-Proa2(l)
(Figure 2.6B). Thus, we can not only transpose the trimerization propensities of the C-Proal (1)
and C-Proa2(l) by modifying C2, but we can also retain the ability to rescue the variant C2S C-
Proal (I) domain that has lost the ability to form disulfide-linked homotrimers into heterotrimers.
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Figure 2.6 | The presence or absence of C2 controls disulfide-dependent collagen-I
assembly
(A) Immunoblot analysis of individually expressed wild-type, HA-tagged C-Proal(I) (red) and
wild-type, FLAG-tagged C-Proa2(l) (green) proteins under non-reducing and reducing
conditions demonstrated that wild-type C-Proal (1) formed a disulfide-linked homotrimer
whereas wild-type C-Proa2(l) did not, recapitulating the known disulfide-dependent assembly
patterns of full length Cola1(l) and Cola2(1). Co-expression of wild-type C-Proa1(I) and C-
Proa2(1) rescued C-Proa2(l) into a disulfide-linked heterotrimer (yellow, representing green and
red overlap), as expected. (B) Immunoblot analysis of individually expressed HA-tagged
Cys1265Ser (C2S) C-Proal (I) (red) and FLAG-tagged Ser1169Cys (S2C) C-Proa2(1) (green)
proteins under non-reducing and reducing conditions showed that the serine variant of C-
Proa1 (I) was no longer able to form a disulfide-linked homotrimer. In contrast, the cysteine
variant of C-Proa2(l) was able to homotrimerize in a disulfide-dependent manner. Moreover, this
single amino acid substitution transposed the functions of C-Proal (1) and C-Proa2(1), as co-
expression of both variants rescued C2S C-Proal (1) into a disulfide-linked heterotrimer (yellow,
representing green and red overlap). Amino acid numbering was derived from the
corresponding full-length collagen-I proteins, as in Figures 2.3 and 2.4. Both (A) and (B) were
developed using secondary antibodies conjugated to red or green dyes.
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2.3.4 C-Pro domain purification and size exclusion chromatography analyses
These observations provide compelling evidence that the presence or absence of C2 in the
collagen-I C-Pro domain is the defining feature controlling the ability to homotrimerize in a
disulfide-dependent manner. However, results derived from non-reducing SDS-PAGE gels do
not address the potential of C-Pro domains to trimerize independent of disulfide bond formation,
as the analyses are necessarily performed under denaturing conditions. To address this critical
issue, we purified mg quantities of His-tagged versions of all four C-Proa(l) variants, cleaving
the 6x-His tag in the final step to yield C-Pro domains with only a two amino acid scar (Gly-Pro)
on the N-terminus of the protein. Figure 2.7A outlines our purification scheme, Figure 2.7B
displays a Coommassie-stained gel highlighting the purity of each recombinant protein under
reducing gel conditions. Dynamic light scattering further suggested the purified proteins are
relatively homogenous, with particles of similar radial size (Figure 2.7C). Figure 2.8 shows
corresponding MALDI-TOF characterization of the purified protein variants under reducing
conditions.
Size exclusion chromatography analyses on the purified proteins suggested that wild-
type C-Proal (1) formed a homotrimer. In contrast, wild-type C-Proa2(l) was predominantly a
monomer with some dimer present (Figure 2.9A). Removing or adding a cysteine transposed
these assembly propensities even under these native conditions, with C2S C-Proa1 (1) eluting
primarily as a monomer with some dimer and S2C C-Proa2(l) predominantly forming a
homotrimer (Figure 2.9B), as predicted based on the non-reducing, denaturing gel analysis in
Figure 2.6.
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Figure 2.7 | C-Pro variants can be purified from culture media to a high degree of purity
(A) Schematic workflow of protein purification. Briefly, HEK293-Freestyle cells were transfected
with each construct, and after 6 d, the conditioned media supernatant was collected and purified
using Ni-NTA beads, eluted and cleaved overnight by HRV-3C protease. (B) Coomassie
staining of a reducing SDS-PAGE gel analysis of recombinantly prepared samples of wild-type
C-Proal (1) and C-Proa2(1) as well as C2S C-Proal (1) and S2C C-Proa2(l) demonstrated a high
level of protein purity. (C) Dynamic light scattering analysis of protein samples in (B), shown as
% of total intensity, confirmed a high level of homogeneity.
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Figure 2.8 1 MALDI-TOF analysis of the C-Pro variants
Each C-Proa(l) was analyzed by MALDI-TOF to determine the exact mass of the reduced,
monomer. The masses are within error of the calculated mass. The mass change from mutating
a cysteine to a serine or vice versa (< 20 Da) are within the error of the instrument, and
therefore the masses identified cannot be compared too closely. Mass to charge ratios are
given for the most intense peak in each spectrum. (A) C-Proal(I) (B) C-Proa2(l) (C) C2S C-
Proal(1) and (D) S2C C-Proa2(l).
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Figure 2.9 1 Size exclusion chromatography demonstrates that constructs missing C2
cannot homotrimerize
(A) Size exclusion chromatography (SEC) analysis of purified wild-type C-Proal (1) and C-
Proa2(1) on a Superdex 200 10/30 GL column under native conditions revealed that C-Proal(l)
eluted as a homotrimer (blue), while C-Proa2(l) eluted predominantly as a monomer with some
dimer also present (red). A molecular weight standard (grey) is shown for reference. (B) SEC
analysis of purified C2S C-Proal (I) and S2C C-Proa2(1) on a Superdex 200 10/30 GL column
under native conditions revealed that C2S C-Proal (1) eluted predominantly as a monomer with
some dimer also present (blue), while S2C C-Proa2(l) eluted predominantly as a homotrimer
(red). A molecular weight standard (grey) is shown for reference.
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2.3.5 Sedimentation equilibrium analyses of C-Pro domain assembly
We next obtained sedimentation equilibrium data to more quantitatively evaluate assembly
propensities under native conditions for each purified C-Pro protein sample. Data were analyzed
using an approach similar to that described by Laue, in which various models containing one
or two species were fit to all the data collected for a given variant. To minimize the impact of
errors in computed values of - (the partial specific volume of the particle) on the fits, each
species was treated as a reduced molecular weight:
MR = MP(1 - Pp),
where Mp is the weight average molecular weight, which for a single species would be the
polypeptide weight, or a multiple of it if a single oligomer. A single species model has one such
term, a two species model has two such fitting terms which may or may not have an a priori
relationship between the species (e.g., one species is a dimer of the other); the two species
model can be elaborated to include an equilibrium among species. The slope of a plot of the
logarithm of the absorbance as a function of the squared distance from the center of rotation is
2RTproportional to MR and other measurement constants; when plotted as -In (A) versus r2 , the
slope is MR and is directly related to the molecular weight. Figure 2.10 provides complete
sedimentation analysis of all four protein variants showing representative data and fits
normalized for speed and temperature such that the slopes are directly proportional to the
molecular weight.
Both wild-type C-Proal (1) and S2C C-Proa2(1) were best fit as a single species with no
evidence for a second species present in solution. From the reduced molecular weights and the
D values from Table 2.1, the calculated molecular weights are 88,500 Da and 90,900 Da,
respectively. These values are most consistent with both species being homotrimers, with
molecular weights approximately 2000 Da larger than the sequence mass, consistent with some
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degree of glycosylation. All the C-Pro constructs employed had a single N-glycosylation site in
each polypeptide. Examples of fits to the observed gradients are shown in Figure 2.11.
For C2S C-Proal(I) and wild-type C-Proa2(1), over the range of concentrations
employed, both protein samples could be fit as a single species, but with molecular weights
intermediate between a monomer and dimer of the respective polypeptide chains (MW = 1.597
and 1.38, respectively). As the MALDI-TOF data (Figure 2.8) do not show evidence of such a
high molecular weight, the data are best viewed as an equilibrium between monomer and dimer.
For C2S C-Proal (1), an equilibrium constant of 76,300 M 1 provided the best fit, while for wild-
type C-Proa2(l) an equilibrium between a species with mw = 1.17 and an equilibrium constant of
6500 M- 1 provided the best fit. The small size of these equilibrium constants is consistent with
the mixtures approximating a single species of intermediate molecular weight over the full
concentration range employed. Examples of these fits are shown in Figure 2.12 with the relative
contributions of the monomeric and dimeric species to the overall gradients also computed and
shown, highlighting that the monomer is the predominant species in both cases.
These observations are fully consistent with the size exclusion chromatography results
in Figure 2.9. Thus, removal of a single cysteine residue in the conserved inter-strand disulfide
bond-forming region of the collagen-I C-Pro does not simply result in a situation where disulfide
linkages can no longer form between monomers. Instead, the proteins are not able to stably
homotrimerize to any significant degree. We conclude that the presence or absence of C2 in the
C-Pro domain is the critical nexus regulating the innate disulfide-linked trimerization propensity
of collagen-1.
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A Wild-type sedimentation B Cys/Ser variant sedimentation
equilibrium analysis equilibrium analysis
50000 50000
0 - 0-
2 -50000 - " - -50000 -
SC-Proa1 (1) -C2S C-Proal1(1)
AC-Pro2(I) A S2C C-Proa2()
-100000 ' ' -100000 1 1
48 49 50 51 52 48 49 50 51 52
Radial Position (cm 2 ) Radial Position (cm 2 )
Figure 2.10 I Analytical ultracentrifugation confirms the presence of trimers only in the
constructs with C2 intact
(A) Sedimentation equilibrium analysis showing that wild-type C-Proal (1) (blue circles) is best
fit as a single species homotrimer (see also Figure 2.11), while wild-type C-Proa2(1) (red
triangles) is best fit as a monomer-dimer equilibrium (primarily monomer; see also Figure 2.12)
with an association constant sufficiently small that over the range of concentrations in the study
the protein sample could be approximated as a single species with a molecular weight
intermediate between that of monomer and dimer. Data and fits shown are normalized for speed
and temperature such that the slopes are directly proportional to the molecular weights. Only
every third data point is shown for clarity. (B) Sedimentation equilibrium analysis showed that
C2S C-Proal (1) (blue circles) is best fit as a monomer-dimer equilibrium (primarily monomer;
see also Figure 2.12) with an association constant sufficiently small to be approximated as a
single species, while S2C C-Proa2(1) (red triangles) is best fit as a single species homotrimer
(see also Figure 2.11). Data and fits shown are normalized for speed and temperature such
that the slopes are directly proportional to the molecular weights. Only every third data point is
shown for clarity.
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Table 2.1. Molecular properties (calculated and measured) of collagen-I C-Pro variants studied.
wild-type Cys1265Ser wild-type Ser 1169Cys
C-Proa1 (1) C-Proal(I) C-Proa2(1) C-Proca2(1)
residues 251 251 252 252
Ms(kDa) 27,909 27,893 28,225 28,241
V (mL/g) 0.723 0.723 0.728 0.728
E (W cm~') 39,420 39,420 43,890 43,890
MALDI-TOF (Da) 29,183 29,174 29,371 29,476
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A B
C-Proal(1) S2C C-Proa2(1)
10.9 JM 15.9 JM
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Figure 2.11 I Example global fits of the data collected for each homotrimerizing C-Pro
variant during sedimentation equilibrium analyses
(A-B) Single species fits for wild-type C-Proal (I) and S2C C-Proa2() at a single initial
concentration and multiple speeds. The fitted single species molecular weights based on a
global fit to all the data available for each variant were 88,500 Da and 90,900 Da, respectively
(showing only every 2 nd data point for clarity).
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Figure 2.12 I Wild-type Cola2() and C2S Colal(l) are predominantly monomeric, with
only minor contributions from a dimeric species
(A-B) Fitted results for two of the speeds and initial concentrations used in the global fitting to a
simple monomer-dimer equilibrium model for C2S C-Proal (1) and wild-type C-Proa2(l). The
fitted gradient superimposes on the measured data (showing only every 2 nd data point for
clarity). The contribution of the monomer and dimer species to the total gradient are shown as
well, based on fitted equilibrium constants of 76,300 M~1 and 6500 M- 1 , respectively. These
distributions could be replaced by a single gradient with a molecular weight intermediate to the
monomer and dimer.
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2.3.6 Disulfide mapping of the homotrimerizing collagen-I C-Pro domains
We next asked whether the homotrimeric S2C C-Proa2(l) domain is properly folded. In the
absence of a crystal structure to assess foldedness and compare to the other homotrimeric C-
Pro domain structures, we used mass spectrometry to interrogate the disulfide bonds present in
the homotrimer. The recently published crystal structure (Figure 2.2A) provides the disulfide
bonding pattern for C-Proal(I) homotrimer (Figure 2.2B). Thus, using the Colal(I) crystal
structure as a guide, we expected the S2C C-Proa2(l) C-Pro domain to show the same pattern
of disulfide bonds.
We first trypsinized homotrimeric C-Proal (1) protein and analyzed the digested peptides
by mass spectrometry. A schematic of the expected disulfide-linked tryptic peptides is given in
Figure 2.13A. Digesting with trypsin does not separate C4 from C5 due to a lack of arginine or
lysine between the two cysteine residues. Therefore, we anticipated finding the mass
corresponding to the sum the peptides containing C1, C4C5, and C8. After manually searching
for the expected masses, we identified the C1-C4C5-C8 as well as the C2-C3 linked peptides.
We were unable to detect the C6-C7 linked peptides, owing to the presence of the N-linked
glycan on the peptide containing C6. To detect the C6-C7 disulfide linked peptide we digested
the sample with PNGase F to remove the N-glycan prior to trypsinization. Indeed, when we
removed the glycan we detected all of the expected disulfide bonded peptides (Figure 2.13B
shows only data for PNGase F treated C-Proal(l)). These data are consistent with the C-
Proal(l) homotrimer being properly folded, as expected, and suggest that our mass
spectrometry-based disulfide mapping strategy can help to confirm that the S2C C-Proa2(l) is
also properly folded.
Using the same protocol, we digested the S2C C-Proa2(l) homotrimer with trypsin and
manually searched for the expected disulfides based on the confirmed Colal(l) disulfide map.
As with C-Proal(l), C4 and C5 are not separated by a tryptic digest. Additionally for the C-
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Proa2(1), C2 and C3 are also maintained on the same peptide when digested with trypsin. A
schematic of the S2C C-Proa2() homotrimer digested with trypsin is given in Figure 2.14A. We
identified masses corresponding to C1-C4C5-C8 and C2-C3 disulfide linkages, matching our
expectation based on the Colal (1) crystal structure (Figure 2.14B). These data suggest that the
S2C C-Proa2(l) homotrimer is properly folded, and forms the same network of disulfide bonds
as the wild-type C-Proal (1) homotrimer.
84
A
C1C2 C3 C4 C5 C6 C7 C8
C-Proa1(I) N-- C
C-Proal(l) N C
C-Proal (I) N--7 -- C
N Cysteine Residue
- Disulfide Bond
B
Disulfide linkage Expected m/z Observed m/z
C1-C4C5-C8 1150.9508 1151.1593
C2-C3 976.4274 976.0990
C6-C7 748.9442 748.9440
Figure 2.13 1 C-Proal(l) disulfide bonded peptides identified by mass spectrometry
(A) Expected disulfide bonding map based on tryptic digestion of C-Proal(I), based on the
published crystal structure. For simplicity, one of each type of disulfide bonded peptide is in
bold, while the rest of the structure is lighter in color. (B) Expected and observed mass/charge
ratio for disulfide bonded tryptic peptides.
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A C1 C2 C3 C4 C5 C6 C7 C8
S2C C-Proa2(l) N C
S2C C-Proa2(1) N C
S2C C-Proa2(1) N -- C
* Cysteine Residue
- Disulfide Bond
B
Disulfide linkage Expected m/z Observed m/z
C1-C4C5-C8 1227.0876 1226.8440
C2-C3 1249.3996 1249.4039
Figure 2.14 1 S2C C-Proa2(l) disulfide bonded peptides identified by mass spectrometry
(A) Expected disulfide bonding map based on tryptic digestion of S2C C-Proa2(), based on the
published crystal structure. For simplicity, one of each type of disulfide bonded peptide is in
bold, while the rest of the structure is lighter in color. (B) Expected and observed mass/charge
ratio for disulfide bonded tryptic peptides.
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2.3.7 C2 and C3 are both essential for homotrimer formation
Our work described above outlines a detailed understanding of the essential role that C2 plays
in homotrimerization. Based on the published crystal structures (see Figure 2.2A), we also
expected C3 to participate in the interstrand disulfide bond, covalently linking the monomers
together into a trimer, regardless of the collagen C-Pro domain in question (a schematic
representation of the disulfide bonding is provided in Figure 2.2B). As above, we mutated C3S
in both C-Proal (1) and S2C C-Proa2(l) and monitored each protein's ability to homotrimerize by
non-reducing SDS-PAGE. Both variants migrated as monomers under non-reducing conditions,
perfectly mirroring the Colal (1) and Cola2(l) variants with a serine in the place of the second
cysteine (Figure 15). Paired together, these data highlight the importance of both positions 2
and 3 being occupied by Cys residues for a given strand to be able to form a disulfide-linked
homotrimer.
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a1(I) a2(1) a 1 (1) a2(1)
S2C S2C
V wt r2 9CS wt 59C r5 r. _q V~2 M 9 M wt R 9 r. r
90kDa
a-HA (red)
a-FLAG (green)
30 kDa
non-reducing reducing
Figure 2.15 1 C2 and C3 are required for trimerization
Immunoblot analysis of C2S and C3S variants of Cola1 (1) and Cola2(l) under non-reducing and
reducing conditions. Under non-reducing conditions, only C-Pro variants that contain both C2
and C3 cysteine residues can homotrimerize.
88
2.3.8 A generalizable rule for all fibrillar collagen C-Pro domains
The observation that a single amino acid substitution can swap the oligomerization propensities
of the Colal(1) and Cola2(l) C-Pro domains raises the provocative possibility that this simple
cysteine-based code for collagen assembly could be generalizable beyond just collagen-1.
Strikingly, alignment of the C-Pro domains of all of the human fibrillar collagens reveals that
collagen strands known to form homotrimers consistently have all four cysteine residues in the
interstrand disulfide-bonding region (Figure 2.16A). In contrast, those that are only known to
form heterotrimers always lack one of the interstrand disulfide bonding cysteine residues, C2 or
C3.
To test the generality of the cysteine code, we created HA-tagged constructs for
expression of wild-type C-Pro domains for all of the fibrillar collagens and FLAG-tagged
constructs for expression of appropriate variants. We observed that all of the wild-type fibrillar
C-Pro domains that lack a single cysteine residue migrated as monomers on SDS-PAGE gels
(Figure 2.16B), just as was observed for wild-type C-Proa2(l) (Figure 2.6). Moreover, re-
introduction of the missing cysteine residue always conferred the ability to form disulfide-linked
homotrimers. Similarly, all of the wild-type fibrillar C-Pro domains that naturally retain all four
cysteine residues and are known to form homotrimers migrated as disulfide-linked homotrimers
on SDS-PAGE gels (Figure 2.16C). Notably, for all of these C-Pro domains, we were able to
identify a single cysteine residue whose conversion to a serine eliminates the ability to form
disulfide-linked homotrimers. Finally, we observed that co-expression of a monomeric, C2S form
of collagen-Ill's C-Pro domain could be rescued into a heterotrimer by co-expression with the
wild-type C-Proa(ll) containing all four cysteine residues (Figure 2.17). Thus, the cysteine-
based molecular code for collagen trimerization appears to be conserved across a diverse suite
of collagen types. We note that non-fibrillar collagens also rely on additional factors.
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Figure 2.16 | The cysteine-based code for collagen C-Pro assembly is generalizable
across all of the fibrillar collagens
(A) Alignment of the interstrand disulfide-bonding region of all of the human fibrillar collagen C-
propeptides highlights that all C-Pro domains known to homotrimerize contain all four conserved
cysteine residues, whereas all C-Pro domains known to only form heterotrimers lack a single
cysteine. The residue colored red in each protein sequence corresponds to the mutated residue
analyzed in Figures 2.16B, 2.16C, and 2.17. below. Amino acid numbering was derived from
the corresponding full-length collagens. (B) Immunoblot analysis of individually expressed wild-
type fibrillar collagen C-Pro domains known to only form heterotrimers. Assembly was analyzed
under non-reducing and reducing conditions. Wild-type variants (HA-tagged; red) all migrated as
monomers, while all variants in which the fourth cysteine residue was re-introduced (FLAG-
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tagged; green) gained the ability to homotrimerize in a disulfide-dependent manner. (C)
Immunoblot analysis of individually expressed wild-type fibrillar collagen C-Pro domains known
to have the capacity to homotrimerize. Assembly was analyzed under non-reducing and
reducing conditions. Wild-type variants (HA-tagged; red) all migrated as disulfide-dependent
homotrimers, while all variants in which a single cysteine residue was mutated to Ser (FLAG-
tagged; green) lost the capacity to form disulfide-linked homotrimers.
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non-reducing
C-Proal (Ill)
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wt
veh wt C2S C2S
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Figure 2.17 I Wild-type Cola (Ill) can rescue C2S Cola (III) into a heterotrimer
The wild-type collagen-ll C-Pro domain homotrimerizes in a disulfide-dependent manner, but
the C2S variant does not (see also Figure 2.16C). Immunoblot analysis of co-expressed wild-
type C-Proal(III) and C2S C-Proa1(IIl) revealed that the wild-type protein rescued the Ser
variant into a disulfide-linked heterotrimer, mimicking the results obtained for C-Proa(l) in
Figure 2.6.
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2.3.9 Forming 1:1:1 Homotrimers
Both our mutational data and the disulfide mapping experiments indicate the importance of C2
and C3 for a given strand to form a homotrimer. Thus, we would expect the same residues to be
involved in disulfide bonds in a heterotrimer. In collagen-1, we would hypothesize that C2 and
C3 would form disulfides on adjacent chains, leaving one of the C3 residues of Colal (I) free,
due to the uneven number of cysteine residues in the molecule (Figure 2.18A consistent with
the modeling of Cola2(1) into the Colal (I) homotrimer).
We next considered the possibility of a 1:1:1 heterotrimer. If a set of collagen strands
were to form a 1:1:1 heterotrimer, the cysteine requirements would be slightly different. It would
require that one strand have cysteine residues in position 2 and 3, one strand with a cysteine in
position 2, and the third with a cysteine in position 3 (shown schematically in Figure 2.18B).
Looking to nature, this patter occurs in type-I collagen of both rainbow trout and zebrafish
(Figure 2.18C). Gene expression analysis demonstrated that the a3(l) strand is expressed in
discrete locations within each organism, suggesting it may play a distinct role in trimer formation
from the other two strands.' Moreover, this same pattern also occurs in humans in the case
of another fibrillar collagen, type-V, which is also known to form a 1:1:1 heterotrimer. In
summary, it appears likely that the cysteine code for collagen trimerization extends to the
formation of 1:1:1 heterotrimers.
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B C1 02 C3 C4
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E Cysteine Residue
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C
Rainbow trout Type I Collagen
C1 C2 C3 C4
al(l) PAR DLKC PDWKSGEYWIDPDQ C QDAIKV MET2 80
a2(l) PAR IDIRIS PDWSSGFYWIDPNQ C ADAIKANC)FST11 87
a3(l) P IIIDIR. C4PEWKSGQYWVDPNQ SJLDAVQVNCJE 1 2M 9
Zebrafish Type I Collagen
C1 C2 C3 C4
a1(l) PAR DL" PDWKSGEYWIDPDQ QDAIKVCMET
a2(l) PARIDIRI SPEWSSGFYWIDPNQ BCMDAIKA C)FST1 18 5
a3(l) P DLRV PEWKSGSYWVDPNQ LDAIKV MET
Figure 2.18 I Forming a 1:1:1 homotrimer requires that one strand contain cysteines in
the C2 and C3 position, while the other two strands must contain one cysteine each
(A) Proposed disulfide-bonding network of a collagen heterotrimer that requires 2:1 assembly.
This disulfide bonding network was also proposed by modeling C-Proa2(l) into the homotrimeric
crystal structure of Colal (). (B) Proposed disulfide-bonding network of a collagen heterotrimer
that requires 1:1:1 assembly. (C) Alignment of rainbow trout and zebrafish collagen-I C-Pro
domains (C1-C4) only shown. The expected cysteine network for a 1:1:1 homotrimer in Figure
2.18B is present in both instances where collagen-I has three alpha strands in nature.
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2.4 Concluding Remarks
Collectively, the work presented in this chapter takes a significant step towards defining the
molecular code for collagen C-Pro assembly. Nature evolved different collagen strands that can
homotrimerize, and others that can only heterotrimerize. The code for homo- versus
heterotrimerization resides in the cysteine network of the C-Pro domain. Fibrillar collagen C-Pro
domains require cysteine residues in both positions 2 and 3 to form disulfide-linked
homotrimeric structures. The presence of these cysteine residues is both necessary and
sufficient for collagen homotrimerization, in contrast to results suggested by prior work.
Our data are consistent with the following model for homotrimer assembly: fibrillar
collagen C-Pro constructs of the same type of can transiently dimerize and trimerize
intracellularly. Stable trimer formation, however, requires the ability to form disulfide bonds
between C2 and C3 of neighboring strands to lock-in the structure for subsequent triple-helix
formation.
Our model is not in conflict with a role for the CRS in determining type-specific collagen
assembly. Further, the amino acids identified by Sharma and co-workers8 as important for
incorporating Cola2(l) into a heterotrimer are also consistent with our data, but we conclude
they are not the critical residues as disulfide-linked homotrimers of Cola2(l) can be formed even
in their presence. The next step is to understand why homotrimers of Colal (I) are not more
commonly observed in biology, as the cysteine network is intact and homotrimerization should
be possible. Transient trimerization with Cola2(l) may be more prevalent, or localized
expression of the strands in cells may play an important role. This question is the subject of
ongoing investigation in our laboratory.
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2.5 Experimental Methods and Supplies
2.5.1 Materials and Reagents
DMEM, 0.25% trypsin/EDTA solution, L-glutamine, penicillin/streptomycin were purchased from
Corning/Cellgro. Serum-free media for HEK293-Freestyle cells was purchased from Life
Technologies. Antibodies used were obtained from the following suppliers: Santa Cruz: HA
probe (sc-7392); Agilent Technologies: Rat Anti-DYKDDDDK (200474); and Sigma: actin
(A1978). Secondary antibodies were obtained from LiCor Biosciences: 800CW Goat Anti-
Mouse, 800CW Goat Anti-Rat, 680LT Goat Anti-Mouse, and 680LT Goat Anti-Rat. All media
and cell culture reagents were obtained from Corning/Cellgro. DNA/RNA preparation kits were
obtained from Omega BioTech. Co/IAI and Co/IA2 genes were obtained from the Origene
True Clone Repository, Accession Numbers SC112997 and SC126717, respectively. All other
fibrillar C-Pro domain sequences were designed and purchased from Genewiz. Lipofectamine
3000 was purchased from Life Technologies. Proteomics-grade dithiothreitol (DTT) and
iodoacetamide was purchased from VWR. Sequencing-grade trypsin was purchased from
Promega. PNGase F was purchased from New England BioLabs.
2.5.2 Plasmids
The C-Pro-encoding sequences (from the endogenous C-proteinase cleavage site to the C-
terminus of the protein) were PCR-amplified using primers to incorporate the Notl and EcoRV
sites and inserted into pcDNA3.1 vectors encoding the preprotrypsin signal sequence upstream
of an HA or FLAG epitope tag, respectively. Variants were created by site-directed mutagenesis
using the QuikChange XL I1 Kit from Agilent Technologies. For purification of recombinant
collagen-I C-Pro domains, these vectors were modified to incorporate a cleavable 6x-His tag
fused to the N-terminus of each C-Pro domain via an HRV-3C protease cleavage site such that
both the 6x-His and HA/FLAG tags could be cleaved by a protease during protein purification.
This cleavage only left a two-amino acid scar (Gly-Pro) on the recombinant protein.) Genes
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encoding C-Pro domains for the other human fibrillar collagens were cloned into the same
pcDNA3.1 vectors downstream of a preprotrypsin signal sequence and either an HA or FLAG
epitope tag. The C-Pro gene for Col5A2 was inserted using Notl and Xbal sites. All other
collagen C-Pro-encoding genes were inserted between the Notl and EcoRV sites. FLAG-tagged
type-Il, -111, -V, -XI, -XXIV, and -XXVII genes were further modified by site-directed mutagenesis,
as required.
2.5.3 Cell culture
Adherent HEK293 cells were cultured in DMEM supplemented with L-glutamine,
penicillin/streptomycin, and 10% fetal bovine serum. HEK293 Freestyle suspension cells were
cultured in Freestyle media. Transient transfections of pcDNA3.1 C-Pro domain-encoding
plasmids were performed using Lipofectamine 3000 (Thermo Fisher Scientific). For all
experiments not involving protein purification, transfection media was changed to fresh DMEM
24 h post-transfection. Media and lysates were harvested from cell culture 24-72 h post-
transfection for analysis. When cell lysate samples were required, cells were harvested and
then lysed on ice for 10 min in lysis buffer containing 50 mM Tris-HCI, pH 7.5, 150 mM sodium
chloride, 1 mM EDTA, 1.5 mM magnesium chloride, 1% Triton X-100, and protease inhibitor
tablet (Thermo Fisher Scientific).
2.5.4 Immunoblotting
Prior to SDS-PAGE analyses, media samples were treated with 100 mM iodoacetamide in the
dark for 1-2 h to prevent disulfide shuffling, or 100 mM dithiothrietol for 1 h at rt to reduce
disulfides. All samples were then treated with 6x gel loading buffer (300 mM Tris, pH 6.8, 15%
glycerol, 6% SDS and 10% (w/v) bromophenol blue) and boiled for 10 min prior to protein gel
electrophoresis. Samples were then separated by SDS-PAGE using 12% polyacrylamide gels
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and analyzed by immunoblotting on nitrocellulose membranes using a Licor Odyssey Scanner
for detection.
2.5.5 Collagen C-Pro expression and purification
HEK293 Freestyle cells were transfected with appropriate plasmids using 293Fectin, according
to the manufacturer's protocol (Thermo Fisher Scientific). Cells were expanded, as necessary,
and the supernatant was harvested 6 d post-transfection after pelleting the cells by
centrifugation. Clarified media was supplemented with 50 mM potassium phosphate at pH 7, 5
mM imidazole, 150 mM sodium chloride, and 10 mM Tris (final concentrations). The protein was
bound to Ni-NTA resin by gravity flow, washed with four column volumes of 300 mM sodium
chloride, 10 mM imidazole, and 150 mM potassium phosphate at pH 7, and then eluted with 300
mM sodium chloride, 250 mM imidazole, 150 mM potassium phosphate at pH 7, into a final
EDTA concentration of 30 mM. Samples were eluted into EDTA to prevent free nickel ions from
causing the protein to precipitate. The eluted proteins were then concentrated using a 10 kDa
MWCO filter, buffer-exchanged into 20 mM bis-Tris Propane at pH 7,150 mM sodium chloride,
and subjected to o/n cleavage with 6xHis-tagged HRV-3C protease (Pierce). The cleaved
protein mixture was applied to a new Ni-NTA column, such that the cleaved His epitope and the
His-protease bound to the beads while the tag-less, purified protein was collected. The sample
was then concentrated and further purified by a Superdex 200 10/30 GL column. Samples were
separated using an isocratic flow 20 mM bis-Tris Propane at pH 7,150 mM sodium chloride at
0.5 mL/min. Fractions containing protein as indicated by the absorbance reading at 280 nm
were collected and used for further analysis.
2.5.6 Dynamic light scattering analyses
Purified C-Pro domain proteins were analyzed using a DynaPro NanoStar from Wyatt
Technology. Briefly, concentrated samples were inserted into disposable plastic cuvettes and
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equilibrated to rt. Data were collected using a light source wavelength of 658 nm and a fixed
scattering angle of 90*
2.5.7 Analytical ultracentrifugation
All data were collected at 25 *C with gradients monitored at 275 nm in a Beckman XLA
analytical ultracentrifuge. 1.2 cm pathlength double-sector, charcoal-filled Epon centerpieces
were used for all samples with -100 tL on the sample side and -110 IAL of buffer or water as
the reference. In most instances, three samples of a construct were spun, diluted as required.
Equilibrium data used in the analyses were collected at four or more speeds for each sample
with equilibrium ascertained as superimposable gradients collected 3 h apart. A non-
sedimenting contribution was measured after high-speed depletion of protein. This component
was generally minor (< 0.04 au) and treated as a fixed, measured parameter in the data
analyses. After attaining equilibrium at the highest speed, the speed was typically reduced to
one of the earlier speeds and the sample allowed to re-equilibrate. In all tested cases, the
gradients were nearly identical, suggesting no irreversible loss of material during the
experiment.
For the variants, the sequence weights (Ms) and the partial specific volumes (P) were
computed from the sequences using tabulated values.26 While the polypeptides were shown to
be glycosylated, the extent and specific nature of the glycosylation was unknown and likely
heterogeneous. However, MALDI-TOF mass spectra yielded masses (shown in Table 2.1 and
spectra shown in Figure 2.8) only slightly higher than the sequence weights. Therefore, the
potential impact of glycosylation on P values was ignored. The buffer used for sedimentation
equilibrium experiments was 20 mM bis-Tris propane at pH 7.0 with 150 mM sodium chloride.
Buffer density was measured at 25 "C by an Anton Paar DMA 5000 to be 1.005 g/mL. The
extinction coefficients at 280 nm were calculated based on average values for W and Y,
ignoring potential contributions from disulfides.27 In equilibrium constant calculations, this
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extinction coefficient was used without adjustment for the 275 nm wavelength used in data
collection. These molecular properties are summarized in Table 2.1.
3.5.8 Disulfide bond mapping by mass spectrometry
Protein samples were purified from HEK293 Freestyle cells as described above. The collagen-I
C-Pro domain is N-glycosylated and the glycosylation site is located on one of the cysteine-
containing tryptic fragments. Therefore, samples were treated with PNGase F overnight at 370
C, to remove the glycan (subsequently requiring us to search for an asparagine to an aspartic
acid mutation: deamination). Samples were then applied to a 50 MWCO filter and spun, to
remove the PNGase F enzyme. 1 tg of sequencing-grade trypsin (Promega) was added to each
sample, and digested over night at 370 C. Peptides were injected onto an EASY-nLC 1000 LC-
Q-Exactive Orbitrap. Peptides were separated on a 15 cm PepMap analytical column, over a 3
h gradient starting with 100% Buffer A / 0% Buffer B (Buffer A was 0.1% formic acid, Buffer B
was 80% acetonitrile, 0.1% formic acid), and ending with 0% Buffer A / 100% Buffer B.
2.5.9 Proteomic searching and analysis
Oxidized peptides are not searchable using traditional methods of comparing to a database.
Due to the possible variability in the disulfide linkages, the searches quickly become unwieldy
for Proteome Discoverer to handle. Therefore, all disulfide-bonded peptides were searched for
by hand in the raw LC-MS data file. Precursor masses of each peptide were calculated and
summed accordingly, in addition to multiple charge states for each peptide. Samples were then
manually searched for peptides with the expected masses.
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Chapter 3:
Mapping and Exploring the Collagen-I Proteostasis Network
This chapter is adapted from the following manuscript:
DiChiara, A.S., Taylor, R.J., Wong, M.Y., Doan, D.N., Del Rosario, A.M., Shoulders, M.D. ACS.
Chem. Biol. 11, 1408-1421 (2016).
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3.2 Introduction
Collagen-I is the predominant proteinaceous component of human tissues, including skin and
bone.' The supramolecular properties of the collagen-I-based extracellular matrix are
determined, in large part, by the upstream, intracellular processes of collagen-I folding,
modification, and quality control. These processes are governed by the endoplasmic reticulum's
(ER's) proteostasis network.2 Imperfections in collagen-I structure, most often caused by
missense mutations in collagen-I genes, lead to debilitating diseases known as the
collagenopathies, including osteogenesis imperfecta and Ehlers-Danlos Syndrome.3 4 A key
underlying problem in these typically autosomal dominant disorders is the failure of the ER's
proteostasis network to properly fold and/or subject misfolding collagen-I variants to quality
control.5 Understanding the mechanisms of collagen-I proteostasis in the ER is therefore
essential not just for our basic understanding of collagen biogenesis, but also for the long-term
development of therapies for the collagenopathies.
The process of folding and secreting collagen-I is highly complex. Collagen-I triple
helices are 2:1 heterotrimers of collagen-al(l):collagen-a2() strands. Both this stoichiometry
and the overall triple-helix register are governed by nucleation at the globular disulfide-linked C-
terminal propeptide domain6 (see Chapter 2 for progress towards understanding this process).
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Consequently, nascent >1200 amino acid collagen-I polypeptide strands must remain in a
monomeric, unfolded form until their C-termini enter the ER, fold into native disulfide-bonded
globular states, and properly associate. Extensive co- and post-translational modifications,
including glycosylation and hydroxylation, must also be completed prior to triple-helix folding.7
During triple-helix formation, peptidyl prolyl isomerases (PPlases) act to ensure the hundreds of
prolyl peptide bonds are in the trans configuration required in folded triple helices."
In contrast to the marked complexity of collagen-I production, our knowledge of the
proteostasis mechanisms that assist the process remains incomplete. Many of the known
players were discovered as a result of either their relative abundance in collagen-producing
cells (e.g., HSP47)9 or via the identification of a genetic defect that causes a collagenopathy
(e.g., CRTAP, FKBP10).10 ," Despite these seminal discoveries, many questions still remain. For
example, although the N-linked glycan is highly conserved across the various types of fibrillar
collagen as well as across species, its function and the roles of the extensive lectin-based ER
chaperone and quality control machineries in collagen-I folding are poorly understood.
Additionally, proteins responsible for surveying nascent collagen-I structure and directing
misfolding or aggregating strands to clearance or unfolding/refolding mechanisms remain
unknown. Beyond recognition of a misfolded triple helix, the method by which collagen is
degraded has not been fully elucidated.
A detailed, well-validated map of the collagen-I proteostasis network is essential to
begin to answer these and many other questions regarding collagen-I biogenesis. Unfortunately,
appropriate reagents and cell culture model systems for molecular biology, genetics, and
proteomics experiments on full-length collagen-I are either unavailable or unwieldy. A further
complication is the lack of immunoprecipitation/mass spectrometry (IP/MS)-grade collagen-I
antibodies, precluding systematic, proteomics-based characterization of the collagen-I
proteostasis network.
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Herein, I describe the development and application of an HT-1080 human cell-based
platform for collagen-I studies that overcomes these challenges. Extensive characterization of
the collagen-I produced confirms that native collagen-I folding and modification are faithfully
recapitulated in our platform. We illustrate the value of the platform by performing quantitative,
comparative proteomics characterization of the collagen-I interactome under biologically
relevant experimental conditions. Biochemical studies validate the roles of identified novel
interactome components in collagen-I production, and lead to the discovery of a novel collagen-I
post-translational modification. Further mechanistic work delineates a role for the prominent, but
largely unannotated, endoplasmic reticulum protein 29 (Erp29) in collagen-I quality control.
Altogether, these applications of our platform yield both new insights and a compelling roadmap
for continued studies of the mechanisms of production of this important extracellular matrix
protein that is intimately associated with both normal and diseased states.
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3.3 Results
3.3.1 Vector Construction
We sought to create a robust and experimentally flexible platform for biochemical studies of
collagen-I folding and misfolding that would allow us to (1) readily distinguish between
distinctive procollagen-I (referred to throughout as "collagen-I") strands and (2) perform robust
and reliable IPs of intracellular collagen-I to enable accurate mapping of its proteostasis network.
We began by cloning both the COLIAI and COL1A2 genes into pTRE-Tight vectors for
doxycycline (dox)-dependent control of gene transcription. Because collagen-I folding begins at
the C-terminus,6 we incorporated a short (<10 amino acid) antibody epitope tag at the amino-
terminus of collagen-l's N-propeptide domain. We rationalized that this location was unlikely to
disrupt collagen-I folding or structure because it is the final domain to fold. We used the HA
epitope and the FLAG epitope for wild-type collagen-al(I) and collagen-a2(l), respectively, to
facilitate individual strand isolation and identification (Figure 3.1A).
Vector construction using the GC-rich collagen-I genes proved exceptionally
challenging. Each collagen-I gene has about 65% GC-content overall, and local regions of each
gene contain 85% GC content within a 50 base-pair span. The high local GC-content made
PCR amplification of the collagen-I genes difficult, resulting in yields lower than expected and
many small PCR fragments, likely due to incomplete synthesis of the genes. The yield of the
full-length collagen-I genes was slightly boosted by increasing the final extension time by about
1.25 fold. Furthermore, each collagen-I gene is over 4000 base pairs in length, more than
double the size of the pTRE-Tight expression vector, requiring an altered molar ratio when
ligating the two linear pieces of DNA. Even with modified ratios, the most common ligation
product observed was the pTRE-Tight vector ends being ligated together, despite the use of
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incompatible Notl and EcoRV restriction enzymes to digest the vector. Sequencing confirmed
that, in a rare event, the sticky end of the Notl site was destroyed, leaving a blunt end of DNA
that ligated to the EcoRV blunt end. This rare intramolecular ligation was more favorable and
occurred more frequently than insertion of the collagen-I genes. To avoid this problem, de-
phosphorylation of the vector backbone with Antarctic phosphatase prior to ligating the two
pieces of DNA was essential for successful insertion of the collagen genes.
We ultimately succeeded in ligating pTRE-Tight and the collagen-I PCR amplicons,
confirmed by sequencing the resulting clones with a primer that binds to the vector, providing
evidence for the presence of both the 5'-and the 3'-ends of the collagen-I genes. Unfortunately,
in the case of Co/IAI, sequencing of the full gene confirmed that a recombination event
occurred, effectively removing > 1000 base pairs of the gene. To circumvent the propensity to
recombine the CollAl gene, we thereafter transformed all Co/IAI-containing vectors into
recombination deficient Sure2 E.coli cells. When grown at 30* C, recombination was effectively
shut down in these cells, finally allowing for the synthesis and propagation of intact collagen-I
genes.
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3.3.2 Inducible Expression of Orthogonally Tagged Collagen-I Strands in Human Cells
We next identified an appropriate cell line for heterologous expression of these collagen-I genes.
HT-1 080 fibrosarcoma cells secrete non-fibrillar collagen-IV, suggesting that they are capable of
properly handling collagen-I without producing confounding endogenous forms of the protein.
Indeed, HT-1080 cells were previously shown to permit the expression and secretion of
thermostable, hydroxylated collagen-a1 (1) homotrimers,15 although native collagen-
a1(l):collagen-a2(1) heterotrimer-producing cells have not been reported. We transfected HT-
1080 Tet-Off cells that constitutively express the tetracycline transactivator with our wild-type
HA-collagen-al (I)- or FLAG-collagen-a2(i)-encoding pTRE-Tight vectors, selected for stable
incorporation of the genes, and isolated genetically homogenous single colonies to analyze for
collagen-I expression and secretion. Expression of the tetracycline transactivator allows for
doxycycline (dox)-inducible expression of the collagen-I genes of interest. We optimized
HT1080 culture conditions by varying the concentration of dox for 48 h, and then split each
concentration into two conditions: continued culture in the same concentration of dox, or no dox
in tet-free FBS containing media. Figure 3.1B demonstrates that 1 ng/mL dox, 1000-fold lower
than the recommended concentration, efficiently suppresses both collagen-I genes, and
removal of the dox-containing media and replacement with dox-free media induces both genes,
and the resultant proteins are secreted into the media.
As previously observed,15 genetically homogeneous single colony cell lines inducibly
expressing collagen-I proved difficult to obtain in the HT1080 cells. After screening over 24
colonies for expression of either Cola1 (1) or Cola2(1), we were eventually able to identify unique
cell lines that displayed significant lysate and secreted levels of either protein (Figure 3.1C). We
note that the complex banding patterns we observe are common for collagen-I owing to
extensive proteolytic processing and post-translational modificatoins (for example, see
immunoblots of native collagen-a2(l) secreted from primary fibroblasts in Figure 3.4B below).
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Native collagen-I is a heterotrimer of collagen-a1 (I) and collagen-a2(l). Therefore, with
cell lines inducibly expressing either wild-type collagen-al (1) or collagen-a2(l) in hand, we next
transfected the FLAG-collagen-a2(l) expressing cells with the corresponding inducible HA-
collagen-al(I) plasmid, and again selected single colonies. Ultimately, we identified a cell line,
termed HT-1080coI-I cells, that inducibly expresses moderate levels of both collagen-al(l) and
collagen-a2(1) observable in the lysate and media using their respective antibody epitope tags
(Figure 3.2A). We observe no apparent activation of unfolded protein response-regulated
genes16 in HT-1080co'-' cells upon collagen-I induction (Figure 3.2B with primers from Table
3.1), indicating that collagen-I expression at these levels in HT-1080 cells does not cause ER
stress.
To ensure that the collagen-I is trafficking properly through HT-1080col-1 cells, we
employed confocal microscopy. We observe strong co-localization of collagen-I with ER
markers (Rmean = 0.45 0.12), as well as partial co-localization with Golgi (Rmean = 0.22 0.06)
and lysosomal markers (Rmean = 0.19 0.05) (Figure 3.2C) in the absence of ascorbate (ER-
retention conditions), consistent with previous studies.1 7 We assessed collagen-I secretion
kinetics using metabolic labeling and found that the majority of the collagen-I is secreted in < 3 h
with minimal degradation, recapitulating endogenous collagen-I secretion kinetics in primary
fibroblasts18 (Figures 3.2D and 3.2E) and further confirming that the HT-1 080 cells are properly
handling our collagen-I constructs.
Although beyond the scope of the work outlined in this chapter, one of our goals is to
map the proteostasis network for disease variants of collagen, and compare the results to the
wild type counter part. The work outlined here is aimed at establishing the wild type proteostasis
network, as a benchmark for future work on the disease variants. Mutations to collagen-I genes
cause an autosomal dominant form of osteogenesis imperfecta, an incurable brittle bone
disease. Therefore, a cell-based platform for studying 01 requires the cell line to synthesize wild
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type Colal (1) and Cola2(), in addition to the 01-variant of interest. We were able to express c-
Myc tagged Cys1299Trp Colal(1)' 9 in the HT-1080coiI- cells using replication incompetent
adenovirus, thereby creating an autosomal dominant model system for studying 01 with each
collagen strand differentially tagged (Figure 3.3). This work is ongoing in the lab, and the
remainder of this chapter will focus solely on the HT-1 0 8 0 col-' cells.
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Figure 3.1 1 Dox-inducibility of the collagen-I genes
(A) Schematic of collagen-1 expression constructs. (B) Experimental timeline for dox treatments
on collagen-1 producing cells. Secretion analysis of Cola1(I) and Cola2(l) under varied dox
concentrations, after two days of treatment. (C) Immunoblotting analysis of inducible HA-
collagen-al(l) or FLAG-collagen-a2(l) levels in the lysates and media of HT-1080 cells
expressing either construct.
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Figure 3.2 1 Expression of Orthogonally Tagged Collagen-I Strands in HT-1080 Cells
(A) Immunoblotting analysis of inducible HA-collagen-al(I) and FLAG-collagen-a2(l) levels in
the lysate and media of HT-1080coII cells expressing both constructs. (B) qPCR analysis of
unfolded protein response-regulated genes in HT-1080coI cells upon induction of collagen-I
expression. Tunicamycin (Tm; 5 pg/mL, 12 h)- and thapsigargin (Tg; 1 pM, 12 h)-mediated
unfolded protein response activation are shown as positive controls. qPCR data are reported
relative to untreated HT-1080 cells as the mean 95% confidence interval. (C) Confocal
microscopy imaging of collagen-I trafficking in HT-1 0 80 co1- cells under ER-retention conditions.
PDI is an ER marker, LAMP1 is an early lysosome marker, GM130 is a Golgi marker, and
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DRAQ5 is a nuclear marker. (D) Representative autoradiograms of [3 5S]-labeled HA-collagen-
al(l) immunoisolated from HT-1080coi-1 media and lysates following induction of collagen-I
expression. Control media and lysate were harvested from uninduced HT-1080coII cells. (E)
Quantification of autoradiograms in Figure 2.1D. Collagen-I % remaining was calculated by
normalizing the secreted and lysate collagen-I signals at the stated times to the total amount of
labeled collagen-I observed at time = 0 h. Collagen-I % secreted was calculated by normalizing
the secreted collagen-I signal to the total amount of collagen-I present at time = 0 h. Error bars
represent SEM from biological replicates (n = 3).
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Table 3.1. Compilation of primers for qPCR used in Figure 3.2 and Figure 3.10.
Forward Reverse
5'-CCATTCAGCTCACTGATAACCTT-3' 5'-CGTCGCCTCCTACCTGCT-3'
Transcript
RPLP2
COLIAI
(triple helix)
COLIA2
(triple helix)
COL IAI1
(C-propeptide)
COLIA2
(C-propeptide)
CHOP
BiP
Erdj4
ANXA2
ASPH
CKAP4
CRTAP
DNAJBI I
EROIL
ERP29
P4HB
RCN1
SERPINHI
SPARC
TGM2
GOLIM4
CALU
PRKCSH
5'-TGGTAGCCGTGGTTTCCCTG-3'
5'-TGGCTCGAGAGGTGAACGTG-3'
5'-GCAACAGCCGCTTCACCTAC-3'
5'-TCGCTCAGCACCTTCTCTCAG-3'
5'-GGAGCTGGAAGCCTGGTATG-3'
5'-GCCTGTATTTCTAGACCTGCC-3'
5'-GGAAGGAGGAGCGCTAGGTC-3'
5'-CCTTATCTGGCCACCTGGAG-3'
5'-GGTTCCTGTGGAGGCAGAAC-3'
5'-ACGTGGAGGAGCTGAAGAGG-3'
5'-TCCGGTTGAGAAATTTGTGG-3'
5'-GAACCCCTCGTCAGCAAGAC-3'
5'-AAGAGGCCGTGTCCTTTCTG-3'
5'-CTTCCCCTGGATACGGTCAC-3'
5'-AAATCAAGCCCCACCTGATG-3'
5'-CCACTGGATCCTCCCTCAAG-3'
5'-CAGCCTCATCATCCTCATGC-3'
5'-AGAAGCTGCGGGTGAAGAAG-3'
5'-TGGCATGGTCAACTGCAACG-3'
5'-AACGAGAAGCAGCCAACCTC-3'
5'-TTATGTGCCTGTCCCTGTGC-3'
5'-CGACTGCAAAGATGGCTCTG-3'
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5'-TCCAGTCAGACCCTTGGCAC-3'
5'-AGCACCGTTGACTCCAGGAC-3'
5'-AGCCGAATTCCTGGTCTGGG-3'
5'-TGGGTGGCTGAGTCTCAAGTC-3'
5'-GCCAGAGAAGCAGGGTCAAG-3'
5'-TTCATCTTGCCAGCCAGTTG-3'
5'-ATCCTGCACCCTCCGACTAC-3'
5'-GCTCCTGGTTGGTTCTGGAG-3'
5'-GGTTCTCCTGTGGGTCCATC-3'
5'-AAGTCCTGAGGAGGCAGACG-3'
5'-GGTTCTGCTGCATGACCTTG-3'
5'-TCTCTTGCCGACAATTGCAC-3'
5'-TCCACTGCTCCAAGTCGTTC-3'
5'-CTGCCACCAAGAGATCATCG-3'
5'-TATCCCAAATGGGAGCCAAC-3'
5'-CCCCGTAATTGGTAGCTTGG-3'
5'-TTCTGCAGGTCATGGGTCAC-3'
5'-GGAGAGGTACCCGTCAATGG-3'
5'-GCACTGGCCATACTTGACGC-3'
5'-GCAAAGCTTCCTGGTGTTCC-3'
5'-TTGCTTCTTCAGCACCCAAG-3'
5'-GCCGCTGTTGTACTCGTCTG-3'
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Figure 3.3 I Expression of Cys1299Trp in the HT1080c'-' Cells
Cells were transduced with replication-incompetent human adenovirus-V carrying a
constitutively expressed Colal(l) Cys1299Trp full length collagen-I gene tagged with c-myc
epitope tag. Each protein was differentially identified by the corresponding epitope tags. The
results shown are immunoblot analysis of secreted media, demonstrating our ability to make an
01-like, autosomal dominant mimicking cell line.
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3.3.3 Molecular Properties of Collagen-I Produced by H T- 10 8 0 co"-I Cells
We next asked whether the collagen-I produced by HT-1080coI- cells displays the expected
molecular properties of endogenous collagen-1. We first tested for a direct intracellular
interaction between the collagen-al (1) and collagen-a2(l) polypeptides. We observe that an IP
of collagen-al (1) using HA-antibody beads co-IPs collagen-a2(l), and also that the reverse is
true when using FLAG-antibody beads (Figure 3.4A). These results confirm the heteromeric
assembly of collagen-al (I) and collagen-a2(1) strands produced by HT-1080co1 cells.
The triple-helical domain of properly folded, extracellular collagen-I is resistant to
proteases such as trypsin and chymotrypsin, 20 whereas poorly folded collagen-I is highly
sensitive to proteolytic digestion. Indeed, we observe that collagen-I secreted from primary
dermal fibroblasts that endogenously secrete the protein displays only a small shift in molecular
weight upon protease treatment (Figure 3.4B), consistent with propeptide sensitivity and triple-
helical resistance. Collagen-I secreted from HT-1080col-I cells displays an identical pattern upon
protease digestion (Figures 3.4B), confirming that the collagen-I produced is folded into a
stable triple helix.
Another key modification of collagen-I is N-glycosylation within the C-propeptide of
collagen-I. Although the biological function of this conserved N-glycan remains unclear,2 1 it is
likely to enable interactions with the important lectin-based components of the ER proteostasis
network. To test whether the collagen-I produced by our HT-1 0 80coi- cells is N-glycosylated, we
immunoprecipitated collagen-al(l) and treated half of the eluate with PNGase-F, an
endoglycosidase that hydrolytically cleaves N-glycans. The treated and untreated samples were
separated by SDS-PAGE and the subsequent immunoblot was probed with concanavalin A
(ConA), a lectin that recognizes N-glycans. In the absence of PNGase-F treatment, we observe
a ConA signal that overlaps with the signal for collagen-al (I), while treatment with PNGase-F
eliminates ConA reactivity, confirming that the collagen-I produced by our HT-1080col- cells is
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indeed N-glycosylated (Figure 3.4C).
Native collagen-I undergoes other essential co- and post-translational modifications
beyond just N-glycosylation during its folding and maturation in the ER.7 Most important among
these are the 4R-hydroxylation of Yaa-position Pro residues in the Gly-Xaa-Yaa repeats of the
triple-helical domain,' 3S-hydroxylation of Xaa-position Pro residues, and Lys hydroxylation.7
To quantify the extent of collagen-I hydroxylation in HT-1 0 8 0 coi cells, we used the stable
isotope labeling by amino acids in cell culture (SILAC) technique23 to generate light, medium,
and heavy Lys- and Arg-labeled HT-1 0 8 0col- cells. Because ascorbate is an essential
hydroxylase cofactor,2 we induced collagen-I expression in the medium-labeled cells by
removing dox without ascorbate (ER-retention conditions25) and in the heavy-labeled cells by
removing dox with added ascorbate (secretion-promoting conditions), using the light cells as a
control that expresses collagen-I lacking an HA tag. After IP of intracellular collagen-a1 (1) using
HA-antibody beads, MS analyses showed that any given hydroxylated collagen-I peptide is
much more abundant in the ascorbate-treated sample, while non- or minimally-hydroxylated
collagen-I peptides are relatively more abundant in the absence of ascorbate (Figure 3.5A
presents representative data). As expected for an analysis of intracellular collagen-, we
observe a wide range of hydroxylation states for any given collagen-I peptide, ranging from no
hydroxylation to apparently complete hydroxylation of Yaa-position Pro residues. None of the
observed peptides ever display a larger number of hydroxylation events than should be possible
based on the total number of Yaa-position Pro residues and Lys residues in a given peptide.
Most notably, Pro986 in collagen-a1 (1) and Pro707 in collagen-a2(l) are the only two Xaa-
position Pro residues where 3S-hydroxylation is known to occur in native collagen-. We
observe both of these hydroxylation events in our MS analyses and the hydroxylation is again
ascorbate-dependent, as expected (Figures 3.5B and 3.5C for MS2 scans). These results
demonstrate that collagen-I produced by HT-1080coli- cells displays the known hydroxylation
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patterns of endogenous collagen-1.
Cumulatively, the data in Figures 3.4 and 3.5 indicate that our HT-1080col-' cells
produce heteromeric, proteolytically stable, and properly modified collagen-1, faithfully
recapitulating key molecular properties of the native protein. These findings strongly motivate
the application of HT-1080col- cells as a convenient platform both for mapping the collagen-I
proteostasis network and for more detailed mechanistic biochemistry studies.
120
ACola1 (1) IP Cola2(l) IP
ctrl exp ctrl exp
a-HA I a-FLAG
(Cola1(0))L (Cola2(l))
a-FLAG a-HA
(Cola2()) (Cola1 (1))
C
cell line: ctrl
PNGase-F: - +
ConA
a-HA
(Cola1 (1))
Merge
HT1 080cO
- +
B Primary Fibroblasts HT1 080co
trypsin: - + - - + -
chymotrypsin: - - + - - +
-
a-collagen-I
4U
a-Cola2(1)
Figure 3.4 | Molecular Properties of Collagen-I Produced by HT-1080'co' Cells
(A) Collagen-a2(l) co-IPs with collagen-al(I) and vice versa, demonstrating their intracellular
association. The control sample represents HT-1 080 cells that do not express HA/FLAG-tagged
collagen-I upon induction. (B) Trypsin and chymotrypsin digests of collagen-I secreted from
primary fibroblasts and HT-1080coI-1 cells demonstrate the presence of a stable, protease-
resistant triple helix. (C) Analysis of the N-glycosylation of intracellular HA-tagged collagen-al (1)
immunoprecipitates. In the absence of PNGase-F treatment, HA-antibody reactivity overlaps
with ConA reactivity, while treatment with PNGase-F eliminates ConA reactivity. The control
sample represents HT-1 080 cells that do not express HA-tagged collagen-I upon induction.
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Figure 3.5 1 Hydroxylation of Collagen-I Produced by HT-1080co'i Cells
(A) MS1 scans showing the enrichment of the hydroxylated peptide in the heavy (ascorbate-
treated) sample, and enhanced abundance of the unmodified peptide in the medium (ascorbate-
deficient) sample. (B) MS1 scans showing that Xaa-position Pro residues 986 in collagen-al (1)
and 707 in collagen-a2() (numbering beginning at the first Gly-Xaa-Yaa repeat) are
hydroxylated in HT-1080co" cells. (C) Top Panel: MS2 data showing hydroxylation on proline
986 of collagen-al(l) upon ascorbate treatment of collagen-I expression induced HT-1080coi
cells. The internal fragment labeled as PlGP*-28 and Y6 together provide clear evidence for the
Xaa-position Pro being hydroxylated. Bottom Panel: MS2 data showing hydroxylation on
proline 707 of collagen-a2(l) upon ascorbate treatment of collagen-I expression induced HT-
10 80co'I cells. The a6 peak provides clear evidence for the Xaa-position Pro being hydroxylated.
For both spectra, numbering of amino acids begin at the first Gly-Xaa-Yaa repeat. Asterisks (*)
indicate the site of modification. In the case of prolyl modification, the * indicates hydroxylation.
In the case of cysteine modification, the * indicates alkylation during the mass spectrometry
workflow to prevent re-oxidation of cysteines. For labeling of spectra, the b-ion is termed a
fragment of the parent ion, originating at the N-terminus of the parent peptide, and extending the
number of amino acids into the peptide indicated. y-lons are the same, but originating at the C-
terminus of the peptide. An a-ion is a b-ion that has lost a carboxyl group during the
fragmentation. For clarity, not all y and b ions are labeled on the peptide sequence, but all ions
identified are labeled in each spectrum.
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3.3.4 Covalent Crosslinking for Robust Co-Immunoprecipitation of the Collagen-I Proteostasis
Network
We found that we can reliably IP collagen-al (I) using HA-antibody beads or collagen-a2(l)
using FLAG-antibody beads (Figure 3.4A). However, a pilot MS study of the co-
immunoprecipitated interactome identified a very limited suite of interactors (Figure 3.SA). The
failure to observe even well-established components of the collagen-I proteostasis network,
including the lysyl hydroxylases and the PPlases, suggested to us that most proteostasis
network interactions with collagen-I are too transient to be maintained during a traditional IP, as
has also been observed for other ER proteostasis network client proteins.26,27
To overcome this obstacle, we immortalized interactions with collagen-I in live HT-
10 8 0 co'I cells by incubating with the cell-permeable, lysine-reactive, and reversible crosslinker
dithiobis(succinimidyl propionate) 28 (DSP; Figure 3.6B). Collagen-al(l) displays 57 lysine
residues distributed along the length of the protein, so it is in principle possible to identify
interactors that engage each collagen-I domain using this crosslinking strategy. We found that a
30 min treatment with 200 pM DSP followed by rapid quenching with Tris buffer is optimal to
stably co-IP known, well-established collagen-I proteostasis network components (Figures 3.6C
and 3.6D) that are not otherwise observable via traditional IP workflows.
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Figure 3.6 | Covalent Crosslinking to Enable Robust Co-Immunoprecipitation of the
Collagen-I Proteostasis Network
(A) LC-MS/MS-mediated analysis of the stable collagen-I interactome in the absence of
covalent crosslinker. The control sample represents HT-1080 cells that do not express HA-
tagged collagen-I upon induction. (B) Structure of the covalent crosslinker employed,
dithiobis(succinimidyl propionate) (DSP). (C) Optimization of crosslinking conditions for robust
co-IP of the collagen-I interactome using HA-antibody beads. The control sample represents
HT-1080 cells that do not express HA-tagged collagen-I upon induction. (D) Immunoblot
showing the ability to co-IP an array of known components of the collagen-I proteostasis
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network using the covalent crosslinking protocol, compared to HT-1080coI-1 cells that produce
collagen-I that is not HA-tagged.
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3.3.5 Quantitative Proteomic Mapping of the Collagen-I Proteostasis Network
Having demonstrated that well-established collagen-I interactions can be identified by
immunoblotting after covalent crosslinking, we shifted to a quantitative MS proteomics approach
to enable unbiased mapping of the collagen-I proteostasis network. Using the light, medium,
and heavy SILAC-labeled HT-1080coI- cells described above, we induced collagen-I expression,
performed covalent crosslinking with DSP, and then used HA-antibody beads to IP collagen-
al (1) and its interactors in biological triplicate (Figure 3.7). The light-labeled negative control
HT-1080 cells inducibly expressed collagen-I lacking the HA epitope. The medium- and heavy-
labeled HT-1 080coii cells (both expressing HA-tagged collagen-al (I)) were treated without or
with ascorbate, creating ER-retention and secretion-promoting conditions, respectively.
Ascorbate is an essential co-factor for the hydroxylases required for proper collagen-I
biogenesis.24 Therefore, we hypothesized that comparing the collagen-I interactome in the
presence or absence of ascorbate would provide insight into proteostasis network components
that differentially engage collagen-I under ER-retention versus secretion-promoting conditions.
After elution from stringently washed antibody beads, samples were further processed and
tryptic peptides were injected on a Thermo QExactive LC-MS/MS. Peptides were then identified
and quantified using the Mascot Database and Proteome Discoverer.29
One salient feature of the MS data collected was the sheer abundance of the bait protein,
HA-tagged Colal (I) and its counterpart, Cola2(1). Collagen peptides accounted for 75-85% of
the total peptides observed in a given run. While desirable for the bait protein to be the most
abundant protein identified, thus indicating the efficiency of the IP, the size of collagen and total
number of tryptic peptides generated by digestion dominated the signal detected by mass
spectrometry, minimizing the signal from the interacting proteins. Therefore, prior to digestion,
the IP-eluate was filtered through a 100-kDa molecular weight cutoff filter to remove the
collagen-I protein. The solution that passed through the filter was then digested and analyzed by
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MS. It is likely that filtering the elutions through a 100-kDa molecular weight cut off filter would
preclude us from detecting interacting proteins larger than 100 kDa. We chose the risk of not
detecting very high molecular weight interactors, as most proteostasis network components of
the secretory pathway are smaller than 100 kDa.
Filtration did not completely extract collagen-I from the sample, as 60% of the peptides
identified by this workflow in the heavy and medium samples correspond to either collagen-a1 (1)
or collagen-a2(l). The presence of collagen-I peptides in the flow through sample is likely due to
the presence of reducing and denaturing agents as a method of elution from the beads.
Although still larger than 100 kDa, the collagen-I monomers likely pass through the membrane
more readily in a reduced and denatured state. However the increased depth of coverage
proved sufficient to identify a more comprehensive collagen-I interactome. Further optimization
of the elution and filtration technique could further illuminate less abundant collagen-I
interactions.
Overall, a total of 171 proteins were identified across all samples, and 91 of those
proteins were quantified with heavy:light and/or medium:light ratios. In Table 3.2, we present
the results for all high-confidence interactors defined by meeting the following additional criteria:
(1) 2 2 unique peptides identified in 2 2 biological replicates and (2) an average enrichment in
either the heavy or medium sample 2 2-fold relative to the light control sample (or complete
absence from the light sample). We categorize these high-confidence components of the
collagen-I interactome based on their expected functions in the ER, grouping complexes where
appropriate, and rank the proteins within each category based on their relative enrichment in the
heavy-labeled (ascorbate-treated) sample.
The result is the first map of the collagen-I proteostasis network (Table 3.2 and Figure
3.8A), comprising a total of 48 proteins and encompassing interactors with previously unknown,
poorly characterized, and already well-characterized roles in collagen-I maturation. Importantly,
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several features of the data support that our workflow identifies the bona fide collagen-1
interactome. First, we note that >80% of the interactors are unequivocally localized to the
secretory pathway (Figure 3.8B), where collagen-I is targeted for folding and modification.
Although interactors that are not localized to the secretory pathway may be artifacts,
considering the overall reliability of our data set (further verified below) it is also possible that
annotations are incomplete or that these interactors engage collagen-I that has been
transported from the ER for quality control purposes. Second, we are only identifying a small
percentage of the known ER proteome, indicating that we are maintaining high specificity for
actual collagen-I interactors. Third, of the 48 proteins identified, approximately 30% already
have well-characterized roles in collagen-I maturation. Indeed, we successfully identified all the
most prominent known players in collagen-I proteostasis, particularly notable in the collagen-
specific chaperones, PPlase, and collagen modification groups (Table 3.2 and Figure 3.8A).
Two well-established collagen-I chaperones, HSP479 and PPIB, 3 are the most highly enriched
of all the proteins identified. We also identify FKBP10, an ER PPlase whose absence causes
autosomal recessive osteogenesis imperfecta. The robust enrichment of these known
collagen-I proteostasis network components enhances our confidence in the entirety of the
dataset. Of the 34 remaining high-confidence proteins in our interactome, 29 putative interactors
have, to the best of our knowledge, ill-defined or previously unknown roles in collagen-I
proteostasis (indicated by "*" in Table 3.2). The other five interactors have been implicated in
collagen-I proteostasis-related functions, although mechanistic characterization remains
incomplete.
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Figure 3.7 j Mass spectrometry workflow
(A) Schematic representation of mass spectrometry workflow employed. Collagen was eluted
from the antibody beads, and applied to a 100 kDa cut off filter. The low molecular weight
fraction was trypsinized and analyzed by mass spectrometry.
130
A Collagen-I Proteostasis Network Map
Modifications PDIA4 PDIA6 Disulfide/Redox
LH2 LH3 GTD1PA4PA6 Ero1 L.
PDIA3 Erp29 // -fLHI P4Ha1/2-- PDIA3 Erp46
P3H3 ASPH PDI Erp44 PRDXI/4
P3H
Collagen-Specific
HSP47
CRTAP
HSP4O/70/90
PPlass PPIB Grp94 BiP,--
FKBP10 ERDJ3
FKBP9 Collagen-al (1)
HYOU1
RCN1
Calu Cola2(1)
CaluCola1((11)
Calcium Binding Collagen
FN C~AnxA2 CNPY2 ar'UGGT1
CKAP4Golim4
SPARC - - - - - - -TGM2 Gl'--GANAB
Secretory Pathway/Diverse Function N-Glycosylation
B
Unknown/
Other
Secretory
Pathway
Proteins
Figure 3.8 j Map of the Collagen-I Proteostasis Network
(A) Interactomics map of the collagen-I proteostasis network (illustrated by solid black lines) and
respective complex components known to interact with each other (illustrated by dotted black
lines). (B) Pie chart showing enrichment of secretory pathway proteins in the collagen-I
interactome.
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Table 3.2. Mass Spectrometry-Based Mapping of the Collagen-I Proteostasis Network in the
Presence or Absence of Ascorbate
Protein (Common Name) Gene Name Asc Fold- - Asc Fold- UniqueProei (Cmmn ame GneEnrichmenta Enrichment Peptides
Collagen-Specific Chaperones
Heat shock protein 47 (HSP47) SERPINH1 30.5 37.6 4
Peptidyl Prolyl Isomerases
Peptidyl-prolyl cis-trans isomerase B PP/B 41.2 22.0 9(CyPB)
Peptidyl-prolyl cis-trans isomerase FKBPIO 4.0 1.4 2FKBP65
Peptidyl-prolyl cis-trans isomerase FKBP9 2.4 1.7 2FKBP9*
Co- and Post-Translational Collagen ModificationsIProtein disulfide isom rase (PDI) P4HB 19.4 29.3 7
Prolyl-4-hydroxylase-al P4HAI 9.0 14.9 5
Prolyl-4-hydroxylase-a2 P4HA2 4.5 7.0 2
Procollagen galactosyltransferase 1 COLGALTI 14.0 8.5 3(GLT251)
Peptidyl-prolyl cis-trans isomerase B PP/B 41.2 22.0 9(CyPB)
Cartilage-associated protein (CRTAP) CRTAP 13.2 23.5 4
Prolyl-3-hydroxylase 1 (P3H1) LEPREI 7.9 14.6 3
Aspartyl-asparaginyl beta hydroxylase*' ASPH 7.4 9.4 2
Prolyl-3-hydroxylase 3 (P3H3) LEPREL2 4.8 9.4 3
Procollagen-lysine, 2-oxoglutarate 5- PLOD3 4.3 8.8 2dioxygenase 3 (LH3)
Procollagen-lysine, 2-oxoglutarate 5- PLOD2 2.3 2.4 2dioxygenase 2 (LH2)
Procollagen-lysine, 2-oxoglutarate 5- PLOD1 2.0 5.3 3dioxygenase 1 (LH1)
Disulfide Bond Formation / Shuffling and Cellular Redox Chemistry
Protein disulfide isomerase (PDI) P4HB 19.4 29.3 7
Thioredoxin domain-containing protein 5 TXNDC5 8.4 13.5 3(Erp46)*
Protein disulfide isomerase A4 (Erp72)* PDIA4 8.2 15.4 3
Protein disulfide isomerase A3 (Erp57)* PDIA3 7.4 14.3 10
Endoplasmic reticulum protein 29* ERP29 4.8 8.3 2
ERO1-like protein-ac ERO1L 4.3 6.6 2
Protein disulfide isomerase A6 (Erp5)* PD/A6 4.1 8.3 5
Peroxiredoxin-1 or peroxiredoxin-4 (PAG PRDXI or 0.8 2.9 3
or Prx-IV)* PRDX4
Endoplasmic reticulum resident protein- ERP44 0.2 2.0 3
44 ,ER40.2.3
Hsp40/70/90
BiP (Grp78) HSPA5 13.6 22.9 20
Endoplasmin (Grp94)* HSP90BI 4.4 6.4 11
Hypoxia up-regulated protein 1*"D HYOUI 2.2 6.1 3
DnaJ homolog subfamily B member 11 DNAJB11 2.0 2.6 3
(Erdj3)*
Glucosidase-2 P subunit (GI\ Neutral alpha-glucosidase A
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N-Glycosylation and Lectin-Assisted Folding
1)* PRKCSH 6.9
B* GANAB 2.8
7.2
2.9
4
3
UDP-glucose:glycoprotein
glucosyltransferase 1
Calreticulin*
UGGTI
CALR
4.1
3.4
6.9
5.5
3
4
Calcium Binding
Calumenin* CALU 20.4 25.3 5
Reticulocalbin-1* RCNI 7.5 8.1 2
Secretory Pathway-Localized/ Diverse Functions
Golgi integral membrane protein 4
(Golim-4/GPP130)*,C GOLIM4 14.3 19.0 2
Protein canopy homolog 2* CNPY2 12.6 17.9 3
Cytoskeleton-associated protein 4* CKAP4 11.5 11.1 5
Secreted protein acidic and rich in SPARC 9.8 5.3 2cysteine (SPARC)
Annexin A2* ANXA2 6.7 0.9 2
Fibronectin FN1 5.2 4.5 9
Protein-glutamine gamma- TGM2 2.0 1.6 10glutamyltransferase 2*
Collagen
Collagen a-1(11) COL2AI 5.3 1.5 3
Collagen a-2(l) COL1A2 2.6 .5.4 55
Not Known to be Secretory Pathway-Localized
ATP synthase subunit a, mitochondrial* A TP5A1 4.6 0.5 3
Major vault protein (MVP)* MVP 2.6 1.9 19
Heat shock protein HSP 90-s* HSP90AB1 2.5 0.4 4
Poly[ADP-ribose] polymerase 4* PARP4 2.3 1.1 4
40S ribosomal protein S3* RPS3 2.3 1.3 2
40S ribosomal protein SA* RPSA 0.4 20.1 2
aAll protein quantifications calculated for proteins with > 2-fold enrichment across at least two biological
replicates with at least two unique peptides used to positively identify the protein, unless otherwise noted.
bPeptides corresponding to this protein were identified in all three replicates, but could not be quantified in
all replicates owing to the control (light) peptide levels falling below the limit of detection.
cPeptides corresponding to this protein were identified in two replicates, but could not be quantified in
both replicates owing to the control (light) peptide levels falling below the limit of detection.
Note: Blue lines along the left-hand side of the chart denote complexes. Some proteins are repeated
throughout the table due to multiple subgroup classifications or to indicate a complex. Asterisk (*)
represents proteins with ill-defined or previously unknown roles in collagen-I proteostasis.
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3.3.6 Establishing new roles for putative interactions
Prior to our MS studies, we established an efficient protocol for ensuring well-known collagen-I
proteostasis network components co-IP with the HA-collagen-al(l) (see Figures 3.6C and
3.6D). To ensure that the other -35 proteins with ill-defined roles in collagen-I proteostasis that
we identified were not artifacts, we performed the same co-IP/immunoblot analysis on a panel of
the new putative interactors. Of the ten new interactors tested, we observe robust, immunoblot-
detectable co-IP of nine: Erp44, Golim-4, reticulocalbin-1, protein disulfide isomerase-3 (PDIA3),
protein disulfide isomerase-4 (PDIA4), Erdj3, HYOU1, Erp29, and ER oxidase-like protein 1
(ErolL) (Figure 3.9A). Calumenin was the only tested interactor that could not be positively
identified, possibly because the calumenin protein runs at the same location as the HA-antibody
light chain on an SDS-PAGE gel, rendering detection difficult as both our HA antibody and the
calumenin primary antibody were produced in mice.
Although the HT-1080coI cell line is ideal for MS studies, as it does not express
potentially confounding endogenous collagen-, it could theoretically introduce false positives.
We next employed IPs and immunoblotting to explore whether interactions are recapitulated in
Saos-2 osteosarcoma cells that natively express collagen-I. 33 We prepared stable Saos-2 cells
that inducibly express our HA-tagged collagen-al(l) construct under control of the tetracycline
repressor and probed the crosslinked co-IP for putative interactors from Figure 3.9A. The
majority of the interactions tested are clearly recapitulated in Saos-2 cells (Figure 3.9B),
although a few proved difficult to detect likely owing to the fact that low levels of the HA-tagged
collagen-al (1) are competing for proteostasis network interactions with abundant endogenous
collagen-I in Saos-2 cells. This high reproducibility across multiple cell lines of the novel putative
collagen-I interactions observed in our HT-1 080coli cells engenders further confidence in our
map of the collagen-I proteostasis network (Table 3.2 and Figure 3.8A).
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Next, we obtained lentiviruses expressing shRNAs (see Table 3.3) against a select set
of the putative collagen-I interactors we identified. We generated fifteen stable Saos-2 cell lines
in which a single interactor was uniquely knocked down (see Figure 3.10A for qPCR validation
of knockdown cell lines). To discern effects of each knockdown on collagen-I secretion, we
differentiated Saos-2 cells for 3 d to stimulate endogenous collagen-I secretion, and then
analyzed collagen-I levels in the corresponding media samples using immunoblotting (Figure
3.11). Our results confirm that many of these interactors are relevant to collagen-I proteostasis.
For example, RCN1, ErolL, SPARC, and TGM2 knockdowns considerably enhance collagen-I
secretion. RCN1 is particularly intriguing because it is an abundant ER protein that currently has
no well-defined function beyond calcium binding. However, recent work identified another
member of the reticulocalbin family, RCN3, as a novel negative regulator of collagen
production.36 These findings further validate our collagen-I interactome and, most importantly,
very strongly motivate follow-up studies to delineate the molecular mechanisms of action of
these interactors in collagen-I proteostasis. We also note that there are minimal effects on
collagen-I secretion induced by knockdown of several of the novel collagen-I interactors
identified by MS, including Erdj3 and calumenin. Considering the overall demonstrated reliability
of our interactome (see results both above and below), it is perhaps most likely that these
interactors play roles in collagen-I production that are simply not possible to discern in a
secretion assay-or that they are most important under other conditions, such as when
collagen-I is misfolding (e.g., in the collagenopathies).
A particularly surprising finding in our proteomics data is the observation that collagen-I
robustly interacts with aspartyl-asparaginyl P-hydroxylase (ASPH). Asp hydroxylation in collagen
has not been previously reported, to the best of our knowledge. Supporting an actual role for
ASPH in collagen-I biosynthesis, our MS data on collagen-I immunoprecipitated from HT-
1 08 0 col-i cells is consistent with hydroxylation of both Asp7l and Asp72 in the N-propeptide
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domain of collagen-al(I) (Figure 3.12A). As expected, the MS1 spectrum indicates that the
modified peptide is more prominent in the ascorbate-treated, heavy sample. To address the
possibility that the result is an artifact of working in HT-1080 cells, we also performed MS
analyses on collagen-I immunoprecipitated from Saos-2 media, and again identified apparent
Asp hydroxylation specifically on Asp7l of collagen-al(l) (Figure 3.12B), providing further
confirmation that Asp hydroxylation is a native collagen-I N-propeptide modification. Asp
hydroxylation in collagen-I has likely been previously overlooked because traditional MS
protocols for analysis of collagen begin with proteolytic removal of the propeptides. Intriguingly,
ASPH mutations were very recently identified as causative factors in facial dysmorphism,37
supporting a possible role in the maturation of extracellular matrix proteins like collagen-I and
motivating further mechanistic work in this area.
Cumulatively, the observations that a diverse set of putative collagen-I interactors do
indeed engage collagen-I across multiple cell lines and that numerous members of a panel of
shRNA-mediated knockdowns of those interactors modulate collagen-I secretion provides
compelling validation of our map of the collagen-I proteostasis network. Equally important, we
are able to identify a probable functional consequence of an unanticipated collagen-linteraction
with ASPH-the apparent hydroxylation of at least one collagen-I N-propeptide Asp residue.
Such a discovery is made possible by our proteomics-guided approach to understanding
collagen-I proteostasis.
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Figure 3.9 1 Validation and Characterization of Putative Collagen-I Proteostasis Network
Components
(A) HA antibody-mediated IP of HA-collagen-al(l) from HT-1080co" cells coimmunoprecipitates
numerous novel or poorly characterized collagen-1 interactions identified by mass spectrometry.
The control sample represents HT-1080 cells that do not express HA-tagged collagen- upon
induction. (B) Validation of the biological relevance of the interactions identified in the HT-1080
cells by immunoprecipitating HA-tagged wild type collagen-al(l) from osteosarcoma Saos-2
cells and then immunoblotting. Collagen-I expression was induced by treatment with 1 tg/mL
dox and 50 ItM ascorbate. The control sample represents untreated Saos-2 cells.
137
a-HA
a-ERDJ3
a-HYOU1
a-Erol L
a-PDIA3
a-PDIA4
a-Erp44
a-Golim4
a-RCN1
a-Erp29
B
Table 3.3. Compilation of shRNA constructs used in Figures 3.10-3.13.
Gene Name Oligo Sequence (5' to 3')
Non-Mammalian CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT
Erp29 CCGGCAAGTTCGTCTTGGTGAAGTTCTCGAGAACTTCACCAAGACGAACTTGTTTTT
P4HB CCGGAGGTGAAATCAAGACTCACATCTCGAGATGTGAGTCTTGATTTCACCTTTTTTG
SerpinHi CCGGCCTCTACAACTACTACGACGACTCGAGTCGTCGTAGTAGTTGTAGAGGTTTTT
AnxA2 CCGGCGGGATGCTTTGAACATTGAACTCGAGTTCAATGTTCAAAGCATCCCGTTTTTG
CRTAP CCGGCTTTACTCTCCAAAGTGAAAGCTCGAGCTTTCACTTTGGAGAGTAAAGTTTTTTG
EroIL CCGGCCTCATAAATGACCCATAATTCTCGAGAATTATGGGTCATTTATGAGGTTTTTG
Golim4 CCGGGAAGATATAAACCCAGCAGATCTCGAGATCTGCTGGGTTTATATCTTCTTTTTTG
RCNI CCGGCCGCAGAGTTTCATGATTCTTCTCGAGAAGAATCATGAAACTCTGCGGTTTTT
Calu CCGGGTTAGAGATGAGCGGAGGTTTCTCGAGAAACCTCCGCTCATCTCTAACTTTTTG
ASPH CCGGCGTGGTTTATGGTGATTGCATCTCGAGATGCAATCACCATAAACCACGTTTTTG
CKAP4 CCGGGCAGGATTTGAAAGCCTTAAACTCGAGTTTAAGGCTTTCAAATCCTGCTTTTTG
DNAJB 11 CCGGGTTGGCTTTGAGATGGATATTCTCGAGAATATCCATCTCAAAGCCAACTTTTT
PRKCSH CCGGCAGCCTTCAAAGATGGGTAAACTCGAGTTTACCCATCTTTGAAGGCTGTTTTTG
SPARC CCGGCGGTTGTTCTTTCCTCACATTCTCGAGAATGTGAGGAAAGAACAACCGTTTTT
TGM2 CCGGACAGCAACCTTCTCATCGAGTCTCGAGACTCGATGAGAAGGTTGCTGTTTTTTG
PD/A3 CCGGGCTTACTATGATGTGGACTATCTCGAGATAGTCCACATCATAGTAAGCTTTTTTG
PD/A4 CCGGCCTGAGAGAAGATTACAAATTCTCGAGAATTTGTAATCTTCTCTCAGGTTTTTG
Erp44 CCGGGCACCCAGTGAATATAGGTATCTCGAGATACCTATATTCACTGGGTGCTTTTTG
Erp46 CCGGGCCAAGCGAAAGACGAACTTTCTCGAGAAAGTTCGTCTTTCGCTTGGCTTTTTG
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Figure 3.10 1 Stable shRNA Knockdown Saos-2 Cell Lines Analyzed By qPCR
Bar charts showing the extent of knockdown for each individual stable Saos-2 cell line assayed
for collagen-I secretion in Figures 11 and 13. Samples were normalized to the given gene's
expression in a corresponding non-mammalian shRNA control sample. The shRNA construct is
listed along the x-axis, and the corresponding gene analyzed is listed as the title of the graph.
Results are presented as the mean 95% confidence interval.
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Figure 3.11 | Alterations in Secretion in the Presence of Different shRNA constructs
(A) Secreted collagen-I levels analyzed by immunoblot in the context of a panel of shRNA
stable knockdowns of the indicated proteins in Saos-2 cells. (B) Quantification of the average
fold change in collagen- secretion compared to control cells (n = 2).
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Figure 3.12 1 Aspartyl Hydroxylation of Cola1(l) N-propeptide
(A) MS1 and MS2 spectra with respective peaks assigned for a peptide whose fragmentation
pattern is consistent with aspartyl-hydroxylation at residues Asp7l and Asp72 (numbering
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beginning at collagen-l's start codon) in the N-propeptide of collagen-al (1) immunoisolated from
HT-1080coI-I cells. (B) MS2 spectrum with respective peaks labeled that is consistent with
aspartyl-hydroxylation at residue Asp7l of collagen-al(I) immunoisolated from Saos-2 media.
For both (A) and (B), asterisks (*) indicate the site of a hydroxylated aspartate or alkylated
cysteine. b-lons are fragments of the parent ion, originating at the N-terminus and extending the
number of amino acids into the peptide, as indicated. y-lons are the same, but originating at the
C-terminus of the peptide.
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3.3.7 Mechanistic Studies Suggest a Role for Erp29 in Collagen-I Proteostasis
Collagen-I secretion from cells that endogenously produce the protein (including Saos-2 cells) is
significantly reduced in the absence of ascorbate. 38 Therefore, we anticipated that quality
control mechanisms might engage collagen-I to a greater extent in the absence of ascorbate
(ER-retention conditions). A log 2 scatter plot of collagen-I interactor enrichment under secretion-
promoting conditions versus ER-retention conditions (Figure 3.13A) initially suggests that the
interactomes in the presence or absence of ascorbate are similar, consistent with ascorbate-
mediated regulation of collagen-I secretion occurring primarily at the level of
transcription/translation. 39 Nonetheless, under-hydroxylated collagen-I produced in the absence
of ascorbate is retained in the ER to a significant extent, implying that there are likely to be
quality control or ER retention factors that can recognize immature collagen-I and help prevent
its secretion. A closer examination of functional subsets of the collagen-I proteostasis network
under collagen-I secretion-promoting versus ER-retention conditions (Figure 3.13B) reveals
quantitatively enhanced collagen-I engagement under ER-retention conditions both for the
HSP40/70/90 class of chaperones and for proteostasis network components functionally or
structurally related to disulfide bond formation/shuffling and cellular redox chemistry, including
PDIA3, PDIA4, Erp44, Erp46, Erp29, 40 and the peroxiredoxins. 41 The observation of new ER
proteins related to disulfide bond formation/shuffling in the collagen-I proteostasis network was
anticipated by us, because both the N- and C-terminal propeptides of collagen-I are cysteine-
rich. However, the discovery that these collagen-I interactors engage collagen-I to a greater
extent under ER-retention conditions prompted us to further investigate their mechanistic roles
in collagen-I proteostasis.
Following the experimental protocol employed in Figures 3.10 and 3.11, we began by
using shRNA-expressing lentiviruses (see Table 3.3) to attempt to stably knockdown the new
putative collagen-I interactors PDIA3, PDIA4, Erp44, Erp46, and Erp29 in Saos-2 cells.
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Interestingly, we found that PDIA3-, PDIA4-, Erp46- and ERP44-targeting shRNAs are highly
toxic to Saos-2 cells, potentially implicating them as having a critical function in cells that
endogenously express collagen-. However, as noted above, we were able to deplete Erp29 to
-20% of normal levels in stable Saos-2 cells (Figure 3.10). Erp29 depletion does not obviously
impact collagen-I secretion under secretion-promoting (ascorbate-treated) conditions (see
Figure 3.11A), nor does it inordinately stress Saos-2 cells, as indicated by a lack of chronic
unfolded protein response activation (Figure 3.13C). Intriguingly, upon analyzing collagen-I
intracellular steady-state levels and secretion under ER-retention conditions, we observe that
Erp29 knockdown has the dual effects of decreasing intracellular collagen-I levels while
simultaneously increasing collagen-I secretion (Figure 3.13D). Because collagen-I cannot be
properly hydroxylated in the absence of ascorbate, this observation implicates Erp29 as playing
a critical role in collagen-I maturation and retaining immature collagen-I in the ER (Figure 3.14).
Erp29 is an abundant and widespread component of the ER proteostasis network,42
displaying a thioredoxin (PDI-like) fold but lacking any catalytic activity for disulfide bond
isomerization.44 In the past 20 years, a number of groups have explored possible roles for Erp29
in the proteostasis of CFTR, thyroglobulin, and viral proteins.43 -4 These studies have led to
various suggestions that Erp29 may accompany nascent proteins out of the cell," that it may
have a role in ER client protein maturation,45 or that it could assist the folding of certain complex
plasma membrane proteins.46 Our findings here, informed by MS-based proteomics in our new
collagen-I expression platform, suggest a novel function for Erp29-retaining immature
collagen-I in the ER to prevent secretion of potentially damaging, improperly modified, and
unstable forms of the protein into the extracellular matrix (Figure 3.11D).
144
C
10
51
5-
PPIB 
.HSP47
SPARC PDI
PDIA3
10
10j I
Log2 Medium:Light Ratio
/'-- PDI
- BiP
- -PDIA4
., -:Erp29
- Erdj3 - HYOU1
4
-Erp44
Log2 Medium:Light Ratio
BiP
10
1.0-
S NM Erp29LL
0
CU
CM
> 10CU(D
ZI
(N
0)
0
-j
Figure 3.13 | A Role for Erp29 in Collagen-I Proteostasis
(A) Scatter plot of the 1092 SILAC ratios for proteins identified in two or more biological replicates
with heavy (ascorbate-treated): light (control) and medium (ascorbate-deficient): light (control)
ratios. (B) Scatter plot of the log 2 SILAC ratios for the Disulfide Redox and HSP40/70/90
functional groups showing that these collagen-I interactors are quantitatively enriched under
ER-retention (ascorbate-deficient) conditions. (C) Relative BiP and Erd4 mRNA levels upon
stable Erp29 knockdown in Saos-2 cells compared to control Saos-2 cells showing no
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146
Figure 3.14 1 Schematic of Collagen Secretion with and without Erp29
Model illustrating the role of Erp29 in collagen-I retention/quality control under ascorbate-
deficient conditions.
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3.4 Concluding Remarks.
Altogether, this work provides numerous valuable resources for continued studies of collagen-I
biogenesis. First, we have generated a panel of cell lines inducibly expressing antibody epitope-
tagged collagen-I strands with validated molecular properties. Key advantages of our cell-based
platform include the abilities to orthogonally visualize and quantify different collagen-I strands in
a single experiment, as well as to reliably IP collagen-I with MS-grade antibodies. This platform
can be easily leveraged in the future to model the autosomal dominant collagenopathies in a
manner that allows differential quantification of mutant and wild-type collagen-I strands. Second,
we have generated the first map of the collagen-I proteostasis network (Figure 3.8A) using our
antibody epitope-tagged collagen-I expressing cell lines and quantitative MS-based proteomics.
Validation efforts not only confirm a number of putative new interactors, but also unveil an
unanticipated collagen-I post-translational modification (Asp hydroxylation). The results yield
new insights into the ER proteostasis network components likely involved in collagen-I
biogenesis, providing a roadmap for ongoing and future studies of collagen-I folding, quality
control, trafficking, and post-translational modification. Third, we delineate a previously unknown
role for the abundant but ill-characterized Erp29 protein in collagen-I surveillance under
ascorbate-deficient, ER-retention conditions.
Cumulatively, the work here highlights the usefulness of our platform for biochemical
studies of collagen-I proteostasis, both for discovery and for hypothesis testing. Continued
development of the platform and mechanistic studies on the newly identified collagen-I
interactors will provide further important insights into how cells handle this critical scaffold for
animal life. Furthermore, we anticipate that our findings here will prove relevant for the twenty-
seven structurally-related collagen types and other fibrous extracellular matrix proteins, as well
as lead to potential new targets to help resolve disease-associated collagen misfolding.
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3.5 Experimental Methods and Supplies
3.5.1 Materials and Reagents
Antibodies used were obtained from the following suppliers: Santa Cruz: HA probe (sc-7392),
PDI (sc-20132), CRTAP (sc-99367), CyPB (sc-20361); ProteinTech: DNAJB11 (15484-1-AP);
GeneTex: GFP (GTX113617), HYOU1 (GTX102255); Sigma: Cola2(l) (SAB4500363), LAMP1
(SAB3500285), GM130 (G7295), actin (A1978); MyBioSource: ColcXl(l) (MBS502153);
Cedarlane: Human Collagen Type I (CL50111AP-1); Agilent Technologies: Rat Anti-
DYKDDDDK (200474); Enzo Life Sciences: HSP47 (ADI-SPA-470), KDEL (ADI-SPA-827),
Calreticulin (ADI-SPA-601), Golim4 (ALX-804-603-C100); IBL America: Reticulocalbin-1
(10367); Abcam: Erp29 (ab11420); Abgent: FKBP10 (AP7383b); Cell Signaling: ErolL (3264),
Erp44 (3798), Erp57 (2881), Erp72 (5033), Calumenin (11991). Antibody beads were obtained
from Sigma: FLAG M1 Agarose Affinity Gel (A4596), FLAG M2 Affinity Gel (A2220), and HA-
Agarose beads (A2095). Secondary antibodies were obtained from LiCor Biosciences: 800CW
Goat Anti-Rabbit, 800CW Goat Anti-Mouse, 800CW Goat Anti-Rat, 800 CW Donkey Anti-Goat,
800CW Streptavidin, 680LT Goat Anti-Rabbit, 680LT Goat Anti-Mouse, 680LT Goat Anti-Rat.
Hygromycin and G418 were obtained from Enzo Life Sciences. Puromycin was obtained from
Corning. All media and cell culture reagents were obtained from Corning/Cellgro, unless
otherwise noted. Restriction enzymes, ligases and polymerases were obtained from New
England BioLabs. DNA/RNA preparation kits were obtained from Omega BioTech. Co/IA1 and
Co/IA2 genes were obtained from the Origene True Clone Repository, Accession Numbers
SCI 12997 and SC1 26717, respectively.
3.5.2 Plasmids
The human Co/IAI and CoIA2 genes were obtained from Origene. Collagen-I genes were
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PCR-amplified to insert into the pTRE-Tight vectors. Q5 Polymerase (New England BioLabs)
was used according to the manufacturer's protocol, with the addition of the High GC Enhancer.
Sequencing of the collagen genes received from Origene revealed a multitude of missense
mutations that were repaired by site directed mutagenesis. Collagen-I genes were PCR-
amplified using the following primers:
Co/IA 1: Forward - 5'-ACATCAGCGGCCGCACAAGAGGAAGGCCAAGTCGAG-3'
Reverse - 5'- AAAAAAGTCGACTTACAGGAAGCAGACAGGG-3'
Co/IA2: Forward - 5'-AAAAAAGCGGCCGCAACATGCCAATCTTTACAAGAGGAAAC-3'
Reverse - 5'-AAAAAAGATATCTTATTTGAAACAGACTGGGCCAATG-3'
After 35-40 PCR cycles with a 2 min extension time each, samples were gel purified using
Omega Gel Purification Kits. Preprotrypsin signal sequences with either HA or FLAG epitope
tags were inserted into pTRE-Tight first, using BamHl and EcoRV, and the collagen-I genes
were then inserted into the respective vectors. Collagen-I vector propagation was always
performed in recB and recJ-deficient Sure2 E. coli, which we found to be essential to prevent
recombination of the GC-rich collagen genes.
Once sequenced, vectors were transfected with XFect (ClonTech) into HT-1 080 TetOff
cells (ClonTech) along with either a puromycin or hygromycin linear selection marker
(ClonTech). 48 h post-transfection, cells were treated with the appropriate antibiotic (0.25 pg/mL
puromycin, or 150 pg/mL hygromycin) for 10-12 d for stable selection. Heterostable colonies
were amplified, and then split to establish genetically homogenous single colonies for the
collagen-I genes. The process was then repeated to create cell lines that express both Co/IA1
and Co/IA2 gene transcripts.
3.5.3 Cell Culture and Transfections
HT-1080 Tet-Off cells (ClonTech) were cultured in complete DMEM supplemented with 10%
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FBS. Saos-2 cells were cultured in complete DMEM supplemented with 15% heat-inactivated
FBS. Transfections of Co/IAI and COLIA2-encoding plasmids along with linear markers for
puromycin or hygromycin resistance were performed using XFect (ClonTech). Stable HT-1080
lines were selected by culturing in 150 tg/mL hygromycin or 0.25 tg/mL puromycin, as
appropriate, as well as continuously cultured in 100 1xg/mL of G418 to maintain the tetracycline
transactivator and 1 ng/mL dox to suppress collagen-I expression. Culturing cells in the
presence of the recommended 1 tg/mL of dox was too high of a concentration, as we found that
removal of the dox-containing media did not induce high enough expression of the collagen-I
genes at 48 hours to be detected by immunoblot of conditioned media or cellular lysate. We
optimized the culture conditions by sub-culturing the cells in varied concentrations of dox for 48
h. Collagen-I expression -in HT-1080 cells was induced by plating cells in 10% Tet-Approved
FBS (ClonTech) complete DMEM supplemented with 50 pM ascorbate for 48 h, with ascorbate
replenishment every 24 h, unless otherwise noted. Healthy primary patient fibroblasts
(GM05294 from Coriell) were cultured in complete EMEM containing 15% FBS. Collagen-I
production by the primary fibroblasts was stimulated by treating with 200 tM ascorbate for 48 h,
supplementing every 24 h.
3.5.4 Lysis, Protein Preparation, and Immunoprecipitations
Collagen-I expression by HT-1080 cells, unless noted otherwise, was induced by removing dox
and adding 50 jM sodium ascorbate (as indicated) for 48 h, with fresh sodium ascorbate
supplementation at the 24 h mark, then cells were harvested and washed three times with 1x-
phosphate buffered saline (PBS). Samples for stable (no covalent crosslinking) IPs were lysed
using the following lysis buffer (LB): 50 mM Tris-HCI, pH 7.5, 150 mM sodium chloride, 1 mM
EDTA, 1.5 mM MgC 2 , 1 % Triton X-1 00, protease inhibitor tablets (Thermo Fisher Scientific) and
1.5 mM phenylmethylsulfonyl fluoride (PMSF; Amresco). Cells used for cross-linking IPs were
151
cross-linked in 1x-PBS in the presence of 0.2 mM dithiobis(succinimidyl propionate) (DSP;
Lomant's Reagent), rotating at rt for 30 min. Cross-linking was quenched by addition of 0.1 M
Tris at pH 8.0 (final concentration), rotating for 15 min at rt. Cells were then lysed in RIPA (150
mM sodium chloride, 50 mM Tris-HCI, pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate), protease inhibitor tablets and 1.5 mM PMSF. All lysed samples were
centrifuged at 21,100 x g for 15 min at 4 *C. Supernatants were collected, quantified for protein
content, normalized, and incubated for 16 h with the appropriate antibody-conjugated beads.
Samples were then washed with the corresponding lysis buffer (LB or RIPA) and eluted using
300 mM Tris at pH 7.5 with 6% SDS by boiling for 10 minutes. Eluates were then subjected to
SDS-PAGE and Western blotting, or prepared for mass spectrometry analysis.
3.5.5 Immunoblotting
SDS-PAGE gels were transferred to a nitrocellulose membrane for 1.5 h at a constant 100 V.
Membranes were rinsed, and blocked with 5% w/v non-fat milk/TBS with 0.01% sodium azide.
Primary antibodies were diluted in 5% BSA according to the manufacturer's instructions, and
incubated 2 h - overnight. Membranes were washed with TBS and incubated with secondary
antibody in 5% w/v non-fat milk/TBS for 45 m, washed with TBS and imaged using the LI-COR
Biosciences Odyssey System.
3.5.6 Quantitative RT-PCR
Relative mRNA expression levels of genes of interest were assessed by quantitative RT-PCR.
Cells were harvested by trypsinization, washed with PBS, and total RNA was extracted using
the Omega RNA Purification Kit according to the manufacturer's instructions. RNA
concentrations were quantified and normalized to 1 tg total RNA for cDNA reverse transcription.
Using the Applied Biosystems Reverse Transcriptase cDNA Kit, cDNA was synthesized in a
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BioRad Thermocycler. LightCycler 480 Sybr Green Master Mix (Roche), appropriate primers
(purchased from Integrated DNA Technologies, Life Technologies and Sigma Aldrich, Table 3.1)
and cDNA were used for amplification in a Light Cycler 480 11 Real Time PCR Instrument in the
MIT BioMicro Center. Primer integrity was assessed by thermal melt and agarose gel analysis
to ensure that a single gene was amplified. Transcripts were normalized to the housekeeping
gene Rplp2, and all measurements were performed in technical and biological triplicate.
3.5.7 Confocal Microscopy
HT-1080coI cells, suspended in complete DMEM with dox (1 ng/mL), were plated on a 24-well
plate with coverslips (Chemglass Life Sciences, NJ) coated in poly-D-lysine and incubated for
24 h at 37 0C in a humidified 5% CO2 atmosphere. The media was changed to Tet-approved
media (ClonTech) and the cells were incubated in the 37 *C incubator for 48 h without dox or
ascorbate. Media was removed and coverslips were washed three times with PBS. The cells
were then fixed with 4% formaldehyde for 30 min and permeabilized with 0.1% Triton in PBS for
another 30 min. Coverslips were incubated for 1 h at rt in a blocking buffer containing 1% BSA
in TBS (pH 7.5). Double-labeling was performed by incubating coverslips in TBS (5% BSA, 0.01%
sodium azide) containing mouse anti-HA (1:200) and then rabbit anti-PDI (1:200), anti-LAMP1
(1:500), or anti-GM130 (1:500) for 2 h at rt or overnight at 4 C. Secondary antibodies (Alexa
Fluor 488-conjugated anti-mouse or Alexa Fluor 568-conjugated anti-rabbit) were diluted
(1:1000) in TBS (5% BSA, 0.01% sodium azide) and then applied to the coverslips for 1 h at rt
in the dark. After each incubation, cells were rinsed with TBS at least three times. Nuclei were
stained for 15 min at rt with DRAQ5 (1 KM). After the final washing with PBS, the sections were
then mounted with ProLong to prevent photobleaching. Negative controls for non-specific
binding of the secondary antibodies obtained by omitting primary antibodies in the staining
protocol were included for each experiment. The subcellular localization was directly analyzed
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with an HCX PL APO 63X/1.40-0.60 oil objective mounted onto a Leica TCS-SP2 confocal
microscope (Buffalo Grove, IL, USA) equipped with a Leica microsystem. Co-localization
quantification was performed using ImageJ software, and calculated for seven different cells per
slide in biological triplicate.
3.5.8 Pulse-Chase Analyses
HT-1080coI' cells were plated on poly-D-lysine-coated plates 36 h before initiating the pulse-
chase, under the appropriate conditions (+/- dox, + ascorbate). Before the pulse with 3S_
methionine/cysteine, cells were starved of methionine and cysteine by treating for 30 min with
Cys/Met-free DMEM (FBS was dialyzed for 16-18 h against PBS prior to making the media).
After starving, cells were pulsed for 30 min with 35S-containing media. Pulsing media was
removed, and full DMEM replaced it for the indicated chase times. At the conclusion of each
time point, cells and media were harvested and immunoprecipitated for HA-tagged collagen-I
overnight, using HA-antibody beads. The next day, samples were washed with RIPA buffer,
eluted from the beads using 6x-loading buffer, and separated by SDS-PAGE. Gels were then
dried using a gel slab dryer for 1 h at 80 0C. Dried gels were applied to the mounting screen,
developed using a GE Healthcare Phospho Screen, and imaged on a Typhoon 3-4 d later.
3.5.9 Protease Digestions
Collagen-I was precipitated from media by treatment with 176 mg/mL ammonium sulfate, 100
mM Tris-HCI pH 7.4, and 1 mM PMSF, at 4 *C overnight. Samples were then centrifuged at
3000 rpm for 15 min to pellet the precipitate. The supernatant was then removed and the
precipitated pellets were resuspended in 400 mM NaCl, 150 mM Tris (pH 7.4). Samples were
aliquoted and treated with trypsin or chymotrypsin (0.1 mg/mL final concentration) 20 prior to
analysis by immunoblotting to determine the extent of stable triple-helix formation.
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3.5.10 MS Sample Preparation and Analysis
HT-1080co cells were propagated for >6 passages in light, medium, or heavy SILAC media
(light media was supplemented with Lys (12C6, 99%; 14N2 , 99%) and Arg (12C6, 99%; 14N4, 99%);
medium media was supplemented with Lys (13C6 , 99%; 14N2 , 99%) and Arg (13C6, 99%; 14N2 ,
99%); heavy media was supplemented with Lys (13C6, 99%; 15N 2 , 99%) and Arg (13C6, 99%; 15N4 ,
99%); Cambridge Isotopes). All media were supplemented with 2 mM unlabeled proline to
reduce the probability of labeled Arg being converted into proline intracellularly. Collagen-I co-
IPs were prepared and MS analyses performed. Labeled cells were lysed, trypsinized and the
subsequent peptides were analyzed by mass spectrometry to ensure >95% incorporation of
isotopically labeled amino acids into the proteome. Upon confirmation, collagen-I IPs were
performed, and after elution from the antibody beads, samples were then treated with 100 M
DTT to release the interactome from the collagen-I bait protein (cleaving the crosslinker, DSP).
Each sample was then centrifuged over a 100 kDa molecular weight cut off filter (100 MWCO,
Millipore) to ensure deeper coverage of the interactome by removing high levels of collagen-I
proteins. The flow-through (i.e., the interactome) samples were precipitated by adding 450 VL of
MeOH to a lysate sample of <150 tL and vortexed. 150 [L of chloroform was then added and
the resulting solution was vortexed. Finally, 450 [xL of water was added and samples were
vortexed and then centrifuged at 10,000 x g for 3 min. The upper aqueous phase was removed
while the precipitate at the solvent interface was preserved. The collected precipitate was then
washed 3 x 1 mL with MeOH, centrifuging between washes. The washed pellet was dried and
resuspended in 8 M urea, 50 mM ammonium bicarbonate. 10 mM DTT was added, samples
were mixed, and then incubated in a 56 0C water bath for 45 min. Samples were then cooled
and incubated with 55 mM iodoacetamide for 1 h in the dark while rotating. Samples were next
incubated with 1 tg of sequencing-grade trypsin (Promega) overnight at rt, while rotating.
Proteolyzed samples were acidified to a final concentration of 5% formic acid and subjected to
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C18 Stage Tips for desalting. Prior to sample addition, Stage Tips were washed with 0.1% TFA,
then 0.1% TFA with 90% acetonitrile, then again with 0.1% TFA. Samples were then loaded,
ensuring all the volume passed through the column. Each column was then washed with 0.1%
formic acid, and eluted with 0.1% formic acid with 80% acetonitrile. Elutions were dried by
speedvac, resuspended up to 20 pL of 0.1% formic acid, and injected onto a nanoflow HPLC,
with MS data acquired on a Thermo QExactive mass spectrometer (LC-MS/MS). Protein
identification was carried out using the Mascot database search software. Database search
results were assembled using Proteome Discoverer. Mascot search parameters were as
follows: mass tolerance for precursor ions was 10 ppm; fragment ion mass tolerance was 0.8
Da; 2 missed cleavages of trypsin; fixed modifications were carbamidomethylation of cysteine;
variable modifications were methionine oxidation, and hydroxylation of proline, lysine, aspartate,
or asparagine. Peptides with Mascot scores greater than 25 and isolation inference less than
30 were considered identified, resulting in an average false discovery rate of 0.0077. SILAC
quantitation was calculated by integrating the area under the curve of the light, medium, and
heavy MS peaks. A fraction of the IP supernatant (proteins that did not bind to the beads
during the initial incubation) was analyzed and used to normalize the quantitation from the
collagen IP to account for potential variability, similar to a loading control.
We later searched our MS data for evidence of aspartyl hydroxylation. In the HT1080co1
heavy-labeled sample, we identified 4 peptides with the sequence VLCDDVICDETK, of which
one was modified as shown in Figure 3.12A, across two replicates. For collagen-I secreted
from Saos-2 cells, we used an inclusion list to better enrich peptides with appropriate m/z ratios
(searching for both the unmodified and hydroxylated VLCDDVICDETK peptides), and found that
1/25 peptides were modified as shown in Figure 3.12B.
3.5.11 Saos-2 Stable Cell Line Generation and Secretion Analysis
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A Col1A1.pENTR1A vector was constructed by ligating COLIAI cut from the
Col1A1.pTRE.Tight vector using the Notl and EcoRV restriction sites into a pENTR1A vector
already containing an ER-targeting preprotrypsin signal sequence and an HA epitope tag. The
resulting construct was inserted into the pLenti.CMV/TO.DEST Gateway destination vector (Life
Technologies) via LR Clonase-mediated recombination (Life Technologies). pLenti vectors were
sequence-confirmed before proceeding with lentivirus production. Lentiviral production was
performed by co-transfecting 293FT cells with the lentiviral plasmids and packaging vectors
encoding RRE, REV, and VSVG using Lipofectamine 2000 (Life Technologies). Briefly, the
plasmid mixture (pLenti vector (15 tg), RRE (15 tg), REV (6 rig), and VSVG (3 kg)) was
incubated with 60 pL of Lipofectamine 2000 in 3 mL of Opti-MEM media for 45 min at rt. The
mixture was then added dropwise to a 10 cm dish of 293FT cells (8 x 106 cells) and incubated
at 37 'C for 12 h. The media was then removed and replaced with DMEM (6 mL) and the plates
were incubated for another 36 h. 48 h post-transfection, viral supernatant was collected and
used immediately for transductions of Saos-2-TREx cells (see below).
To create Saos-2T-REx cells, Saos-2 cells (125,000 cells/well in a 12-well plate) were
transduced with a range of volumes of lentivirus encoding a constitutively expressed tetracycline
repressor protein prepared as described above. Polybrene (4 jg/mL) was added to increase the
efficiency of viral infection. 12 h post-transduction, the media was removed and replaced by
fresh DMEM media for another 24 h before selection. Cells were selected for using 2 tg/mL
blasticidin, and single colonies were isolated and assayed for the colony most responsive to dox
treatment (using Tet-responsive CFP to visualize activity of the tetracycline repressor protein).
Once a genetically homogenous single colony was isolated, Saos-2T-REx cells were
transduced as above with a range of volumes of crude viral supernatants of Tet-Responsive
HA-collagen-a1(l), selected using 250 kg/mL hygromycin, and assayed for expression at the
heterogenous cell population level. The resulting heterogenous cell line was used for IP analysis
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of the collagen interactome and for shRNA knockdowns. For shRNA knockdowns, cells were
transduced with commercially available lentiviruses (Sigma) at an MOI of 2, or with homemade
lentiviruses produced as described above. Stable cells were selected using 2 ptg/mL puromycin.
The resulting heterogenous cell populations were used for further experiments.
3.5.12 Saos-2 Differentiation and Collagen-I Production
Cells were treated as previously described to induce Saos-2 differentiation into osteoblasts.47
Briefly, cells were treated with McCoy's 5A media, supplemented with 10% heat inactivated FBS,
penicillin/streptomycin, L-glutamine, 50 tM sodium ascorbate (refreshed daily) and 5 mM s-
glycerophosphate for three days prior to soluble collagen-I secretion analysis.
3.5.13 Adenoviral Production and Transductions
Col1A1.pENTR1A was mutagenized to contain the Cys1299Trp variant known to cause
osteogenesis imperfecta. After sequence confirmation, the resultant vector was recombined with
Ad.DEST40 (Life Techonologies) using LR Clonase according to the manufacturer's protocol
(Life Technologies). Ad.DEST40 vectors containing the 01-variant collagen gene were digested
with Pac and transfected into 293A cells to produce replication-incompetent adenovirus-V. After
complete cytopathic effect, the viral supernatant was collected, subjected to three freeze (-80*
C)/thaw (37 *C) cycles, centrifuged and amplified on fresh 293A cells. This cycle was repeated
once more, and the resultant viral supernatant was applied to the HT1 08 0colI cells. 2 d post
transduction, media was harvested and analyzed by immunoblot.
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Chapter 4:
The XBP1s arm of the unfolded protein response can selectively
resolve collagen-I secretion defects in osteogenesis imperfecta
primary cells
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4.1 Author Contributions
A.S.D. designed and performed the majority of the experiments. Dr. Ngoc-Duc Doan performed
and analyzed the Ad.ATF6 experiments in Figure 4.4.
4.2 Introduction
The collagenopathies are a class of diseases that affect nearly every tissue in the body. Most
commonly caused by autosomal dominant mutations to one of the 45 different collagen genes,
the collagenopathies are caused by the resulting proteostasis defect that leads to either (1)
insufficient production of folded collagen,1 (2) excessive accumulation of toxic collagen
aggregates in cells leading to ER stress-induced apoptosis, 4~6 (3) or failed quality control
allowing misfolded collagen molecules to be deposited in the extracellular matrix (ECM).'' The
relative contribution of these possibilities to pathology for different collagenopathy genotypes is
likely variant-dependent. Unfortunately only palliative treatments are currently available to
patients suffering from a collagenopathy.
The prototypical collagenopathy is osteogenesis imperfecta (01).9 01 is a bone disease
that most commonly manifests at an early age. Patients with 01 can display a wide range of
symptoms ranging from virtually undetectable with slightly below average height, to perinatal
lethality as a result of malformed, dysfunctional bones. 10-12 Mild cases of 01 often present with
possibly hundreds of fractures before the patient reaches puberty, curvature in their long bones
and spine, difficulty hearing, and dwarfism. More severe cases present symptoms including
shortening of the long bones, abnormal ribcage and skull formation, multiple vertebra crush
fractures and decreased mobility.13
Bisphosphonates traditionally used to treat osteoporosis showed some promise in the
early stages of treating 01. The mechanism of action of this class of drugs, however, inhibits
bone resorption, by ultimately inhibiting osteoclasts and inducing apoptosis in these cells.14'15
The long-term side effects of treating with bisphosphonates, especially in pediatrics where
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symptoms of the collagenopathies often present, are currently unknown.1 6-19 Furthermore,
bisphosphonates indirectly address only one of the two main causes of the collagenopathies,
that of decreased bone mass. These treatments do not improve the cellular stress induced by
the collagen disease variants. If treatment options are to be improved for patients with a
collagenopathy, we must gain a better understanding of the molecular underpinnings that cause
collagen to be retained in the presence of a disease-causing variant.
01 is most commonly caused by autosomal dominant missense mutations in one of the
collagen-I genes, Co/IA1 or CoIIA2. To date, over 1500 01-causing mutations in these genes
have been identified.2022 Most commonly, glycine residues in the triple helical domain are
mutated to serine residues. Removal of a Gly residue in the Gly-Xaa-Yaa repeats of the triple-
helical domain disrupts one of the essential interstrand hydrogen bonds that stitch the triple
helix together, as any amino acid side chain larger than a hydrogen atom cannot fit inside the
sterically constricted triple helix. 2 3,24 Beyond Gly to Ser mutations, many other mutations that
remove essential Gly residues and/or disrupt collagen-I assembly in the C-propeptide domain
can also cause 01.525-30 Interestingly, there is considerable variability in the patient phenotypes
displayed for a given variant.31 3 3 As such, a clear genotype-phenotype remains elusive, making
the prediction of disease prognoses extremely difficult.2 0,34
While the underlying reason for autosomal dominant pathologic consequences in 01
remains unclear, one hallmark of 01 is a sharp reduction in the total amount of collagen-I
secreted with a corresponding increase in the retention of collagen-I intracellularly.5 ,36 The
stress response pathway typically responsible for addressing the accumulation of misfolded
proteins in the ER is the unfolded protein response (UPR).37 The UPR transcriptionally
upregulates ER chaperones and quality control machinery to assist in resolving protein folding
stress in the ER lumen. The pro-folding and pro-quality control aspects of the UPR are
predominantly accomplished by activation of two of the three transcriptionally regulated arms of
the UPR: ATF6 and XBP1s. 38 If upregulation of chaperone and quality control factors is
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insufficient to clear the unfolded protein from the ER lumen, the third arm of the UPR, PERK,
will induce cellular apoptosis. 37
In an effort to devise new treatment strategies for other ER proteostasis defect-related
diseases, extensive work suggested that stress independent activation of XBP1s and/or ATF6
can enhance quality control, improve folding, and reduce chronic ER stress in a variety of
disease model systems. 39 44 Specifically in the case of light chain amyloidosis, UPR activation
selectively decreased the amount of amyloidogenic protein secreted from cells, while showing
no effect on the secretion of a more stable, non-amyloidogenic variant. Furthermore, stress
independent, arm-selective activation of ATF6 was sufficient to cause the same selective
retention of the disease-variant protein in the absence of cytotoxicity engendered by global UPR
activation. 454 These data suggest the possibility that resculpting the ER proteostasis landscape
could also be a viable strategy for the collagenopathies.
At least in principle, improving collagen-I quality control could both reduce toxic
intracellular collagen-I accumulation and reduce deposition of misfolded collagen-I in the ECM.
Enhancing collagen-I folding could similarly reduce intracellular accumulation and correct the
01-associated collagen-I secretion defect. Perhaps surprisingly, the vast majority of 01-variants
that cause collagen-I misfolding do not activate the UPR.47 Even though the ER quality control
machinery does not normally recognize the misfolded 01 variants, it is possible that remodeling
the proteostasis network would engender a recognition event that could assist in handling the
misfolded molecules. While perturbation of the UPR-chaperone system is one viable option, it
is also possible to consider specific chaperone targeting by small molecules,37 or using recently
developed Cas9 technology to target individual nodes within the ER that are essential loci of
quality control decisions for the fate of an 01-variant collagen-1.48
Herein, I describe our efforts towards resolving 01-associated collagen-I proteostasis
defects via chemical and genetic manipulation of the UPR. We used a stress-independent
induction of the UPR's ATF6 and XBP1s arms to probe effects on 01-causing disease variants
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of collagen-I. While we observed no change upon ATF6 activation, tightly regulated forced
expression of XBP1s selectively increases collagen-I secretion from a subset of 01 patient
fibroblasts, with no change on wild-type fibroblast collagen-I secretion. Mechanistic follow-up
suggests the surprising possibility that XBPls-mediated improvements in collagen-I secretion
require both enhanced quality control and improved folding. These studies set the stage for
future work in animal models to define the potential therapeutic benefits of resolving 01-
associated collagen-I proteostasis defects.
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4.3 Results
4.3.1 Collagen-I secretion is defective and the protein accumulates inside 0/ patient primary
fibroblasts
One prominent reported hallmark of 01 is a collagen-I proteostasis defect that manifests as an
inability to secrete normal amounts of properly folded collagen-. For at least some 01 variants,
reduced secretion levels may also correlate with intracellular accumulation of collagen-1, and
consequent chronic ER stress. Resulting decreases in cell health would further reduce collagen-
I secretion levels, creating a potentially devastating negative feedback loop culminating in the
bone pathology clinicians associate with 01.
To investigate this reported collagen-I secretion defect, we obtained primary patient
dermal fibroblasts from the Coriell Cell Repository corresponding to a wild-type line and several
01-causing collagen-I variants lines: Gly247Ser and Gly352Ser in Colal(l), and Gly502Ser,
Gly6lOCys and Gly907D in Cola2(). Each cell line's collagen-I secretion profile was analyzed in
the presence and absence of ascorbate for 24 h.4 Most of the lines tested have comparably low
collagen-I levels in the absence of ascorbate in the media (note that collagen-I should be only
minimally secreted under such conditions). In contrast, all four 01 cell lines secreted significantly
less collagen-I upon ascorbate treatment when compared to a wild-type primary fibroblast line
(Figure 4.1).
Intriguingly, our data and that of others suggest that the 01 patient lines synthesize
normal amounts of collagen-1, they just cannot secrete it.50 Instead, the collagen-I either
accumulates or is degraded. Consistent with accumulation, while wild-type fibroblasts show a
strong decrease in Colal (1) and Cola2(1) in the lysate when secretion is stimulated by treatment
with ascorbate, the 01 lines maintain high intracellular levels of collagen-1. Such accumulation of
collagen-I in 01 patient lines might be toxic, especially when constantly stimulated to synthesize
collagen-1. Alternatively, accumulation could have other deleterious effects. One such effect
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could be that the proteostasis network becomes effectively inaccessible to other ECM proteins
due to excessive engagement with accumulated collagen-, resulting in a global secretion
defect. Strikingly, in one atypical 01 mutation, Warman and co-workers showed that enhancing
secretion of 01 collagen-I by expression of an LRP5 protein variant that increases bone mass
resolves many aspects of disease pathology,51 -3 highlighting that if we learn how to resolve the
secretion defect it could present a new opportunity to treat the disease.
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Figure 4.1 1 A unifying
collagen-I secretion
feature of osteogenesis imperfecta cell lines is the reduction in
Equal numbers of cells were plated and treated with or without 200 pM sodium ascorbate for 24
h. Conditioned media was analyzed by SDS-PAGE immunoblot. Cells were harvested and lysed
and analyzed by SDS-PAGE immunoblot.
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4.3.2 Global UPR activation does not improve collagen-I secretion
The work outlined in Chapter 3 provides a list of known and putative collagen-I interacting
proteins that likely play a role in collagen-I maturation and folding (Table 3.2). A subset of the
interacting proteins identified is transcriptional targets of the UPR (fold change enrichment over
negative control in HT1080 cells shown in Figure 4.2A). For typical globular and membrane
proteins, as unfolded or misfolded proteins build up in the ER, the UPR is activated to
ameliorate the stress. This trend is somewhat surprisingly not observed in 01 patient cells,
despite apparent collagen-I misfolding and accumulation. For example, in all the cell lines tested
here the UPR is consistently not activated, as indicated by equal protein levels of GRP94 and
BiP, as compared to the levels in wild-type fibroblasts (Figure 4.1). Although the cell apparently
cannot sense the misfolding of triple helix collagen-I variants (perhaps because an unfolded or
misfolded triple helix does not display prototypical hydrophobic regions for sensing) given the
strong overlap between UPR targets and the collagen-I proteostasis network it is still possible
that remodeling the ER proteostasis network by artificial UPR activation could resolve the
collagen-I secretion defect.
We tested whether global UPR activation using thapsigargin (Tg, inhibits calcium flux)
could similarly improve collagen-I secretion from 01 fibroblast lines. Unfortunately, at all
concentrations of Tg that activated the UPR, we observed a strong decrease in collagen-I
secretion from not just 01 patient lines but also wild-type cells (Figure 4.2B; note that qPCR
data confirms dosable upregulation of the UPR-target genes BiP, Erd4, and CHOP by Tg
treatment, see Figure 4.2C; Table 4.1 provides the list of primers used). The decrease in
collagen-I secretion was not specific to Tg treatment, as another UPR activator tunicamycin
(Tm, N-glycosylation inhibitor) also reduced collagen-I secretion in all the cell lines tested
(Figure 4.3). Given that wild-type fibroblasts responded identically to the 01 fibroblasts when
treated with a global UPR stressor, we concluded that this was not a viable method for
correcting the collagen-I secretion defect in 01 patient primary fibroblasts. Collagen-I is both N-
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glycosylated,54 and putatively binds calcium in the C-propeptide domain, based on the crystal
structure of homotrimeric Cola1 (1).55 Furthermore, collagen-I is known to engage chaperones in
the ER that require calcium in order to function properly.5-55Therefore, perturbations to either of
these processes would likely decrease the folding efficiency collagen-. Moreover, Tg and Tm
are ER stressors that globally induce ER protein misfolding, so their ineffectiveness for resolving
a protein folding at even low concentrations is perhaps unsurprising.
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Figure 4.2 1 Thapsigargin treatment decreases collagen-I secretion
(A) UPR transcriptional targets that were identified in Chapter 3 as part of the proteostasis
network of collagen I. Their corresponding fold enrichments over a negative control IP in
HT1 080 cells is given in the chart. (B) Secreted collagen-I analysis for wild-type and Gly247Ser
cells in the presence of increasing concentrations of thapsigargin. Erdj3 secretion increases as
the concentration of thapsigargin increases, and serves as a marker for UPR activation.85 (C)
qPCR data validating the transcriptional response to increasing concentrations of thapsigargin
for both wild-type and Gly247Ser cells. Error bars represent SEM from three biological
replicates.
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Figure 4.3 1 Tunicamycin treatment decreases collagen-I secretion
(A) Collagen-I secretion analysis from cells treated with increasing concentrations of
tunicamycin. Erdj3 serves as a marker for UPR activation. (B) qPCR validating the
transcriptional activation of the UPR upon treatment with tunicamycin. Error bars represent SEM
from three biological replicates.
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Table 4.1 List of qPCR primers
Transcript Forward Reverse
RPLP2 5'-CCATTCAGCTCACTGATAACCTT-3' 5'-CGTCGCCTCCTACCTGCT-3'
CHOP 5'-GGAGCTGGAAGCCTGGTATG-3' 5'-GCCAGAGAAGCAGGGTCAAG-3'
BiP 5'-GCCTGTATTTCTAGACCTGCC-3' 5'-TTCATCTTGCCAGCCAGTTG-3'
Erdj4 5'-GGAAGGAGGAGCGCTAGGTC-3' 5'-ATCCTGCACCCTCCGACTAC-3'
(trpL e Ix) 5'-TGGTAGCCGTGGTTTCCCTG-3' 5'-TCCAGTCAGACCCTTGGCAC-3'
(tripl eIx) 5'-TGGCTCGAGAGGTGAACGTG-3' 5'-AGCACCGTTGACTCCAGGAC-3'
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4.3.3 Stress-independent activation of A TF6 does not improve 0/ collagen-I secretion
The UPR has three arms that coordinate a transcriptional response to an unfolded protein
stress in the ER: ATF6, IRE1 and PERK. PERK attenuates translation and ultimately induces
apoptosis in the face of a chronic protein folding stress. It seemed, therefore, unlikely that PERK
activation would be a productive method to enhance collagen-I secretion. In contrast, ATF6 and
IRE1 generally target and upregulate genes responsible for increasing the protein folding
capacity of the ER by directly upregulating chaperones and quality control machinery.
Therefore, ATF6 and IRE1 are attractive targets for ameliorating misfolding protein stress in the
ER37 ,38 (Figure 1.7).
We began by testing the potential of the ATF6 arm of the UPR for addressing collagen-I
secretion defects. The most well-established method for chemical genetic, arm-selective
activation of ATF6 is fusion of the active form of ATF6 to a destabilized domain (DD; schematic
shown in Figure 4.4A).59 The destabilized domain (in this case, E.coli dihydrofolate reductase
(ecDHFR)) is targeted for proteasomal degradation in the absence of the pharmacological
chaperone, trimethoprim (TMP). When TMP is present, the fusion protein is rescued from
degradation and allows the active transcription factor to upregulate its target genes. This
approach allows for dosable control of ATF6 activity, without inducing an actual stress on the
cells.
To test whether stress-independent ATF6 activation increased collagen-I secretion by 01
patient cells, we generated replication-incompetent adenovirus-V for delivery of a constitutively
active form of ATF6 (ATF6, amino acids 1-373) fused to ecDHFR.38 Cells were transduced,
split, and subsequently treated with ascorbate, in the presence or absence of the TMP. After 24
h of activation, collagen-I secretion was induced for an additional 24 h, and media samples were
analyzed by immunoblotting. We found that the DHFR-ATF6 construct was a potent, TMP-
dependent ATF6 activator in the primary fibroblast cells. As expected, when the MOI of
Ad.ATF6 was too high, all three arms of the UPR were activated in a TMP-independent
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manner. 31 While we were able to find an amount of virus that selectively upregulated only ATF6
targets (Figure 4.4B), ATF6 activation did not enhance collagen-I secretion (Figure 4.4C).
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Figure 4.4 ATF6 activation does not alter collagen-I secretion from 01 cell lines
(A) Schematic representation of destabilized domain technology. In the absence of a
pharmacologic chaperone, the fusion protein is degraded by the proteasome. When the
pharmacological chaperone is present, the destabilized domain is no longer targeted for
degradation, and the fusion protein is maintained and can perform the function desired. (B)
qPCR analysis of cells treated with Ad.ATF6 in the presence and absence of trimethoprim
(TMP). At higher MOls, the transcriptional activity of ATF6 was not dosable and activated the
entire UPR non-selectively. We found concentrations of virus that efficiently activated the ATF6
arm of the UPR while leaving the others largely untouched. Error bars represent SEM from
178
three biological replicates. (C) Immunoblot analysis of secreted collagen-I from each wild-type
and 01 cell line, transduced with Ad.YFP or Ad.ATF6 shows no change in collagen-I secretion
profiles for any of the 01 lines tested.
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4.3.4 XBPIs selectively increases collagen-I secretion from 01 patient primary fibroblasts
We next tested whether stress-independent activation of the IRE1 arm of the UPR could
increase collagen-I secretion from 01-variant cell lines. IRE1 is a transmembrane protein,
spanning the ER membrane. When an unfolded protein stress is sensed on the ER luminal side,
IREI self-olimogerizes and through a phosphorylation-dependent signaling cascade activates
an RNase domain in its cytosolic domain. The RNase domain specifically excises 26
nucleotides from XBPIu mRNA to form XBPIs. XBP1s is the active form of the transcription
factor associated with the IRE1 arm of the UPR.60 Here, we used replication-incompetent
human adenovirus-V to deliver a constitutively expressed XBP1s gene (Ad.XBPls) to fibroblast
cells. We also transduced cells with a constitutively expressed GFP (Ad.GFP) as a negative
control transduction, and compared the secretion of collagen-I from each cell line for each
sample. Remarkably, we observed a selective increase from two 01-variant fibroblasts that
express the most common type of missense mutation in 01, glycine to serine (Figure 4.5), with
no change in the amount of collagen-I secreted from wild-type fibroblasts. The collagen-I
increase from cells expressing Gly502Ser Cola2(l) could not be quantified, as the Ad.GFP
transduction shows no detectable collagen-I secretion. We note that the extent of increased
secretion from this cell line appears to be sensitive to age in culture and the details of
conditions, and although the results are compelling we did not study the Gly502Ser Cola2(l)
variant further. Collagen-I secretion from cells expressing Gly247Ser Colal(I) consistently
increases 2-3 fold when treated with Ad.XBP1s compared to Ad.GFP. This result was highly
consistent and robust, and we therefore used these cells in the remainder of our analyses.
Notably, we discovered that a very tight window of Ad.XBP1s MOls was essential for
producing the secretion results. To define the MOI at which Ad.XBP1s needed to be
transduced, we titrated viral supernatant on a fixed number of wild-type or Gly247Ser Colal (I)-
producing cells. Collagen-I secretion was then induced for 24 h in each treated cell line, and we
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analyzed the conditioned media by SDS-PAGE immunobiot (Figure 4.6A). Too low of an MOi
did not activate XBP1s transcriptional targets sufficiently to increase collagen-I secretion, while
too high of an MOI decreased collagen-I secretion likely owing to global UPR activation (Figure
4.6B) as also observed when ecDHFR.ATF6 was induced to high levels (see above).
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Figure 4.5 | XBPIs activation selectively
and Gly502Ser 01 patient primary cells
increases collagen-I secretion from Gly247Ser
Representative immunoblot analysis of secreted collagen-I from the wild-type, Gly247Ser
Colal(l) and Gly502Ser Cola2(l) cells in the presence of either Ad.GFP or Ad.XBP1s. Top
immunoblots are probed for secreted collagen-I in the conditioned media. Bottom immunoblots
are intracellular lysate levels of collagen-, GRP94 and BiP (probed for using the KDEL
antibody) as validation of the XBP1s activity, and actin as a loading control.
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Figure 4.6 1 Optimization of adenoviral titering in wild-type and Gly247Ser cells
(A) Cells were transduced with increasing volumes of Ad.XBP1s, induced for collagen-1
synthesis, and the media was analyzed by immunoblot. Shown are the results for increasing
volumes of Ad.XBPls, left to right. (B) qPCR analysis of the viral titrations. Left panel shows
transcriptional upregulation of UPR genes in the presence of Ad.GFP, compared to the right
panel when treated with Ad.XBP1s. Error bars represent SEM from three biological replicates.
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4.3.5 XBPIs induction does not alter cell viability
A simple explanation for observing an increase in collagen-I secretion is that XBP1s
transduction increased the growth rate of the Gly247Ser-producing fibroblasts, but does not
change the growth of wild-type fibroblasts. To probe whether XBP1s increases cellular growth
rate, we first transduced cells with either Ad.GFP or Ad.XBPls, induced for collagen-I
expression by treating with ascorbate, and assayed cell viability with both resazurin and
CellTiter G oTM assays (Figure 4.7). Each sample was normalized to the corresponding
negative control treatment of the same cell line. We found that Ad.XBPls does not change the
growth rate of the cells over the time course of our experiments, ruling out altered cell
viability/growth as a cause of the observed increased secretion levels.
4.3.6 XBPIs does not alter transcript levels of the collagen-I genes
Another possible explanation for the increased collagen-I secretion we observe upon Ad.XBP1 s
treatment could be that XBP1s transcriptionally upregulates collagen-I mRNA, thereby
increasing the amount of collagen-I synthesized during ascorbate treatment. We used qPCR to
compare the levels of CoIIA1 and CoIIA2 mRNA under Ad.GFP and Ad.XBP1s transduction
conditions. Neither viral transduction changed the mRNA levels of CoIIAI or Co1A2 compared
to cells that were not transduced with virus (Figure 4.8). More importantly, the mRNA levels
between the two viral transductions showed no statistical difference in the Gly247Ser cell line,
based on a Student's t-test. Therefore, the increase in collagen-I secretion is likely not due to a
change in transcription of the collagen-I genes.
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Figure 4.7 | Adenoviral transduction does not change cell viability
(A) Resazurin assay for cell viability comparing different adenoviral transductions, normalized
within each cell line, to the ascorbate-only treated control. All cells were treated with ascorbate.
(B) CellTiter Glo assay for cell viability comparing Ad.XBP1s treatment to Ad.GFP. Data are
normalized to Ad.GFP transductions. Error bars for both the CellTiter Glo assay and resazurin
represent SEM from the average of six biological replicates.
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Figure 4.8 I XBP~s does not increase collagen-I transcript levels
qPCR analysis of CoIIAI (black bars) and CoIIA2 (grey bars), normalized to ascorbate-only
control cells. Error bars represent SEM from three biological replicates.
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4.3.7 XBP1s does not alter global protein or collagen-I synthesis
While XBP1s did not change the transcript level of collagen-1, it is still possible the translation
rate of the collagen-I genes could be altered and result in an increase in secretion. Indeed,
translational attenuation is an established UPR mechanism for relieving a protein folding
stress.61 We performed metabolic labeling experiments to determine if the protein synthesis
rates are different between Ad.GFP and Ad.XBP1s treated samples. Using 35S-Cys/Met to label
all nascent chains synthesized in a ten-minute span, we measured the rates of protein synthesis
and analyzed the result by gel electrophoresis. Figure 4.9A shows a representative 35S-labeled
gel, with the quantitation for 3 biological replicates in Figure 4.9B. The total signal in each lane
corresponds to the total amount of proteins synthesized during the 35S pulse. The signal for
each condition within each cell line tested does not change, regardless of treatment, suggesting
that global protein synthesis was not altered by the addition of Ad.XBP1s.
To determine which signal on the gel corresponds to collagen-I synthesized during the
pulse, samples were split in half, and treated with or without bacterial collagenase. Collagenase
treatment identifies which signal is due to newly synthesized collagen-1. By this analysis,
collagen-I synthesis itself also does not change with Ad.XBP1s treatment, compared to control
transductions (Figure 4.9C). These results indicate that the 01 collagen-I secretion
enhancement mediated by XBP1s cannot be attributed to either collagen-I-specific or proteome-
wide translational effects, acting instead by a post-translational mechanism.
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Figure 4.9 1 Metabolic labeling reveals no change in proteome or collagen-I synthesis
upon XBP1s expression
(A) Representative SDS-PAGE gel of 35S-Cys/Met-labeled protein samples. Samples were split
in half and treated with and without bacterial collagenase for 3 d to determine which protein
bands were derived from collagen-I signal. (B) Quantification of the total signal per lane,
averaged over three biological replicates and normalized to the corresponding Ad.GFP for each
cell line. Error bars represent SEM. (C) Quantification of the collagen-I signal in each cell line
transduced with Ad.XBP1s, normalized to the signal in the Ad.GFP transduced sample,
averaged over three biological replicates. Error bars represent SEM. Bar charts in both (B) and
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(C) are normalized to Ad.GFP signal, which was omitted from the plot. Normalized Ad.XBP1s is
plotted for each cell line.
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4.3.8 XBPIs does not significantly alter triple-helical stability of collagen-I secreted by
Gly247Ser 0/ patient primary fibroblasts
Malformed triple helices are thought contribute to the 01 symptoms of brittle, structurally
unsound bones, potentially compromising the overall strength of bone.6 2,6 3 One of the unique
characteristics of collagen-I is that folded triple helices are resistant to protease digestion.36,64
Measuring protease stability of triple helices as a function of temperatures is one common
assay to assess the stability of collagen-I molecules. We applied this assay to assess whether
the enhanced collagen-I secretion by 01 patient cells was resulting in production of increasing
amounts of malformed collagen-I or collagen-I of similar quality. We began with a mild
proteolysis protocol, treating purified procollagen- with trypsin or chymotrypsin at rt for 2 h, and
then analyzed degradation of the triple helices by SDS-PAGE immunoblotting. Prior work
indicated the need to test resistance to multiple proteases, because each protease probes
different misfolding events.64 Regardless of whether XBP1s is present or not, collagen-I helices
harvested from each cell line are stable to prolonged treatment with trypsin and chymotrypsin
(Figure 4.1OA).
These initial experiments prompted us to more rigorously assess the thermal stability of
the secreted collagen-I helices. We used a temperature gradient to probe the temperature at
which each set of helices unfolds and thus becomes susceptible to protease digestion. After a 2
min incubation at a range of temperatures between 25-44 *C, procollagen- samples were
cooled to rt and treated with a mixture of trypsin and chymotrypsin for 2 min, after which the
reaction was quenched and analyzed by SDS-PAGE immunoblot (Figure 4.10B). The data
suggest that the helices isolated from each cell line with or without XBP1s activation have
roughly the same stability, unfolding within the range of temperatures that wild-type triple helices
typically begin to unfold.36'64-6 XBP1s activity therefore does not decrease the quality of the
collagen-I helices secreted.
190
A
Ad.GFP
Trypsin - + - - + -
Chymo - - + - - +
ct-colct2(l) -wuw %WM
a-Type-I
Collagen
Wild Type Cola1 (1)
G247S
Ad.XBP1s
- + - - + -
- - + - - +
Wild Type Coa10 (1)
G247S
B
IB:a-Type-l
Collagen
T/C Mix:
Temp (0C).
Ad.GFP
Ad.XBP1s
250 250 30.8 32 5 35.5 388 410 425440
Iww%4" r 177~
Figure 4.10 | Triple helices produced under XBP1s activated conditions are protease-
resistant
(A) Room temperature treatment of purified procollagen-I molecules with trypsin or
chymotrypsin for 2 h demonstrates protease resistance in all samples tested. (B) Temperature
gradient and subsequent treatment with a trypsin and chymotrypsin mixture to assess stability.
Both representative immunoblots are representative of collagen-I secreted form the Gly247Ser
cells after treatment with Ad.GFP (control) or Ad.XBP1 s.
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4.3.9 XBP1s activation changes the ratio of wild-type to Gly247Ser variant secreted
We next asked what the ratio of wild-type to Gly247Ser protein was altered upon treatment with
Ad.XBP1s compared to Ad.GFP treatment. We first induced collagen-I synthesis and secretion
by addition of ascorbate for 24 h with and without XBP1s activation in the Gly247Ser cell line.
Media was collected after 24 h and the collagen-I was precipitated, then resolubilized and
treated with pepsin for 36-48 h at 4 *C. Stable triple helices were then precipitated with NaCl,
solubilized, run on a 6% SDS-PAGE gel, and stained with Coomassie67 (Figure 4.11). These
pepsin-treated collagen-I samples demonstrate that the helices are resistant to digestion by yet
a third protease over time. Cola1(l) and Cola2(l) separate well, and the Cola1(1) band was
excised, reduced, alkylated and trypsinized. The resultant peptides were analyzed by LC-
MS/MS analysis to determine the abundance of the wild-type- and Gly247Ser-containing
peptides.
The Gly247Ser-containing tryptic peptide and its wild-type counter part eluted from the
column with roughly the same retention time (Figure 4.12A). Figure 4.12B provides a sample
MS1 scan demonstrating that we can detect the precursor m/z ratios of the correct mass. To
quantify the difference between the wild-type and 01-variant peptides we analyzed the area
under the curve of the LC trace for each peptide in Figure 4.12A. When transduced with
Ad.GFP, the wild-type allelic product is about four-fold more abundant than the serine
containing peptides. In contrast, transducing with Ad.XBP1s shifts the ratio to almost 1:1 wild-
type to Gly247Ser variant (Figure 4.12C). An increase in the 01-variant being secreted from the
cell suggests that XBP1s activation rescues the serine variant from an intracellular fate of
degradation or aggregation, promoting its assembly instead into folded triple helices that can be
secreted.
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Figure 4.11 | Pepsin resistance of collagen-I triple helices
Coomassie stained SDS-PAGE gel demonstrating stability of collagen-I helices from wild-type
and Gly247Ser cells after treatment with Ad.GFP or Ad.XBP1s. Colal(l) has a slower
electrophoretic mobility than Cola2(l). Colal(I) was extracted from the gel, and analyzed by
mass spectrometry in Figure 4.12.
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Figure 4.12 | Mass spectrometry analysis of secreted collagen-I demonstrates a change
in the ratio of wild-type to mutant allelic product when XBP1s is activated
(A) Representative LC traces for each tryptic peptide of interest. Mass/charge ratios of 651.83
and 666.83 correspond to the peptide without lysine hydroxylation, while the ratios of 659.82
and 674.33 account for the hydroxylated lysine. (B) Representative MS1 scan highlighting the
four relevant m/z ratios. (C) Quantification of the wild-type and mutant allelic products in the
presence of Ad.GFP or Ad.XBP1s.
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4.3.10 Treatment with Ad.XBPls rescues collagen-I from autophagic degradation
To address the intracellular fate of collagen-1, we hypothesized that collagen-I was likely being
degraded in the absence of XBP1s activation. Some data suggest that collagen-I can be
targeted to either endoplasmic reticulum associated degradation (ERAD) or autophagy.
Thus we inhibited both of these processes to identify the fate of collagen-I in the presence and
absence of XBP1s. Unfortunately, proteasome inhibitors cannot be used in fibroblasts when
studying collagen-I because they decrease transcript levels of ColIA1 and CoIIA2 .70 Therefore,
we inhibited ERAD upstream of the proteasome using the VCP (p97) inhibitor eeyarestatin-l, a
compound that prevents ER client protein retrotranslocation.71 We used bafilomycin A to inhibit
autophagy.72 Cells were co-treated with ascorbate and either of these ERAD and autophagy
inhibitors to determine if and by what mechanism 01-variant collagen-I was degraded.
All samples were treated in the presence of ascorbate and small molecule inhibitor for
24 h before harvesting and analyzing the conditioned media as well as the lysate. Figure 4.13
shows representative data for the inhibition studies in wild-type and Gly247Ser-producing cells.
In the case of Ad.GFP treatment, VCP inhibition did not alter the levels of collagen-I in lysate
compared to DMSO-treated controls. Bafilomycin A, on the other hand, increased the collagen-I
signal in the lysate in both wild-type and Gly247Ser lysates under control transduction
conditions. In contrast, when either cell line was treated with Ad.XBPls, the amount of collagen-
I rescued by bafilomycin A treatment was drastically reduced, suggesting that the collagen-I was
no longer being targeted for autophagy when XBP1s was present. Our results suggest that
XBP1s is likely affecting collagen-I folding in such a way that less of the nascent protein is
targeted for autophagy.
195
Eeyarestatin-l:
Bafilomycin Al:
Ad.GFP:
Ad.XBPls:
Healthy
- + - - + -
- - + - - +
+ + + - - -
-- - + + +
G247S
- + - - + -
- - + - - +
+ + + - - -
-- - + + +
Colal (1)
a-KDEL
a-actin
Figure 4.13 | Small molecule inhibitors of ERAD and autophagy demonstrate that XBPIs
is rescuing collagen-I from autophagy
Cells were transduced with Ad.GFP or Ad.XBP1s and co-treated with ascorbate and either
eeyarestatin-l or bafilomycin. The eeyarestatin concentration was 750 ng/mL and the
bafilomycin concentration was 100 nM. Cells were lysed and immunoblotted for KDEL as a
marker for XBP1 s activation and actin as a loading control.
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4.3.11 XBPls perturbs autophagy in 0! patient primary cells
Autophagy is a complex intracellular degradation process. The combination of LC3 lipidation
(formation of LC3-ll) and p62 degradation are considered the most concrete evidence that
autophagy is activatied. 73 ,74 In contrast, LC3-II formation coinciding with an increase in p62
levels indicates that autophagy is inhibited, unless levels of p62 are perturbed in some other
way. We began by testing levels of LC3-ll and p62 in lysates of cells treated with either Ad.GFP
or Ad.XBP1 s. In both wild-type and Gly247Ser cells, we observed a large increase in both LC3-
I and p62 levels when Ad.XBP1s was present (Figure 4.14A). Given that XBP1s is a
transcription factor, a protein-level increase cannot be adequately interpreted until transcript-
level changes are also assessed. qPCR confirmed that XBP1s does upregulate both LC3 and
p62 at the transcript level (Figure 4.14B). Therefore, our data suggest that Ad.XBP1s perturbs
autophagic flux, but we cannot specify the direction of that perturbation based on our current
data.
4.3.12 Gly247Ser cells exhibit characteristics of defective autophagic flux
An increase in the size and or number of p62-positive protein bodies inside cells is indicative of
defective or inhibited autophagy. Positing that perturbations to autophagy by XBP1s played a
role in the observed increase in collagen-I secretion, we asked whether autophagic flux was
stalled in the presence of the Gly247Ser variant of collagen-1, compared to cell expressing wild-
type collagen-I. We transduced cells at the same MOI with baculovirus carrying RFP-p6276 and
monitored fluorescence intensity, size and localization after 72 h of expression. Gly247Ser cells
show a massive increase in fluorescence intensity as well as number and size of the fluorescent
puncta when compared to wild-type cells (Figure 4.15). With a larger amount of puctated RFP
signal than the wild-type, this data suggests that basal autophagic flux in the Gly247Ser cells is
decreased.
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Figure 4.14 1 XBP1s upregulates autophagic targets
(A) Protein level changes in LC3 and p62 upon Ad.XBP1s treatment compared to Ad.GFP
treatment. GRP94 and BiP upregulation validate XBP1s was active. Immunoblot was probed
with the a-KDEL antibody, and then with a-p62. The signal from both antibodies is shown in one
image due to their proximity on the membrane. (B) Transcript levels of p62 increase when cells
are treated with Ad.XBPls, normalized to Ad.GFP. Error bars represent SEM from three
biological replicates.
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Figure 4.15 1 Gly247Ser cells likely exhibit defective autophagic flux
Representative images of wild-type and Gly247Ser cells expressing an RFP-p62 fusion protein.
The Gly247Ser cells display many more p62 puncta, as well as much larger staining throughout
the cells than that of the wild-type line.
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4.3.13 XBPIs-dependent collagen-I secretion relies on the ability to activate autophagy
Our data suggest that autophagy may play an important role in XBPIs-dependent secretion
from Gly247Ser cells. We next asked whether autophagy is essential to increase collagen-I
secretion from the Gly247Ser cell line, or whether it is a secondary, unrelated effect of XBP1 s.
We used a genetic approach to uncouple XBPls perturbations to autophagy from its other
proteostasis network effects. In this way, we could determine if autophagy activation was
required for the increase in collagen-I secretion to be observed, or whether changes to
autophagy were a secondary effect of XBP1s, unrelated to collagen-I secretion. Beclin-1 is a
cystosolic protein that regulates and initiates macroautophagy. 73 Beclin-1 is a transcriptional
target of XBP1s in endothelial cells, 77-79 and thus we began by knocking it down and monitoring
collagen-I secretion in its absence. Using lentivirus we delivered control or beclin-1 targeting-
shRNA constructs to wild-type and Gly247Ser cells prior to adenoviral transduction to deliver
the XBP1s active construct. Media was then analyzed by SDS-PAGE immunoblotting, and cells
were lysed to analyze RNA transcript levels for the targeted proteins.
We first validated beclin-1 knockdown by qPCR, finding only 10-20% percent of the
BECN-1 transcript remaining in the knockdown samples (Figure 4.16A). Figure 4.16B shows
the immunoblot analysis for secreted collagen-I in the presence or absence of XBP1s, with
different shRNA constructs transduced into each cell population. There was no detectable
change in collagen-I secretion from the Ad.GFP transductions treated with control or beclin-1
targeting shRNAs. In contrast, the control shRNA transduced into Gly247Ser cells with
Ad.XBP1s showed the expected increase in collagen-I secretion, as compared to the paired
Ad.GFP transduced cells. However, when beclin-1 was knocked down in the presence of
Ad.XBP1s, collagen-I secretion decreased to levels comparable to the control transduction.
Both beclin-1-targeting shRNA constructs tested produce the same, XBPls-dependent
decrease in collagen-I secretion. Without beclin-1, collagen-I secretion is reduced to basal
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levels in the Gly247Ser cells, suggesting that autophagy activation is a necessary part of the
XBPIs-dependent result.
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Figure 16 j Autophagic activation is necessary for the XBPls-dependent increase in
secretion
(A) qPCR validating the knockdown of BECN-1 using two different shRNA constructs. All
samples are normalized to the non-mammalian (NM) transduction control, targeting GFP
mRNA. Error bars represent SEM from three biological replicates. (B) Representative
immunoblot data of secreted collagen-I in the presence of each shRNA construct.
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4.3.14 Autophagy alone is insufficient to increase collagen-I secretion
Knowing that the XBP1s-dependent secretion result relied on autophagic activation, we next
probed whether autophagic activation was sufficient to increase collagen-I secretion from the
Gly247Ser cells in the absence of XBP1s. To address this question, we pretreated cells with
small molecule activators of autophagy, and assayed for collagen-I secretion after 48 h of
activation. Wild-type and Gly247Ser cells were treated with rapamycin, 0 tat-beclin-1,8 and
carbamazepine82 to activate autophagy, with media changes and drug supplementation every
24 h to ensure autophagy was constitutively activated. After 48 h, media was replaced with the
corresponding drug one more time and supplemented with 200 [M ascorbate to stimulate
collagen-I synthesis and secretion. After a final 24 h, media was then harvested and analyzed
by immunoblot, and cells were harvested to validate that autophagy was activated.
We found that autophagy activation by small molecules is insufficient to increase
collagen-I secretion (Figure 4.17) with rapamycin actually causing a decrease in collagen-I
secretion. Intracellular levels of p62 levels decrease, validating the activation of autophagy.
Therefore, autophagy activation alone is insufficient to cause an increase in 01-variant primary
cell lines. Resculpting of the ER chaperone landscape by XBP1s is also required.
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Figure 17 I Autophagic activation alone is insufficient to cause an increase in collagen-I
secretion
Immunoblot analysis of secreted collagen-I from cells treated with autophagy activators. The
rapamycin concentration was 500 nM. The tat-beclin-l concentration was 10 iM.
Carbamazepine concentration was 100 pM. Lysate levels of p62 show a decrease compared to
the control sample, confirming that autophagy was activated.
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4.4 Concluding Remarks
Our data provide the first example of XBP1s addressing a loss of function defect, here by
selectively increasing collagen-I secretion from 01 patient-derived primary fibroblasts. The data
suggest the following model: Gly247Ser cells accumulate collagen-I intracellularly due to a
folding defect. In the absence of XBP1s, collagen-I perpetually accumulates with minimal
degradation, and effectively overcrowds the folding environment of the ER. When secretion of
collagen-I is induced with ascorbate treatment, the newly synthesized collagen-I strands are
blocked from being secreted as a result of the misfolded collagen-I accumulation in the ER. It is
tempting to speculate that the chaperones necessary for collagen-I folding are likely saturated
by the misfolded variants, leaving nascent chains even more likely to misfold without the
assistance from necessary chaperones. XBP1s ameliorates the stress caused by constitutive
Gly247Ser misfolding by two mechanisms. Autophagy induction likely clears the blockage of
misfolded collagen-I in the ER. Concurrently, XBP1s reloads the ER with an upregulated
chaperone network that is no longer saturated by misfolding collagen-I variants. In this manner,
when collagen-I synthesis is induced, nascent chains experience an ER with fewer misfolded
collagen-I variants, and a higher chaperone capacity to handle the challenge of folding disease-
variant forms of collagen-.
This model suggests a new mechanism of improving proteostasis for a disease variant:
a combination of enhanced quality control and improved folding, rather than just one or the
other. Activation of a degradation pathway might suggest several characteristics of the
misfolded collagen-I variants: (1) these variants are terminal and cannot be rescued to any
sufficient extent by disaggregases, holdases or foldases; and (2) the basal expression of the ER
proteostasis network does not provide adequate support for recognizing and degrading
misfolding variants of a complex protein such as collagen-1.
Our work provides a step forward in our understanding of how cells handle the complex
folding problem of collagen-1. Collagen-I is a complex multidomain protein to fold, and as such
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even wild-type collagen-I likely misfolds to some degree. If we consider the Gly247Ser variant
as an exacerbated version of wild-type collagen-1, it is likely that autophagic elimination of even
wild-type collagen-I occurs to some extent. The Gly247Ser variant likely overwhelms the
proteostasis system and causes a severe blockage, but similar mechanisms are likely at play
with the wild-type form of the protein as well. However, with a lower flux of protein into the
misfolded state, the process is likely more efficient.
Future work aims at better understanding this mechanism and investigating the role
XBP1s could play in improving organismal health. Ideally, we would validate our findings in cells
using small molecule activators of the endogenous IRE1 arm of the UPR. Unfortunately,
currently available small molecule activators generally lack specificity and/or potency for IRE1
activation. Development of an IRE1 activator would be useful not only for our systems, but
for applications beyond the scope of 01, including the other collagenopathies. While testing our
results in animal models would be ideal, we note that the currently available 01 mouse models
are not particularly relevant as they do not display the prototypical glycine to serine mutation in
the triple helical domain. One of the main questions with increasing 01-variant secretion is the
viability of the organism and how increasing mutant secretion would affect the bone structure,
stability and health. Creation of an appropriate 01 mouse model is necessary to assess the
answers to these questions with greater rigor.
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4.5 Experimental Methods and Supplies
4.5.1 Materials and Reagents
EMEM, trypsin, L-glutamine, Penicillin-streptomycin and FBS were all purchased from
Corning/Cellgro. Eeyarestatin-l and bafilomycin were purchased from Sigma. Premo-Autophagy
RFP-p62 was purchased from Life Technologies.
4.5.2 Cell culture
Primary dermal fibroblasts were obtained from Coriell Cell Repository, with no method to identify
the patients' identities. Cells were maintained in EMEM supplemented with 15% FBS,
penicillin/streptomycin, and L-glutamine. When sub-cultured, cells were trypsinized and
resuspended in ample fresh media, centrifuged at 1000 rpm for 5 min, and resuspended in
complete fresh media to count the cells. Cells were counted using the Countess 11 FL (Life
Technologies).
4.5.3 Adenoviral amplification and transduction
1.0x105 cells were plated the day before transduction in a 6 well plate. After 24 h, media was
replaced and supplemented with adenoviral supernatant. After 24 h of incubation with virus, the
media was removed, and the cells were either split accordingly for the appropriate experiments,
or supplemented with fresh media. 48 h post media change or split, media was removed and
replaced with 1 mL of media with 200 pM ascorbate supplemented every 24 h as necessary. 6-
24 h post later, media and cells were harvested for downstream analysis. Cells and viral MOI
was scaled accordingly as necessary. Baculoviruses were transduced identically to that of our
homemade adenoviruses.
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4.5.4 Quantitative PCR
Relative mRNA expression levels of genes of interest were assessed by quantitative RT-PCR.
Cells were harvested by trypsinization, washed with PBS, and total RNA was extracted using
the Omega RNA Purification Kit according to the manufacturer's instructions. RNA
concentrations were quantified and normalized to 0.5-1 tg total RNA for cDNA reverse
transcription. Using the Applied Biosystems Reverse Transcriptase cDNA Kit, cDNA was
synthesized in a BioRad Thermocycler. LightCycler 480 Sybr Green Master Mix (KAPA),
appropriate primers (purchased from Integrated DNA Technologies, Life Technologies and
Sigma Aldrich, Table 1) and cDNA were used for amplification in a Light Cycler 480 11 Real
Time PCR Instrument in the MIT BioMicro Center. Primer integrity was assessed by thermal
melt and agarose gel analysis to ensure that a single gene was amplified. Transcripts were
normalized to the housekeeping gene Rplp2, and all measurements were performed in technical
and biological triplicate.
4.5.5 Metabolic labeling
72 h post transduction, media was removed from cells and replaced with fresh media with 200
pM ascorbate for 2 h. Media was then replaced with fresh media containing 200 1tM ascorbate
and 100 mCi/mL of 35S-Cys/Met (Perkin Elmer) for 10 min. Media was removed, cells were
washed 2xPBS, and lysed immediately in the plate. After 20 min on ice, samples were collected
and centrifuged at 16,400 rpm, 4 *C for 15 minutes. Supernatants were collected and split
equally into two tubes, both supplemented with 8x collagenase buffer (50 mM HEPES, pH 7.5,
360 pM calcium chloride). Half of the samples were treated with 5 pg/mL final concentration
bacterial collagenase (Worthington Biochemical) for 3 d at 37 *C. Samples were then loaded
onto a 10% gel, dried and imaged using the Phosphor screen and Typhoon 7800 after
developing for 2 d.
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4.5.7 Cell lysis and SDS-PAGE analysis
Cells were trypsinized, the trypsin was neutralized and lysed in unconditioned DMEM. Samples
were then centrifuged at 1,500 rpm, for 5 min at rt. Cell pellets were washed 1 xPBS,
centrifuged again, and lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-HCI, pH 7.5, 1% Triton-
X 100, 0.5% SDS, and 0.1% sodium deoxycholate, a protease inhibitor tablet (Pierce) and 1 mM
PMSF). Samples were lysed on ice for 20-30 min, centrifuged at 16,800 rpm at 4 *C, quantified
and normalized for SDS-PAGE analysis. Protein gels were transferred to nitrocellulose
membranes using the TransBlot Turbo system from BioRad, blocked in 5% non-fat milk w/v and
probed with the corresponding primary antibody for 2 h-o/n. Images were analyzed using an
Odyssey Scanner.
4.5.8 Procollagen-l purification and proteolysis
2.50 x105 cells were plated in a 6cm dish, and transduced 24 h later with Ad.GFP or Ad.XBP1s.
Media was changed on the cells after 24 h, and 72 h post-transduction the cells were induced
with 200 M ascorbate for 24-48 h. Media samples were then collected, chilled and treated with
1 mM PMSF, 100 mM Tris-HCI, pH 7.4, and 176 mg/mL ammonium sulfate, o/n end over end
mixing at 4 *C. The next day, samples were centrifuged and the supernatant removed, with the
pellet being resolubilized in 400 mM NaCl, 100 mM Tris-HCI, pH 7.4. Procollagen- samples
were then aliquotted accordingly, and treated with 0.1 mg/mL trypsin and/or 0.2 mg/mL
chymotrypsin, or 0.2 mg/mL pepsin.
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4.5.9 Autophagy visualization
Cells were first plated, and transduced with the corresponding viruses for 24 h, when the media
was replaced with fresh media. We used an MOI of about 30 for the Premo Autophagy RFP-
p62. After 24 h, media was replaced with fresh media, and cells were imaged.
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Appendix A:
Further investigation of the cysteine network in the collagen-I C-Pro
domain
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A.1 Introduction
In Chapter 2, we redefined the essential role of the C-terminal cysteine network in regulating
any fibrillar collagen C-Pro domain's ability to form a disulfide-linked homotrimer. We
determined that C2 and C3 (the same nomenclature derived from Chapter 2) are essential,
highly conserved cysteine residues required to form a homotrimer. If one of these two cysteine
residues is not present in a fibrillar collagen strand's C-Pro domain, that C-Pro domain will be
unable to form stable homotrimers. Two remaining questions that follow our work from Chapter
2 are: (1) What role do the six other cysteine residues play in collagen assembly and (2) Does
this cysteine code extend to full-length collagen-I?
Based on the crystal structure, the other cysteine residues in each C-Pro domain all
participate in intrastrand disulfide bonds.' The function of the intrastrand disulfide bonds,
however, is unknown. Several disease variants of collagen-I result in mutations to the cysteine
network, and cause osteogenesis imperfecta. In particular, removal of C1 or C8 of Cola2(1) (due
to a missense mutation or an early stop codon, respectively) slowed collagen assembly and
promoted formation and secretion of Cola1 (1) homotrimers Variants that replace C5 of Colal (I)
decreased collagen secretion, causing overmodified, yet stable triple helices to be secreted.3
Thus, 01 disease phenotypes demonstrate the importance of the cysteine network of the
collagen C-Pro, but we still lack a biochemical understanding of the role each evolutionarily
conserved cysteine plays in collagen-I assembly. The only systematic interrogation of the role
that each cysteine played in collagen-I assembly was performed using C-Pro domains fused to
short (-200 amino acid) triple helical domains.4 5 As Chapter 2 demonstrated, studying the C-
Pro domain in isolation has distinct advantages that enable a better understanding of the
regulating factors guiding collagen-I assembly. Therefore, in this Appendix I describe our work
toward understanding the essential role of each cysteine in collagen assembly.
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Our data presented in Chapter 2 demonstrates that a single amino acid change in a 30
kDa protein alters the protein's oligomeric assembly. It is tempting to hypothesize that same
single amino acid change could alter the assembly propensity of a 130 kDa protein, in the case
of full-length collagen-. In this Appendix, I also describe the assembly propensities of each full-
length collagen-I strand with and without C2. Our results suggest that there are features of the
Colal (1) triple-helical domain sequence that may further promote homotrimeric triple helix
assembly in the absence of C2, at least in this artificial expression system used. Additionally,
our work with full-length S2C Cola2(1) demonstrates characteristic unfolded protein response
activation, suggesting that cells have quality control mechanisms to recognize aberrantly
assembled collagen-I trimers and potentially explaining why homotrimers of Cola2(1) have not
previously been identified in nature.
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A.2 Results
A.2. 1 The CI-C4 disulfide bond is essential for C-Pro secretion
The crystal structure of homotrimerizing Cola 1(1) demonstrated the following intrastrand
disulfide bonding pairs: C1-C4, C5-C8, and C6-C7.1 To understand how each of the intrastrand
disulfide bonds participates in homotrimer formation, we individually mutagenized each cysteine
residue to serine, transfected the resulting constructs into HEK293 cells, and monitored
expression, secretion and assembly of each construct. To date we have only analyzed C1 and
C4, but future work aims at understanding the roles of C5, C6, C7 and C8.
Our results revealed that C1S and C4S of both Colal (1) and Cola2(1) (in the context of
S2C Cola2(l), because without C2 wild type Colca2(l) cannot form homotrimers) are synthesized
but retained intracellularly (Figure A.1). With no change in the protein level expression of
GRP94 or BiP, two well-established markers for the unfolded protein response (UPR),6'7 we do
not believe that any of the tested variants activate the transcriptional response to unfolded
proteins in the ER. We speculate that the intrastrand disulfide bond formed between C1 and C4
in a given monomer is an essential step in the folding of the C-Pro domain. When this linkage is
not formed, the cell recognizes the C-Pro as a misfolded protein, prevents it from being
secreted, and likely shuttles it to degradation pathways. Ongoing work in our lab is aimed at
understanding the mechanism by which the cell recognizes the C1S or C4S C-Pro domains as
misfolded, and identifying where these variants are targeted for degradation.
Our results recapitulate phenotypes observed in C-Pro variants that cause osteogenesis
imperfecta (01). In one prior study, the authors noted that full-length Cola2(1) C1R (an 01-
causing mutation) does not incorporate into heterotrimers efficiently, and is retained
intracellularly.2 Remarkably, the retention of the full-length protein is fully recapitulated when we
only express the C1S Cola2(1) C-Pro domain. Thus, our results suggest that this autosomal
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recessive form of 01 is likely caused by a failure of the Cola2(l) C-Pro domain to fold properly
when it cannot form the C1-C4 intrastrand disulfide bond.
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Figure A.1 I Serine variants preventing an intrastrand disulfide bond are retained
intracellularly
Immunoblot analysis of transient transfections of wild-type, CIS, C2S, C3S, and C4S of C-
Proa() constructs from Chapter 2. Top immunoblot demonstrates that C1S and C2S of both C-
Proal (1) and C-Proa2(l) are not secreted. Bottom blots are the corresponding lysate samples,
demonstrating that all the transfected constructs are synthesized. None of the transfected
constructs activate the UPR, as shown by no change in GRP94 or BiP levels compared to the
control transfection (v).
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A. 2 C2 variants in full length collagen-I
In order to analyze a given collagen strand's propensity to form and secrete stable triple helices,
we required a cell line that basally expresses the necessary machinery to fold collagen, but
does not produce potentially confounding, endogenous collagen-1. Our prior work as well as
others in HT1080 cells (Chapter 3) established this fibrosarcoma cell line as a viable model for
studying collagen-I assembly and folding.8 1 0 Using replication-incompetent human adenovirus
type V, we delivered each full-length collagen-I gene of interest into HT1080 cells under a CMV
promoter to drive expression. Three days post-transduction, the culture media was
supplemented every 24 h, for 2 d total with ascorbate, a known co-factor for the prolyl-4-
hydroxylases essential for proper triple helical folding." 12 Media was then harvested and
collagen-I was precipitated with ammonium sulfate and prepared for downstream analysis.
Wild-type Colal (1) is efficiently secreted from the cell and displays a slower
electrophoretic mobility when analyzed by non-reducing versus reducing SDS-PAGE,
suggesting the monomers are disulfide bonded to one another. In contrast, full length C2S
Colal (1) migrates as a monomer on an SDS-PAGE gel regardless of the presence of reducing
agent, as we would expect based on the published disulfide bonding map and our own
assembly data in the C-Pro domain above (Figure A.2A). Contrary to what we would expect,
however, both wild type and C2S Cola (1) form stable triple helices, as assayed by protease
resistance and immunoblot analysis (Figure A.2B).
Performing similar analyses on full length wild type and S2C Cola2(1) sheds light on one
of the possible reasons that homotrimers of Cola2(1) have never before been observed.
Analyzing conditioned media for secreted collagen showed that, while wild type ColX2() was
secreted as avidly as the Cola1(l) protein variants, S2C Cola2(l) was not secreted at all.
Instead, the S2C Cola2(1) variant was retained intracellularly (Figure A.3A). Moreover,
expression of the S2C Cola2(I) construct induced the unfolded protein response, as shown by
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qPCR and RT-PCR amplifying XBP1 indicating it is more heavily spliced in the presence of the
S2C variant (Figure A.3B and A.3C). This UPR activation was induced by the full length S2C
Cola2(1), whereas the wild type strand did not activate the UPR. These data suggest that cells
recognize homotrimeric Cola2(1) as a misfolded protein, and may provide a convenient handle
for the future discovery of collagen quality control mechanisms.
Taken together, assembly of heterotrimeric full length collagen is more complex than
was previously understood. Prior to our work, the literature discredited the role that the cysteine
residues play in forming a disulfide linked C-Pro domains. However, we show that the cysteine
network of the C-Pro domain is essential in regulating a strand's propensity to form
homotrimers. Full-length collagen-I data presented here also supports the hypothesis that the
sequence of Colal (1)'s triple-helical domain can also promote its homotrimerization. In the case
of Cola2(1), the misfolded, likely homotrimerized protein complex is recognized by the UPR and
retained intracellularly, likely one of the main reasons that homotrimers of Cola2(l) have never
been observed in nature or in cellulo.
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Figure A.2 I Full-length cysteine variants of Colal(I) suggest there are factors in the triple
helical domain that promote trimerization
(A) Precipitated media samples of full length wild-type Colal (1) and C2S Colal (1) were treated
with and without reducing agent and analyzed by immunoblot. The wild type protein assembles
into a disulfide dependent trimer, based on the higher signal being succeptible to reducing
agent, while the C2S variant does not assembly into higher order oligomers. (B) Preciptiated
wild type and C2S Colal (1) were heated to the temperatures indicated, and treated with a
mixture of trypsin and chymotrypsin to assess the folded state of the triple helix. Remarkably
both wild type and the C2S variant are equally resistant to protease treatment.
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Figure A.3 | Retention of full length S2C Cola2(l) and subsequent UPR activation
(A) Intracellular retention of S2C Cola2() activates the UPR, as indicated by the upregulation of
BiP compared to the control lane (v). (B) qPCR data demonstrating UPR activation in the
presence of the S2C variant, but not the wild type Cola2(l). (C) RT-PCR analysis of XBP1
unspliced to spliced ratio. The proportion of XBP1s is higher in the presence of the S2C variant
compared to the wild-type Cola2(l). S2C induces comparable amounts of XBP1 splicing to Tg
treatment.
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Table A.1 I Primers used for qPCR.
Transcript Forward Reverse
RPLP2 5'-CCATTCAGCTCACTGATAACCTT-3' 5'-CGTCGCCTCCTACCTGCT-3'
CHOP 5'-GGAGCTGGAAGCCTGGTATG-3' 5'-GCCAGAGAAGCAGGGTCAAG-3'
BiP 5'-GCCTGTATTTCTAGACCTGCC-3' 5'-TTCATCTTGCCAGCCAGTTG-3'
Erdj4 5'-GGAAGGAGGAGCGCTAGGTC-3' 5'-ATCCTGCACCCTCCGACTAC-3'
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A.3 Concluding Remarks and Future Work
For the C-Pro domain, the cysteine code is essential and clearly regulates trimerization of
individual chains. The work I describe provides the first systematic approach to determine each
evolutionarily conserved cysteine residue's role in regulating trimer assembly. Studying the C-
Pro domain in the absence of triple helical domains provides a unique platform to directly
interrogate both roles in assembly and mechanistic information regarding the molecular cause
of the more severe cases of 01. Future work will continue to study each cysteine residue in the
collagen-I C-Pro domains, assessing their assembly propensities, secretion kinetics and ability
to incorporate into heterotrimers.
Our C-Pro data demonstrates the importance of the cysteine network in regulating
collagen C-Pro domain assembly. Analyzing the same C2 variants in the context of full length
collagen suggests that even though removal of the second cysteine from Cola1 (1) prevents
disulfide-dependent assembly, there are further factors that we are currently investigating that
guide triple helix formation. On the contrary, in the case of Cola2(), our data suggests that the
lack of a cysteine in the wild type sequence is the only thing preventing Cola2(l) from
homotrimerizing. Furthermore, in the event that Cola2(l) does homotrimerize (in our S2C
construct), nature has engineered a method for detection of such assembled homotrimers,
preventing them from being secreted.
In conclusion, we have unequivocally shown that the cysteine network in the C-Pro
domain of fibrillar collagen is essential for C-Pro trimerization, but it is clearly not the entire
story. Further experimental work will help to illuminate the function the triple helix plays in trimer
assembly, and what role it may play in vivo.
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A.4 Experimental Methods and Supplies
A.4. 1 Adenoviral vector construction and viral amplification
Full-length collagen-I genes were cloned from the vectors in pTRE-Tight of Chapter 3, into
pENTR1A vectors. Full-length wild-type Colal (1) and Cola2(l) were then mutagenized, replacing
the cysteine in position 2 of Colal (1) with a serine, and replacing the serine in position 2 of
Cola2(l) with a cysteine. Samples were then recombined using LR Clonase into Ad-Dest5
(Invitrogen), o/n at rt, according to the manufacturer's instructions. Resultant vectors were
transformed into Stbl3 cells, amplified and sequence-confirmed for the presence of the expected
collagen genes. Vectors were then treated with Pacl to expose the LTRs of the Adenoviral
vector, and transfected into 293A cells using Lipofectamine 2000. Cells were monitored daily for
the formation of plaques, and the viral supernatant was harvested upon full cytopathic effect
(CPE). Viral supernatants were subjected to three freeze/thaw cycles at -80* C and 37* C,
respectively. Cell debris was removed by centrifugation at 1,500 rpm for 15 min at rt, and the
supernatant was collected, aliquotted and used for subsequent amplification. Each virus was
amplified 2-3 more times on 293A cells to create p3 or p4 virus, freeze/thawed, and stored in
single use aliquots to minimize loss of titer due to freeze/thaw.
A.4.2 HT1080 adenoviral transductions
6.0 x 105 HT1 080 cells were plated in each well of a 6-well plate. 24 h later, the media was
changed and supplemented with p3 or p4 viral supernatant. After another 24 h, the media was
changed one final time, or cells were subcultured as necessary. Cells were grown for an
additional 2-3 d to accumulate collagen constructs in the media and lysate samples.
A.4.3 Cell lysis and immunoblot analysis
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6.0 x 105 HEK293 cells were plated. After 24 h cells were transfected with Lipofectamine 3000
(Thermo Fisher Scientific). After 24 h the media was changed, and 72 h post-transfection media
and cells were harvested for immunoblot analysis. Cells were trypsinized, washed 2x with PBS,
and lysed in buffer containing 50 mM Tris-HCI, pH 7.4, 1% Triton-X 100, 150 mM NaCl, 0.5%
sodium dodecyl sulfate, 0.1% sodium deoxycholate, 1 mM EDTA, a protease inhibitor tablet
(Pierce) and 1.5 mM PMSF, on ice for 20 min. Samples were then centrifuged at 40 C for 15
min at 16,4000 x g. Supernatants were collected, quantified and normalized for SDS-PAGE
analysis. Samples were treated with 6x gel loading dye (300 mM Tris-HCI, pH 6.8, 15%
glycerol, 6% SDS, 0.01% bromophenol blue, and 1 M dithiothrietol), boiled for 10 min, and
loaded on a gel for separation.
Media samples were harvested, treated with 6x gel loading dye, with or without reducing
agent (dithiothreitol), boiled and run on a gel. All gels were transferred using the TransBlot
Turbo (BioRad) according to the manufacturer's instructions. Nitrocellulose membranes were
temporarily Ponceau stained, blocked with 5% non-fat milk, and probed with primary antibody in
5% BSA overnight. Membranes were washed with TBS + 0.1% Tween-20, and probed with
secondary antibody in 5% non-fat milk for 45-60 min. Secondary antibody was removed, the
membrane was washed with TBS + 0.1% Tween-20, rinsed with water and scanned on a LiCor
Odyssey Scanner.
A.4.4 Protease digestion of collagen-I
Protease digestion was adapted from prior work.13 HT1080 cells transduced for each collagen-I
variant were grown to confluence in the presence of 50 [tM ascorbate. At 96 h post
transduction, media was harvested and cell debris was removed by centrifugation. The
supernatant was then chilled, supplemented with 100 mM Tris-HCI pH 7.4 (final concentration),
1 mM PMSF, and 176 mg/mL ammonium sulfate. Samples were incubated in an end-over-end
rotator at 40 C o/n. Media was then centrifuged and discarded, collecting the insoluble pellet.
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The pellet was resuspended in 200 IAL of 100 mM Tris-HCI, pH 7.4, 400 mM sodium chloride. 20
pL aliquots were distributed in PCR tubes, and incubated in a thermocycler at the range of
temperatures indicated, for 5 min, then cooled to rt in a water bath. Samples were then treated
with 6 ptL of a mixture of 0.1 mg/mL trypsin and 0.2 mg/mL chymotrypsin for 2 minutes. The
reaction was quenched with 6 pL of 2.5 mg/mL soybean trypsin inhibitor, and then 6.5 VL of 6x
gel loading dye, boiled and analyzed by SDS-PAGE. Immunoblots were quantified and plotted
using Image Studio Lite.
A.4.5 Quantitative PCR analysis
Relative mRNA expression levels of genes of interest were assessed by quantitative RT-PCR.
Cells were harvested by trypsinization, washed with PBS, and total RNA was extracted using
the Omega RNA Purification Kit according to the manufacturer's instructions. RNA
concentrations were quantified and normalized to 0.5 - 1 Vg total RNA for cDNA reverse
transcription. Using the Applied Biosystems Reverse Transcriptase cDNA Kit, cDNA was
synthesized in a BioRad Thermocycler. LightCycler 480 Sybr Green Master Mix (KAPA),
appropriate primers (purchased from Integrated DNA Technologies, Life Technologies and
Sigma Aldrich, Table A.1) and cDNA were used for amplification in a Light Cycler 480 11 Real
Time PCR Instrument in the MIT BioMicro Center. Primer integrity was assessed by thermal
melt and agarose gel analysis to ensure that a single gene was amplified. Transcripts were
normalized to the housekeeping gene Rplp2, and all measurements were performed in technical
and biological triplicate.
A. 4.6 RT-PCR amplification of XBPI
cDNA was synthesized as described above. XBP1 transcript levels were assessed using the
following primers:
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5'-CCTTGTAGTTGAGAACCAGG-3' and
5'-GGGGCTTGGTATATATGTGG-3'
spanning the splicing site. RT-PCR was performed using NEB Q5 Polymerase, according to
manufacturer protocols. The resultant products were loaded onto a 14% polyacrylamide gel and
separated by 1 OOV for three hours. The gel was then incubated with a solution of 0.5% ethidium
bromide solution in TBE buffer for 5 minutes, rinsed with TBE and imaged using 365 nm light.
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